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FSP Section 11,000
Checklists and Illustrative Financial
Statements for Health Care Organizations
Description
.01 Health care organizations may be classified by sponsorship or legal structure within the following
broad categories:

Not-for-profit business-oriented: These are essentially self-sustaining from fees charged for goods and
services. The fees charged by such organizations generally are intended to help the organization
maintain its self-sustaining status rather than to maximize profits for the owner's benefit. Such
organizations often are exempt from federal income taxes and may receive contributions of relatively
small amounts from resource providers that do not expect commensurate or proportionate pecuniary
returns.
Not-for-profit non-business-oriented: These are voluntary health and welfare organizations as defined
in FASB Statement of Financial Accounting Standards (SFAS) No. 117, Financial Statements ofNot-forProfit Organizations. Such organizations are within the scope of the AICPA Audit and Accounting
Guide Not-for-Profit Organizations, rather than that of the Health Care Organizations Guide.

Governmental: Often called public health care entities, the entities are owned and operated by federal,
state, city, or county governments or other political subdivisions.
Investor- (or operator-) owned: These organizations operate as stock corporations, partnerships, or sole
proprietorships.

.02 Health care organizations include, but are not limited to, the following:

•

Clinics, medical group practices, individual practitioners and practice associations, and other ambu
latory care organizations

•

Continuing care retirement communities (CCRCs)

•

Health maintenance organizations and similar prepaid health care plans

•

Home health agencies

•

Hospitals

•

Nursing homes that provide skilled, intermediate, and less intensive levels of health care

•

Parent companies, holding companies, and other organizations that primarily plan, organize, and
oversee health care services

Applicability of This Checklist
.03 This checklist, and the illustrative financial statements included herein, follow the guidance con
tained in the AICPA Audit and Accounting Guide Health Care Organizations (with conforming changes as of
May 1, 2005), referred to as "the Guide." The checklist and illustrative financial statements should be used
for not-for-profit business-oriented and investor-owned health care organizations. Not-for-profit health care
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providers that receive federal financial assistance may be required to have an audit conducted in accordance
with Office of Management and Budget (OMB) Circular A-133, Audits of States, Local Governments, and
Non-Profit Organizations. FSP section 11,300 includes guidance for auditors' reports for audits performed
under OMB Circular A-133.
.04 Although the Guide also applies to state and local government-owned health care providers, this
checklist does not include disclosures or sample financial statements of government-owned providers. Chapter
1 of the Guide discusses the application of generally accepted accounting principles (GAAP) to governmental
health care providers.
.05 In addition, this checklist does not apply to not-for-profit non-business-oriented health care organiza
tions. For these types of organizations, follow the guidance in the AICPA Audit and Accounting Guide
Not-for-Profit Organizations, and the AICPA's disclosure checklist entitled Not-for-Profit Organizations.

Legislation and Regulation
.06 Significant aspects of health care organization operations are affected by government legislation and
regulation with many states adopting laws governing the granting of licenses, as well as scope of services to
be rendered. In addition, many independent organizations and governmental agencies, including Medicare
and Medicaid, evaluate programs and services of health care organizations to determine compliance with
set standards.

Basic Financial Statements
.07 The financial reporting for not-for-profit business-oriented organizations and investor-owned health
care enterprises generally is consistent except for transactions that clearly are not applicable. For example,
not-for-profit business-oriented organizations, by their nature, do not have shareholders' equity. On the
other hand, investor-owned health care enterprises typically do not receive contributions. Throughout this
checklist, disclosure/presentation questions are preceded by certain symbols. Not-for-profit businessoriented organizations should complete all disclosure items denoted with a star (★). Investor-owned health
care enterprises should complete all disclosure items denoted with a diamond (♦).
.08 The basic financial statements of health care providers generally consist of a statement of financial
position or balance sheet, a statement of activities or income statement or statement of operations, a statement
of changes in net assets (equity), a statement of cash flows, and notes to the financial statements. The titles
of the financial statements will depend upon the business form of the provider (i.e., not-for-profit, investorowned, etc.). See the chart below.

Basic Financial Statements
Not-for-Profit
Business-Oriented Organization

Investor-Owned Organization

Balance Sheet/Statement of Financial Position

Balance Sheet

Statement of Operations/Statement of Activities

Statement of Operations/Income Statement

Statement of Changes in Net Assets
*

Statement of Changes in Equity
*

Statement of Cash Flows

Statement of Cash Flows

May be combined with the Statement of Operations.

Note: This publication was extracted from sections 11,000 through 11,500 of the AICPA Financial Statement
Preparation Manual (FSP).
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FSP Section 11,100
Instructions
Purpose
.01 The checklists and illustrative financial statements included in this section have been developed by
the staff of the Accounting and Auditing Publications Team of the AICPA as nonauthoritative technical
practice aids to be used as a memory jogger to aid in the audit of financial statements of health care
organizations. They have not been reviewed, approved, disapproved, or otherwise acted on by any senior
technical committee or the AICPA and do not represent official positions or pronouncements of the AICPA.

The checklists have been updated to include relevant guidance in accounting and auditing
pronouncements issued through June 30,2005. This includes pronouncements issued up to
and including the following:

•

Financial Accounting Standards Board (FASB) Statement of Financial Accounting
Standards (SFAS) No. 154, Accounting Changes and Error Corrections—a replacement ofAPB
Opinion No. 20 and FASB Statement No. 3, and revised FASB Statements issued through
June 30,2005, including
• SFAS 123 (revised 2004), Share-Based Payment

•

FASB Interpretation (FASBI) No. 47, Accounting for Conditional Asset Retirement
Obligations—an interpretation of FASB Statement No. 143

•

FASB Technical Bulletin (FTB) No. 01-1, Effective Date for Certain Financial Institutions of
Certain Provisions of Statement 140 Related to the Isolation of Transferred Financial Assets

•

FASB Emerging Issues Task Force (EITF) consensuses adopted through the June 2005
EITF meeting

•

FASB Staff Positions (FSP) issued through June 30,2005

•

AICPA Statement on Auditing Standards (SAS) No. 101, Auditing Fair Value Measurements
and Disclosures

•

AICPA Statement of Position (SOP) 04-2, Accounting for Real Estate Time-Sharing Transactions

•

AICPA Practice Bulletin (PB) No. 15, Accounting by the Issuer of Surplus Notes

•

AICPA Audit and Accounting Guide Health Care Organizations (with conforming changes
as of May 1,2005)

•

Public Company Accounting Oversight Board (PCAOB) Auditing Standard No. 3,
Audit Documentation—And Amendment to Interim Auditing Standards

The checklists and illustrative financial statements should be modified, as appropriate, for
subsequent pronouncements. In determining the applicability of a pronouncement, its
effective date should also be considered.

Instructions
.02 The checklists consist of a number of questions or statements that are accompanied by references to
the applicable authoritative pronouncements. The checklists provide for checking off or initialing each
question or point to show that it has been considered. Users should check: "yes" if the disclosure has been
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appropriately made, "no" if the disclosure has not been made, or "n/a" if the disclosure is not applicable to
the organization. The auditor should consider the effect of a "no" answer on his/her report. A "no" answer
that is material to the financial statements may warrant a departure from an unqualified opinion. (See
paragraphs 20-63 of SAS No. 58, Reports on Audited Financial Statements, as amended [AICPA, Professional
Standards, vol. 1, AU sec. 508.20-.63].) If a "no" answer is checked, the authors recommend that a note be
made in the right margin to explain why the disclosure was not made (for example, if the disclosure was not
made because it was not material to the financial statements, write "not material" in the right margin). The
right margin may be used for other remarks or comments as appropriate, including cross-referencing to
applicable workpapers where the support to a disclosure may be found. Use of the checklists requires the
exercise of individual professional judgment and may likely require some modification based on the
circumstances of individual engagements.

.03 This checklist is applicable to not-for-profit business-oriented and investor-owned health care organiza
tions. While financial reporting for these types of organizations is generally consistent, there are requirements
that apply to only not-for-profit business-oriented organizations and those that apply to only investor-owned
enterprises. Symbols have been used to indicate the applicability of presentation and disclosure requirements
to these types of organizations. Not-for-profit business-oriented organizations should complete all disclosure
items denoted with a star (★). Investor-owned organizations should complete all disclosure items denoted
with a diamond (♦).

.04 The checklist is not a substitute for the authoritative pronouncements. Users of the checklists and
illustrative financial statements are urged to refer directly to applicable authoritative pronouncements
when appropriate. The checklists and illustrative financial statements do not include all disclosures and
presentation items promulgated nor do they represent minimum requirements. Disclosures prescribed
by pronouncements deemed remote for health care organizations are not included in this document. The
checklists and illustrative financial statements are "tools" and in no way represent official positions or
pronouncements of the AICPA.

.05 If you have further questions, call the AICPA Technical Hotline at 1-888-777-7077.

FSP §11,100.03
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FSP Section 11,200
Financial Statements and
Notes Checklist
.01 This checklist has been developed by the staff of the Accounting and Auditing Publications Team of
the AICPA as a nonauthoritative practice aid. The checklists and illustrative financial statements do not
include all disclosures and presentation items required by GAAP; as a result, pronouncements deemed
unlikely to be encountered in financial statements of health care providers are not included.

.02 Explanation of References:

★=

Disclosure applicable for not-for-profit organizations

♦=

Disclosure applicable for investor-owned organizations

AAG =

AICPA Audit and Accounting Guide Health Care Organizations (with conform
ing changes as of May 1,2005)

AAG-SLA =

AICPA Audit Guide Government Auditing Standards and Circular A-133 Audits
(with conforming changes as of May 1,2005)

AC =

Reference to section number in FASB Accounting Standards—Current Text

APB =

Accounting Principles Board Opinion

ARB =

Accounting Research Bulletin

AU =

Reference to section number in AICPA Professional Standards (vol. 1)

EITF =

FASB Emerging Issues Task Force consensus

FASBI =

FASB Interpretation

FSP =

FASB Staff Position

SAS =

AICPA Statement on Auditing Standards

SFAS =

FASB Statement of Financial Accounting Standards

SOP =

AICPA Statement of Position

TB =

FASB Technical Bulletin

.03 Checklist Questionnaire:
This checklist is organized into the sections listed below. Carefully review the topics listed and consider
whether they represent potential disclosure items for the health care provider. Place a check mark by the
topics or sections considered not applicable; these sections need not be completed. For example, if the entity
does not have any extraordinary items, place a check by "Extraordinary Items" and skip this section when
completing the checklist.
Place by
Sections Not Applicable

•

General
A.
B.
C.

Titles and References
Comparative Financial Statements
Consolidated Financial Statements

FSP §11,200.03
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Place by
Sections Not Applicable

•

Statement of Financial Position/Balance Sheet
A.
B.
C.
D.
E.
F.
G.
H.
I.
J.
K.
L.
M.

•

General
Cash and Cash Equivalents
Investments
Receivables and Loans
Beneficial Interests in Assets Held by Others
Property and Equipment, and Supplies
Deferred Income Tax Assets and Liabilities
Intangible Assets and Goodwill
Current Liabilities
Notes Payable and Other Debt
Other Liabilities and Deferred Credits
Net Assets/Shareholders' Equity
Restricted Resources

Statement of Activities/Income Statement/Statement of
Operations/Statement of Changes in Net Assets
A.
B.
C.
D.
E.
F.
G.
H.
I.
J.
K.
L.
M.
N.
O.

General
Revenue
Income Taxes
Extraordinary Items
Unusual or Infrequent Items
Advertising Costs
Donated or Contributed Services
Donated Materials and Facilities
Fund Raising
Contributions/Pledges
Expenses
Wills
Endowments
Earnings Per Share
Comprehensive Income

•

Statement of Cash Flows

•

Other Financial Statement Disclosures
A.
B.
C.
D.
E.
F.
G.
H.
I.
J.
K.
L.
M.
N.
O.
P.

Accounting Changes and Error Corrections
Accounting Policies
Business Combinations
Commitments and Contingencies
Exit or Disposal Activities
Derivative Instruments and Hedging Activities
Financial Instruments
Nonmonetary Transactions
Pension and Other Postretirement Benefit Plans
Related Organizations and Economic Dependency
Risks and Uncertainties
Segment Information
Subsequent Events
Stock-Based Compensation/Share-Based Payment
Transfers of Financial Assets
Long-Lived Assets and Disposal Groups to Be Disposed Of

FSP §11,200.03
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Place by
Sections Not Applicable

Q.
R.
S.
T.
U.
•

Asset Retirement Obligations
Impaired Loans
Impairment of Long-Lived Assets to Be Held and Used
Lessor Leases
Lessee Leases

_________
_________
_________
_________
_________

Continuing Care Retirement Communities (CCRCs)
A.
B.

C.
D.
E.
F.

Refundable Advance Fees
Fees Refundable to Residents Only From Reoccupancy
Proceeds of a Contract Holder's Unit
Nonrefundable Advance Fees
Obligation to Provide Future Services and Use of Facilities
to Current Residents
Costs of Acquiring Initial Continuing-Care Contracts
Other

_________
_________
_________
_________
_________
_________

•

OMB Circular A-133 Presentation Requirements

_________

•

Auditors' Reports

_________

•

Auditors' Reports on Audits Performed in Accordance With Government
Auditing Standards and Circular A-133 Checklist

_________
Yes

No

N/A

____

____

____

____

____

____

a. Statement of financial position (balance sheet)?

____

____

____

b. Statement of activities (statement of operations/income statement)?

____

____

____

c. Statement of cash flows?

____

____

____

d. Statement of changes in net assets (equity)? (Note: This statement
may be combined with the statement of activities.)

____

____

____

____

____

____

____

____

____

General
A. Titles and References

1.

Are the financial statements suitably titled?
[SFAS 62, par. 7 (AU 623.07); AAG, par. 1.05, fn. 3]

2.

Does each statement include a general reference that the notes are an
integral part of the financial statement presentation?
[Generally Accepted]

★♦3.

Do the basic financial statements of the health care organization
include:

e. Notes to the financial statements?
[SFAS 117, pars. 1 and 6 (AC No5.104); AAG, par. 1.05]
B. Comparative Financial Statements
1.

Has presentation of comparative statements been considered?
[SFAS 117, par. 69; ARB 43, Ch. 2A, pars. 1 and 2 (AC F43.101 and
.102)]

2.

If comparative statements are presented, are the notes and other dis
closures included in the financial statements of the preceding year(s)

FSP §11,200.03
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Yes

No

N/A

repeated, or at least referred to, to the extent that they continue to be
of significance?
[ARB 43, Ch. 2A, par. 2 (AC F43.102)]
3.

If changes occurred in the manner of or basis for presenting corre
sponding items for two or more periods, are appropriate explanations
of the changes disclosed?
[ARB 43, Ch. 2A, par. 3 (AC F43.103)]

C. Consolidated Financial Statements

Note: EITF 97-2, Application ofFASB Statement No. 94 and APB Opinion No.
16 to Physician Practice Management Entities and Certain Other Entities with
Contractual Management Arrangements, provides guidance to assist physi
cian practice management companies (PPMs) in applying SFAS 94 when
PPMs acquire a physician practice.

★ ♦ 1.

If the provider and another entity are related and they meet the criteria
for consolidation, are consolidated financial statements presented?
[AAG, pars. 11.10 and 11.11; ARB 51, as amended (AC C51); SFAS 94
(AC C51)]

★♦2.

If consolidated statements are presented:

a. Is the consolidation policy disclosed?
[ARB 51, par. 5 (AC C51.108); APB 22, par. 13 (AC A10.106)]
b. When the financial reporting periods of consolidated entities dif
fer, is recognition given, by disclosure or otherwise, to the effect
of intervening events that materially affect financial position or
results of operations?
[ARB 51, par. 4 (AC C51.107)]
Note: FASBI46 (revised December 2003), Consolidation of Variable Interest
Entities, an interpretation of ARB No. 51, replaces FASBI 46, Consolidation
of Variable Interest Entities. FASBI 46 (revised December 2003) contains
scope exceptions that should be considered in determining whether its
provisions apply to a particular entity. FSP FIN 46-1, Applicability ofFASB
Interpretation No. 46, Consolidation of Variable Interest Entities, to Entities
Subject to the AICPA Audit and Accounting Guide, Health Care Organiza
tions, has been incorporated into the scope exceptions in paragraph 4(a)
of FASBI 46 (revised December 2003). Special provisions apply to enter
prises that have fully or partially applied FASBI 46 prior to issuance of
FASBI 46 (revised December 2003). Refer to FASBI 46 (revised December
2003) for effective date information.

♦ 3.

Does the primary beneficiary of a variable interest entity disclose the
following (unless the primary beneficiary also holds a majority voting
interest):
a. The nature, purpose, size, and activities of the variable interest
entity?
b. The carrying amount and classification of consolidated assets that
are collateral for the variable interest entity's obligations?

c. Lack of recourse if creditors (or beneficial interest holders) of a
consolidated variable interest entity have no recourse to the gen
eral credit of the primary beneficiary?
[FASBI 46(R), par. 2 (AC C54.123)]

FSP §11,200.03
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Yes

♦ 4.

No

N/A

Does an enterprise that holds a significant variable interest in a
variable interest entity but is not the primary beneficiary disclose:
a. The nature of its involvement with the variable interest entity and
when that involvement began?
b. The nature, purpose, size, and activities of the variable interest
entity?

c. The enterprise's maximum exposure to loss as a result of its
involvement with the variable interest entity?
[FASBI 46(R), par. 24 (AC C54.124)]
♦ 5.

Are the disclosures in paragraph 24 of FASBI 46(R) provided if a
reporting enterprise is not the primary beneficiary but holds a signifi
cant implicit variable interest in a variable interest entity?
[FSP FIN 46(R)-5, par. 6 (AC C54.823)]

Note: FSP FIN 46(R)-5 shall be applied in the first reporting period
beginning after March 3, 2005 for entities to which FASBI 46(R) has been
applied. For entities to which FASBI 46(R) has not been applied, FSP FIN
46(R)-5 is applied according to the effective date and transition provisions
in FASBI 46(R).
[FSP FIN 46(R)-5, par. 7 (AC C54.824)]

♦ 6.

Are disclosures required by SFAS140 about a variable interest entity
included in the same note to the financial statements as the informa
tion required by FASBI 46 (revised December 2003)?
[FASBI 46(R), par. 25 (AC C54.125)]

♦ 7.

If an entity does not apply FASBI 46 (revised December 2003) to one
or more variable interest entities or potential variable interest entities
because of the condition described in paragraph 4(g) of FASBI 46
(revised December 2003), is the following information disclosed:

a. The number of entities to which that Interpretation is not being
applied and the reason why the information required to apply that
Interpretation is not available?
b. The nature, purpose, size (if available), and activities of the entity(ies) and the nature of the enterprise's involvement with the
entity(ies)?

c. The reporting enterprise's maximum exposure to loss because of
its involvement with the entity(ies)?
d. The amount of income, expense, purchases, sales, or other meas
ure of activity between the reporting enterprise and the entity(ies)
for all periods presented? (However, if it is not practicable to
present that information for prior periods that are presented in the
first set of financial statements for which this requirement applies,
the information for those prior periods is not required.)
[FASBI 46(R), par. 26 (AC C54.126)]

♦ 8.

If it is reasonably possible that an enterprise will initially consolidate
or disclose information about a variable interest entity when FASBI
46 (revised December 2003) becomes effective, does the enterprise
disclose the following information in all financial statements initially
issued after December 31, 2003, regardless of the date on which the
variable interest entity was created:

FSP §11,200.03
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a. The nature, purpose, size, and activities of the variable interest
entity?
b. The enterprise's maximum exposure to loss as a result of its
involvement with the variable interest entity?
[FASBI 46(R), par. 271

♦ 9.

Is the effect of applying FASBI 46 (revised December 2003) to an entity
to which FASBI 46 had previously been applied reported as the
cumulative effect of an accounting change?
[FASBI 46(R), par. 39]

Note: SFAS 154, Accounting Changes and Error Corrections, which super
sedes APB 20, is effective for accounting changes made in fiscal years
beginning after December 15,2005. SFAS 154 does not change the transi
tion provisions of any existing accounting pronouncements, including
those in a transition phase as of the effective date of SFAS 154.
[SFAS 154, par. 27]

♦ 10. Is the excess, if any, of (a) the fair value of the newly consolidated
assets and (b) the reported amount of assets transferred by the primary
beneficiary to the variable interest entity over the sum of (1) the fair
value of the consideration paid, (2) the reported amount of any
previously held interests, and (3) the fair value of the newly consoli
dated liabilities and noncontrolling interests allocated and reported
as a pro rata adjustment of the amounts that would have been as
signed to all of the newly consolidated assets as specified in para
graphs 44 and 45 of SFAS 141, as if the initial consolidation had
resulted from a business combination?
[FASBI 46(R), par. 21 (AC C54.121)]

♦ 11. Is the excess, if any, of the sum of (a) the fair value of the consideration
paid, (b) the reported amount of any previously held interests, and (c)
the fair value of the newly consolidated liabilities and noncontrolling
interests over (1) the fair value of the newly consolidated identifiable
assets and (2) the reported amount of identifiable assets transferred
by the primary beneficiary to the variable interest entity reported in
the period in which the enterprise becomes the primary beneficiary
as:
a. Goodwill, if the variable interest entity is a business?
b. An extraordinary loss, if the variable interest entity is not a busi
ness?
[FASBI 46(R), par. 21 (AC C54.121)]

★♦ 12. For limited partnerships or similar entities in the scope of EITF 04-5,
Determining Whether a General Partner, or the General Partners as a Group,
Controls a Limited Partnership or Similar Entity When the Limited Partners
Have Certain Rights, and if the guidance in EITF 04-5 is in effect or is
applied:

a. If Transition Method A is used, (1) are prior year financial state
ments presented as previously reported; (2) is any cumulative
effect of adoption on retained earnings (or other appropriate
components of equity or net assets) at the beginning of the period
that the guidance is first applied, included in the opening balance
of retained earnings (or other appropriate components of equity
or net assets) in the period of change; (3) if early adoption in an

FSP §11,200.03
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Yes

No

N/A

interim period is elected, are the provisions of SFAS 3 applied,
except a cumulative-effect-type adjustment is recognized in begin
ning retained earnings (or other appropriate component of equity
or net assets); and (4) is the effect of adoption on the opening
balance sheet disclosed in the year of adoption?
b. If Transition Method B is used, is the guidance applied by retro
spective application and are the disclosures required by para
graph 17 of SFAS 154 presented?
[EITF 04-5, pars. 22-26]

Statement of Financial Position/Balance Sheet
A. General

★♦1.

2.

★ 3.

★ 4.

For classified statements of financial position/balance sheets, are
assets and liabilities segregated into current and noncurrent classifi
cations, with totals presented for current assets and current liabilities?
[ARB 43, Ch. 3A, pars. 2-8 (AC B05.103-.109); SFAS 78, pars. 5 and 13
(AC B05.102-.109B); SFAS 6, par. 15 (AC B05.118); FASBI8, par. 3 (AC
B05.117); TB 79-3, par. 2 (AC B05.501-.503); SFAS 117, par. 12 (AC
No5.110)]
Are assets not expected to be realized during the current operating
cycle classified as noncurrent?
[ARB 43, Ch. 3A, pars. 5 and 6 (AC B05.106 and .107)]

Does the statement of financial position/balance sheet report total
assets, liabilities, and net assets as well as separate amounts for each
of three classes of net assets with captions used to describe their
meaning as explained in SFAS 117?
[SFAS 117, pars. 10,13, and 100 (AC No5.108, .111, and .131, fn. a)]

★♦6.

B.

____

____

Does the entity provide information about liquidity by one or more
of the following presentations:
a. Sequencing assets according to their nearness of conversion to
cash and sequencing liabilities according to the nearness of their
maturity and resulting use of cash?

____

b. Classifying assets and liabilities as current and noncurrent?

____

c. Disclosing in notes to financial statements relevant information
about the liquidity or maturity of assets and liabilities, including
restrictions on the use of particular assets?
[SFAS 117, par. 12 (AC No5.110)]

5.

____

Are valuation allowances for assets shown as deductions from their
related assets with appropriate disclosure?
[APB 12, par. 3 (AC V18.102)]
Is the need for disclosure of the impact of a new FASB Statement,
issued but not yet effective where restatement of prior periods is
required, considered?
[SAS 1, secs. 9410.13-.18 (AU 9410.13-.18)]

____

____

____

Cash and Cash Equivalents

★♦1.

Is restricted cash appropriately segregated from cash available for
current operations?
[ARB 43, Ch. 3A, par. 6 (AC B05.107); AAG, par. 3.01]

____

FSP §11,200.03
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Yes

2.

Are restrictions on cash (such as for plant acquisition, debt reduction
or working capital maintenance) appropriately disclosed?
[SFAS 5, pars. 18 and 19 (AC C59.120)]

3.

Are personal funds of patients, residents and others under an agency
arrangement reported as unrestricted assets and corresponding li
abilities in the balance sheet/statement of financial position?
[AAG, par. 3.02]

★♦4.

If a concentration of credit risk arises from deposits in excess of
federally insured limits, is it disclosed?
[SFAS 107, as amended by SFAS 133, par. 531 (AC F25.116A); AAG,
par. 3.04]

5.

If the organization has material bank overdrafts or a material balance
of undelivered checks as of the statement-of-financial-position/
balance-sheet date, are:

a. Bank overdrafts presented as a separate caption within current
liabilities?

b. Undelivered checks classified as accounts payable?
[Generally Accepted]
6.

C.

Are internally designated funds reported separately from externally
designated funds?
[AAG, par. 3.01]

Investments

1.

Are investments reported as current or noncurrent assets in conform
ity with GAAP?
[AAG, par. 4.16]

★♦2.

Are the appropriate disclosures made for investments in common
stock accounted for by the equity method?
[APB 18, par. 20 (AC I82.110)]

3.

Are other investments (such as reed estate) reported at amortized cost,
(subject to impairment considerations consistent with SFAS 144, Ac
counting for the Impairment or Disposal of Long-Lived Assets)?
[AAG, par. 4.02]

♦ 4.

Are debt and equity securities classified as (a) held-to-maturity, (b)
available-for-sale, or (c) trading?
[SFAS 115, par. 6 (AC I80.103)]

♦ 5.

For securities classified as available-for-sale, has the reporting entity
made the following disclosures by major-security type as of each date
for which a statement of financial position is presented:

a. Aggregate fair value?
b. Total gains for securities with net gains in accumulated other
comprehensive income?

c. Total losses for securities with net losses in accumulated other
comprehensive income?
[SFAS 115, par. 19 (AC I80.118)]
♦ 6.

For securities classified as held-to-maturity, has the reporting entity
made the following disclosures by major-security type as of each date
for which a statement of financial position is presented:
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a. Aggregate fair value?

b. Gross unrecognized holding gains or losses?
c. Net carrying amount?

d. Gross gains and losses in accumulated other comprehensive in
come for any derivatives that hedged the forecasted acquisition of
the held-to-maturity securities?
[SFAS 115, par. 19 (AC I80.118)]
♦ 7.

For investments in debt securities classified as available-for-sale or
held-to-maturity:

a. Is disclosure made about their contractual maturities as of the date
of the latest balance sheet presented (maturity information may be
combined in appropriate groupings)?
b. If securities not due at a single date (such as mortgage-backed
securities) are allocated over several maturity groupings, is the
basis for allocation disclosed?
[SFAS 115, par. 20 (AC I80.119)]
♦ 8.

For each period for which an income statement is presented, are the
following disclosed:
a. The proceeds from sales of available-for-sale securities and gross
realized gains and losses that have been included in earnings as a
result of those sales?

b. The basis on which the cost of a security sold or the amount
reclassified out of accumulated other comprehensive income into
earnings was determined (i.e., specified identification, average
cost, or other method used)?

c. The gross gains and losses included in earnings from transfers of
securities from the available-for-sale category to the trading category?
d. The amount of the net unrealized holding gain or loss on availablefor-sale securities for the period that has been included in accumu
lated other comprehensive income and the amount of gains and
losses reclassified out of accumulated other comprehensive in
come into earnings for the period?

e. The portion of trading gains and losses for the period that relates
to trading securities still held at the reporting date?
[SFAS 115, par. 21 (AC I80.120)]
♦ 9.

For any sales of or transfers from securities classified as held-tomaturity, are the following disclosed for each period for which an
earnings statement is presented:

a. Net carrying amount of the sold or transferred security?
b. The net gain or loss in accumulated other comprehensive income
for any derivative that hedged the forecasted acquisition of the
held-to-maturity security?

c. Related realized or unrealized gain or loss?

d. The circumstances leading to the decision to sell or transfer the
security?
[SFAS 115, par. 22 (AC I80.121)]
♦ 10. If an option that is not a derivative subject to SFAS 133 (to purchase
securities that will be accounted for under SFAS 115) is classified as
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held-to-maturity or available-for-sale, is the accounting policy for the
premium paid to acquire the option disclosed?
[EITF 96-11]

★♦ 11. For financial instruments, are significant concentrations of credit risk
arising from concentrations of securities of a particular issuer dis
closed?
[SFAS 107, as amended by SFAS 133, par. 531 (AC F25.116A)]
★ 12. Are realized gains and losses; unrealized gains and losses; dividend,
interest, and other similar investment income; and other than tempo
rary impairment losses reported in the statement of activities as
increases or decreases in unrestricted net assets or in temporarily
restricted net assets or in permanently restricted net assets, depending
on the existence of or lack of donor restrictions or law?
[SFAS 124, pars. 8 and 9 (AC No5.154 and .155); AAG, pars. 4.07 and
4.08]

★ 13. Are realized gains and losses; dividend, interest and other similar invest
ment income; and other than temporary impairment losses included in
the performance indicator within the statement of activities?
[SFAS 124, par. 49; AAG, par. 4.07]
★ 14. Are unrealized gains and losses on trading securities (as defined in
SFAS 115) included in the performance indicator within the statement
of activities?
[SFAS 124, par. 49; AAG, par. 4.07]

★ 15. Are unrealized gains and losses on other than trading securities
excluded from the performance indicator within the statement of
activities?
[SFAS 124, par. 49; AAG, par. 4.07]

★ 16. If a provider reports gains and investment income that are limited to
specific uses by donor-imposed restrictions as increases in unre
stricted net assets because the restrictions are met in the same report
ing period as the gains and income are recognized, does the provider:
a. Have a similar policy for reporting contributions received?
b. Report consistently from period to period?
c. Disclose its accounting policy?
[SFAS 124, par. 10 (AC No5.156); AAG, par. 4.09]

★ 17. For each period that a statement of activities is presented, are the
following disclosures made on the face of the financial statements or
in the notes thereto:

a. The composition of investment return including, at a minimum,
investment income, net realized gains or losses on investments
reported at other than fair value, and net gains or losses on
investments reported at fair value?
b. A reconciliation of investment return to amounts reported in the
statement of activities, if investment return is separated into oper
ating and nonoperating amounts?

c. A description of the policy used to determine the amount of invest
ment return included in the measure of operations, if investment
return is separated into operating and nonoperating amounts?
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d. A discussion of circumstances leading to a change, if any, in the
policy referred to in Question 17c above?
[SFAS 124, par. 14 (AC No5.161); AAG, par. 4.11]

No

____

___

a. The aggregate carrying amount of investments by major types
(e.g., equity securities, corporate debt securities, etc.)?

____

___

b. The basis for determining the carrying amount for investments
other than equity securities with readily determinable fair values
and all debt securities?

____

___

c. The methods and assumptions used to estimate the fair values of
investments other than financial instruments, if those other invest
ments are reported at fair value?

____

___

____

___

____

___

____

___

N/A

★ 18. For each period for which a statement of financial position is pre
sented, are the following disclosures made on the face of the financial
statements or in the notes thereto:

d. The aggregate amount of the deficiencies for all donor-restricted
endowment funds, for which the fair value of the assets at the
reporting date is less than the level required by donor stipulations
or law?
[SFAS 124, par. 15 (AC No5.162); AAG, par. 4.11]

★ 19. For the most recent period for which a statement of financial position
is presented, does the provider disclose the nature of and carrying
amount for every individual investment or group of investments that
represents a significant concentration of market risk (market risk may
result from the nature of the investments, a lack of diversity of
industry, currency, or geographic location)?
[SFAS 124, pars. 16 and 86 (AC No5.163); AAG, par. 4.11]

20. Are significant net realized and net unrealized gains and losses that
arose after the latest statement of financial position date, but before
issuance of the financial statements, disclosed?
[SAS 1, sec. 560, pars. 5 and 7 (AU 560.05 and .07)]
Note: EITF 03-1, The Meaning of Other-Than-Temporary Impairment and Its
Application to Certain Investments, requires certain disclosures about unre
alized losses that have not been recognized as other-than-temporary
impairments. EITF 03-1 applies to debt and equity securities within the
scope of SFAS 115, Accounting for Certain Investments in Debt and Equity
Securities, and SFAS 124, Accounting for Certain Investments Held by Not-forProfit Organizations (applicable to investments held by a not-for-profit
health care organization in the scope of AAG). See EITF 03-1 for further
information regarding investments within the scope of this Issue.

★♦21. For all investments in an unrealized loss position for which otherthan-temporary impairments have not been recognized, do the an
nual financial statements disclose:
a. Quantitative information as of each date for which a statement of
financial position presented aggregated by each category of in
vestment that the investor discloses in accordance with SFAS 115
and SFAS 124 and cost method investments, in tabular form:
(1)

The aggregate amount of unrealized losses (that is, the
amount by which cost or amortized cost exceeds fair value),
segregated by those investments that have been in a continu
ous unrealized loss position for less than 12 months and those
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that have been in a continuous unrealized loss position for 12
months or longer?

____

____

____

The aggregate related fair value of investments with unreal
ized losses, segregated by those investments that have been
in a continuous unrealized loss position for less than 12
months and those that have been in a continuous unrealized
loss position for 12 months or longer?

____

____

____

____

____

____

a. The aggregate carrying amount of all cost method investments?

____

____

____

b. The aggregate carrying amount of cost method investments that
the investor did not evaluate for impairment?

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

(2)

b. Additional information in narrative form, as of the date of the most
recent statement of financial position, that provides sufficient
information to allow financial statement users to understand the
quantitative disclosures and the information that the investor
considered in reaching the conclusion that the impairments were
not other than temporary?
[EITF 03-1, par. 21]

22. For cost method investments, is the following additional information
disclosed in annual financial statements, if applicable, as of each date
for which a statement of financial position is presented:

c. The fact that the fair value of a cost method investment is not
estimated if there are no identified events or changes in circum
stances that may have a significant adverse effect on the fair value
of the investment and (1) the investor determined, in accordance
with paragraphs 14 and 15 of SFAS 107 that it is not practicable to
estimate the fair value of the investment, or (2) the investor is
exempt from estimating fair value under SFAS 126?
[EITF 03-1, par. 22]
D. Receivables and Loans
1.

★♦2.

Are charity care revenue and receivables excluded from the financial
statements?
[AAG, par. 5.03]
Are differences between the estimates originally reported and sub
sequent revisions, including final settlements:

a. Included in the statement of activities/income statement in the
period the revisions are made and disclosed, if material?
b. Reported in the current period unless they meet the criteria for
prior-period adjustments?
[AAG, par. 5.08; SFAS 16 (AC A35)]
3.

★ 4.

Are amounts due from third-party payors for retroactive adjustments
of items (such as final settlements or appeals) reported separately in
the financial statements?
[AAG, par. 5.21]

When displaying total assets and total liabilities, are interfund assets
and liabilities eliminated?1
[AAG, par. 5.27]1

1 The display of interfund items in a statement of financial position is not prohibited by SFAS 117. However, since interfund items are
not organizational assets or liabilities, those interfund items must be clearly labeled and arranged in the statement of financial position
to eliminate their amounts when total assets and liabilities are displayed. [SFAS 117, par. 85, fn. 8 (AC No5.109, fn. 4)]
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Note: Accounting for contributions is an issue primarily for not-for-profit
organizations because contributions are a significant source of revenues
for many of those organizations. However, SFAS 116 applies to all entities
(not-for-profit and business enterprises) that receive or make contribu
tions. [SFAS 116, par. 1 (AC C67.101)]

★ 5.

Do entities that receive unconditional promises to give disclose the
following:

a. The amounts of promises receivable in less than one year, in one
to five years, and in more than five years?
b. The amount of any allowance for uncollectible promises receivable?
[SFAS 116, par. 24 (AC C67.121)]

★ 6.

Do entities that receive conditional promises to give disclose the
following:

a. The total of the amounts promised?

b. A description and amount for each group of promises having
similar characteristics (such as amount of promises conditioned
on establishing new programs, completing a new building, and
raising matching gifts by a specified date)?
[SFAS 116, par. 25 (AC C67.122)]

7.

Are all receivables reported net of any related allowance for uncol
lectible amounts, with appropriate disclosure?
[AAG, par. 5.21; APB 12, par. 3 (AC V18.102)]

★♦8.

Are accounts and notes receivable from officers, employees, and
affiliated organizations shown separately with appropriate disclosures?
[ARB 43, Ch. 1A, par. 5 (AC R36.105)]

9.

For financial instruments, are significant concentrations of credit risk
arising from receivables disclosed?
[SFAS 107, as amended by SFAS 133, par. 531 (AC F25.116A)]

10. Are unearned discounts (other than cash or quantity discounts and
the like), finance charges, and interest included in the face amounts of
receivables shown as a deduction from the related receivables?
[APB 6, par. 14 (AC B05.107A, note 3)]

★♦11. Does the summary of significant accounting policies include the
following disclosures:
a. The basis of accounting for loans, trade receivables, and lease
financings, including those classified as held for sale?
b. The method of determining the lower of cost or fair value of
nonmortgage loans held for sale (that is, aggregate or individual
asset basis)?
c. The classification and method of accounting for loans and other
receivables that can be contractually prepaid or otherwise settled
in a way that the holder would not recover substantially all of its
recorded investment (applies to instruments within the scope of
paragraph 14 of SFAS 140)?

d. The method for recognizing interest income on loan and trade
receivables, including a statement about the entity's policy for
treatment of related fees and costs, including the method of amor
tizing net deferred fees or costs?

FSP §11,200.03

18

Health Care Organizations

Yes

e. A description of the accounting policies and methodology the
entity used to estimate its allowance for loan losses, allowance for
doubtful accounts, and any liability for off-balance sheet credit
losses and related charges for loan, trade receivable or other credit
losses, including a description of the factors that influenced man
agement's judgment?

The policy for placing loans (and trade receivables if applicable)
on nonaccrual status (or discontinuing accrual of interest) and
recording payments received on nonaccrual loans (and trade re
ceivables if applicable), and the policy for resuming accrual of
interest?
g. The policy for charging off uncollectible loans and trade receiv
ables?

f.

h. The policy for determining past due or delinquency status (that is,
whether past due status is based on how recently payments have
been received or contractual terms?
[SOP 01-6, par. 13(a)-(c)]
12. Is the aggregate amount of gains or losses on sales of loans or trade
receivables presented separately in the financial statements or dis
closed in the notes?
[SOP 01-6, par. 13(d)]

13. Are loans and trade receivables held for sale presented as a separate
balance sheet category?
[SOP 01-6, par. 13(e)]
14. Are major categories of loans and trade receivables presented sepa
rately in the balance sheet or in the notes to the financial statements?
[SOP 01-6, par. 13(e)]
15. Are the allowances for credit losses and doubtful accounts disclosed?
[SOP 01-6, par. 13(e)]
16. Is the recorded investment in loans (and trade receivables, if applica
ble), on nonaccrual status as of each balance-sheet date disclosed in
the notes to the financial statements? (The recorded investment in
loans, and if applicable, trade receivables, past due ninety days or
more and still accruing should also be disclosed.)
[SOP 01-6, par. 13(g)]
17. Is the carrying amount of loans and trade receivables that serve as
collateral for borrowings disclosed pursuant to paragraphs 18 and 19
of SFAS 5?
[SOP 01-6, par. 13(i)]
18. Is a description of the accounting policies and methodology used to
estimate the allowance for doubtful accounts, allowance for loan
losses and any liability for off-balance-sheet credit losses and related
charges for loan, trade receivable or other credit losses included in the
notes to the financial statements? (Note: Such description should
identify the factors that influenced management's judgment.)
[SOP 01-6, par. 13(b)]

Note: SOP 03-3, Accounting for Certain Loans or Debt Securities Acquired in
a Transfer, is effective for loans acquired in fiscal years beginning after
December 15,2004. Early application is encouraged.
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19. Do the notes to the financial statements describe how prepayments
are considered in the determination of contractual cash flows and cash
flows expected to be collected?
[SOP 03-3, par. 14]

20. Is information about loans meeting the scope criteria of paragraph 3
of SOP 03-3 included in the disclosures required by paragraphs 20(a)
and 20(b) of SFAS 114 if the condition in paragraph 16 of SFAS 115 or
paragraph 8(a) of SFAS 5 is met?
[SOP 03-3, par. 15]
21. In addition to disclosures required by other GAAP principles, for each
balance sheet presented, is the following information disclosed by an
investor about loans within the scope of SOP 03-3:
a. Separately for both those loans that are accounted for as debt
securities and those loans that are not accounted for as debt
securities:

(1)

The outstanding balance and the related carrying amount at
the beginning and end of the period?

(2)

The amount of accretable yield at the beginning and end of
the period, reconciled for additions, accretion, disposal of
loans, and reclassifications to or from nonaccretable differ
ence during the period?

(3)

For loans acquired during the period, the contractually re
quired payments receivable, cash flows expected to be col
lected, and fair value at the acquisition date?

(4)

For those loans within the scope of SOP 03-3 for which the
income recognition model in SOP 03-3 is not applied in accord
ance with paragraph 6 of that SOP, the carrying amount at the
acquisition date for loans acquired during the period and the
carrying amount of all loans at the end of the period?

b. Further, for those loans that are not accounted for as debt securi
ties, does an investor disclose:

(1)

The amount of (a) any expense recognized pursuant to para
graph 8(a) of SOP 03-3 and (b) any reductions of the allowance
recognized pursuant to paragraph 8(b)(1) of SOP 03-3 for
each period for which an income statement/statement of
operations is presented?

(2)

The amount of the allowance for uncollectible accounts at the
beginning and end of the period?
[SOP 03-3, par. 16]

E. Beneficial Interests in Assets Held by Others

★ 1.

If the organization transferred assets to another entity and specified
itself or its affiliate as the beneficiary, has it disclosed the following
for each period in which a statement of financial position is presented:

a. The identity of the recipient organization to which the transfer was
made?

b. Whether variance power was granted to the recipient organization
and, if so, a description of the terms of the variance power?

c. The terms under which amounts will be distributed to the organi
zation or its affiliate?
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d. The aggregate amount recognized in the statement of financial
position for those transfers and whether that amount is recorded
as an interest in the net assets of the recipient organization or as
another asset (such as a beneficial interest in assets held by others
or as a refundable advance)?
[SFAS 136, par. 19 (AC No5.177)]
F. Property and Equipment, and Supplies

1.

2.

Are donor or legal restrictions on the proceeds from the disposition
of donated property and equipment (or of property and equipment
purchased with cash restricted for acquisition of long-lived assets)
disclosed?
[AAG, par. 6.07]
For depreciable assets, do the financial statements or notes disclose:

a. Depreciation expense for each period?
b. Balances of major classes of depreciable assets by nature or function?

c. Accumulated depreciation, either by major classes of assets or in
total?
d. The method or methods used in computing depreciation with
respect to major classes of depreciable assets?
[APB 12, par. 5 (AC D40.105)]
3.

Is the amount of interest cost incurred and charged to expense during
the period disclosed for an accounting period in which no interest cost
is capitalized?
[SFAS 34, par. 21a (AC I67.118)]

★♦4.

Is the amount of interest cost incurred during the period and the
amount that has been capitalized disclosed for an accounting period
in which some interest cost is capitalized?
[SFAS 34, par. 21b (AC I67.118)]

5.

★♦6.

7.

Are material commitments for property expenditures disclosed?
[SFAS 5, pars. 18 and 19 (AC C59.120)]
For an existing property with an asbestos problem, are the costs
incurred to treat the problem, if charged to expense, not classified as
an extraordinary item?
[EITF 89-13]
Is the method of determining inventory cost disclosed?
[ARB 43, Ch. 3A, par. 9 (AC I78.120)]

Notes: If the provisions of SFAS 151, Inventory Costs, are in effect or are
applied, see Question 8. SFAS 151, an amendment of ARB 43, Chapter 4,
is effective for inventory costs incurred during fiscal years beginning after
June 15,2005. Early application is permitted for inventory costs incurred
during fiscal years beginning after the date SFAS 151 was issued (Novem
ber 2004).
[SFAS 151, par. 5]
SFAS 154, Accounting Changes and Error Corrections, which supersedes APB
20, is effective for accounting changes made in fiscal years beginning after
December 15,2005. SFAS 154 does not change the transition provisions of
(continued)
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any existing accounting pronouncements, including those in a transition
phase as of the effective date of SFAS 154.
[SFAS 154, par. 27]

★♦8.

G.

Are the disclosures required by paragraph 19(c) of APB 20 made if
there are significant changes to an entity's inventory accounting as a
result of adopting SFAS 151?
[SFAS 151, par. 4]

Deferred Income Tax Assets and Liabilities

♦ 1.

In a classified balance sheet:
a. Are deferred tax assets and deferred tax liabilities classified as
current or noncurrent based on the classification of the related
asset or liability for financial reporting?
[SFAS 109, par. 41 (AC I27.140)]
b. Are deferred tax assets or liabilities not related to an asset or
liability for financial reporting (including those related to carry
forwards) classified according to the expected reversal date of the
temporary difference pursuant to SFAS 37?
[SFAS 109, par. 41 (AC I27.140)]
c. Is the valuation allowance for a particular tax jurisdiction allocated
between current and noncurrent deferred tax assets for that tax
jurisdiction on a pro rata basis?
[SFAS 109, par. 41 (AC I27.140)]

d. Are the following items offset and presented as a single amount
for a particular taxpaying component and within a particular
taxpaying jurisdiction:

♦ 2.

(1)

All current deferred tax liabilities and assets?

(2)

All noncurrent deferred tax liabilities and assets?
[SFAS 109, par. 42 (AC I27.141)]

Are the components of the net deferred tax liability or asset recog
nized in the balance sheet disclosed as follows:

a. The total of all deferred tax liabilities (measured as described in
paragraph 17b of SFAS 109)?

b. The total of all deferred tax assets (measured as described in
paragraph 17c and 17d of SFAS 109)?
c. The total valuation allowance recognized for deferred tax assets
(determined as described in paragraph 17e of SFAS 109)?
[SFAS 109, par. 43 (AC I27.142)]

♦ 3.

Is the net change during the year in the total valuation allowance
disclosed?
[SFAS 109, par. 43 (AC I27.142)]

♦ 4.

If the reporting entity is a public enterprise, is the approximate tax
effect of each type of temporary difference and carryforward that
gives rise to a significant portion of deferred tax liabilities and de
ferred tax assets (before valuation allowances) disclosed?
[SFAS 109, par. 43 (AC I27.142)]

♦ 5.

If the reporting entity is a nonpublic enterprise, are the types of
significant temporary differences and carryforwards disclosed?
[SFAS 109, par. 43 (AC I27.142)]
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H.

Intangible Assets and Goodwill
Note: Questions 1 through 16 apply if the provisions of SFAS 142, Good
will and Other Intangible Assets, are applied to the financial statements. The
provisions of SFAS 142 are required to be applied starting with fiscal years
beginning after December 15,2001. SFAS 142 is required to be applied at
the beginning of an entity's fiscal year and to be applied to all goodwill
and other intangible assets recognized in its financial statements at that
date. The provisions of SFAS 142 should not be applied to goodwill and
intangible assets acquired in a combination between not-for-profit organi
zations or arising from the acquisition of a for-profit business entity by a
not-for-profit organization until the FASB completes its project on those
types of combinations. (Refer to paragraphs 48 through 61 of SFAS 142 for
effective date and transition guidance.) If the provisions of APB 16 and
APB 17 are applied, see Questions 13 and 14.

★♦1.

At a minimum, are all intangible assets aggregated and presented as
a separate line item in the statement of financial position? (This
requirement does not preclude presentation of individual intangible
assets or classes of intangible assets as separate line items.)
[SFAS 142, par. 42 (AC G40.141)]

2.

Are amortization expense and impairment losses for intangible assets
presented in income statement line items within continuing opera
tions as deemed appropriate for each entity?
[SFAS 142, par. 42 (AC G40.141)]

♦ 3.

Is the aggregate amount of goodwill presented as a separate line item
in the statement of financial position?
[SFAS 142, par. 43 (AC G40.142)]

♦ 4.

Is the aggregate amount of goodwill impairment losses presented as
a separate line item in the income statement before the subtotal income
from continuing operations (or similar caption) unless a goodwill im
pairment loss is associated with a discontinued operation?
[SFAS 142, par. 43 (AC G40.142)]

♦ 5.

Is a goodwill impairment loss associated with a discontinued opera
tion included (on a net-of-tax basis) within the results of discontinued
operations?
[SFAS 142, par. 43 (AC G40.142)]

6.

For intangible assets acquired either individually or with a group of
assets, is the following information disclosed in the notes to the
financial statements in the period of acquisition:

a. For intangible assets subject to amortization:
(1)

The total amount assigned and the amount assigned to any
major intangible asset class?

(2)

The amount of any significant residual value, in total and by
major intangible asset class?

(3)

The weighted-average amortization period, in total and by
major intangible asset class?

b. For intangible assets not subject to amortization, the total amount
assigned and the amount assigned to any major intangible asset
class?
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c. The amount of research and development assets acquired and
written off in the period and the line item in the income statement
in which the amounts written off are aggregated?
[SFAS 142, par. 44 (AC G40.143)]
7.

Has the following information been disclosed in the financial state
ments or the notes to the financial statements for each period for which
a statement of financial position is presented:
a. For intangible assets subject to amortization:
(1)

The gross carrying amount and accumulated amortization, in
total and by major intangible asset class?

(2) The aggregate amortization expense for the period?
(3)

The estimated aggregate amortization expense for each of the
five succeeding fiscal years?

b. For intangible assets not subject to amortization, the total carrying
amount and the carrying amount for each major intangible asset
class?
♦ c. The changes in the carrying amount of goodwill during the period
including:

(1)

The aggregate amount of goodwill acquired?

(2)

The aggregate amount of impairment losses recognized?

(3)

The amount of goodwill included in the gain or loss on
disposal of all or a portion of a reporting unit?
[SFAS 142, par. 44 (AC G40.144)]

♦ 8.

If the entity reports segment information in accordance with SFAS
131, is the above information about goodwill provided in total and for
each reportable segment and are any significant changes in the allo
cation of goodwill by reportable segment disclosed?
[SFAS 142, par. 45 (AC G40.144)]

♦ 9.

If any portion of goodwill has not yet been allocated to a reporting
unit at the date the financial statements are issued, is that unallocated
amount and the reasons for not allocating that amount disclosed?
[SFAS 142, par. 45 (AC G40.144)]

10. For each impairment loss recognized related to an intangible asset, is
the following information disclosed in the notes to the financial
statements that include the period in which the impairment loss is
recognized:

a. A description of the impaired intangible asset and the facts and
circumstances leading to the impairment?
b. The amount of the impairment loss and the method for determin
ing fair value?

c. The caption in the income statement in which the impairment loss
is aggregated?
d. If applicable, the segment in which the impaired intangible asset
is reported under SFAS 131?
[SFAS 142, par. 46 (AC G40.145)]
♦ 11. For each goodwill impairment loss recognized, is the following infor
mation disclosed in the notes to the financial statements that include
the period in which the impairment loss is recognized:
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a. A description of the facts and circumstances leading to the impair
ment?

b. The amount of the impairment loss and the method of determining
the fair value of the associated reporting unit (whether based on
quoted market prices, prices of comparable businesses, a present
value or other valuation technique, or a combination thereof)?
c. If a recognized impairment loss is an estimate that has not yet been
finalized (refer to SFAS 142, par. 22), that fact and the reasons
therefore and, in subsequent periods, the nature and amount of
any significant adjustments made to the initial estimate of the
impairment loss?
[SFAS 142, par. 47 (AC G40.146)]
♦ 12. Are effects on a goodwill impairment charge resulting from the
application of EITF 04-1 reported in operating income?
[EITF 04-1, par. 9]

Note: EITF 04-1, Accounting for Preexisting Relationships between the Parties
to a Business Combination, should be applied to business combinations
consummated and goodwill impairment tests performed in reporting
periods beginning after October 13, 2004. Early application permitted in
periods for which financial statements have not been issued.
[EITF 04-1, pars. 9-101
13. Do disclosures relating to intangible assets include the method and
period of amortization?
[APB 16, par. 95e (AC B50.164e); APB 17, par. 30 (AC I60.111); APB
22, par. 13 (AC A10.106)]

★ 14. Do disclosures relating to intangible assets include the reason for any
unusual reduction of the value and future benefits of intangible assets
recognized during the period?
[APB 17, par. 31 (AC I60.112)]
I.

Current Liabilities

★♦1.

For classified balance sheets and classified statements of financial
position, do current liabilities include:

a. Obligations for items that entered the operating cycle?

b. Collections received in advance of the performance of services?
c. Debts that arise from operations directly related to the operating
cycle?

d. Other liabilities whose regular and ordinary liquidation is likely
to occur within a relatively short time period?
e. Obligations that, by their terms, are due on demand or will be due
within one year (or operating cycle, if longer) from the balancesheet date, even though liquidation may not be expected within
that period?
[ARB 43, Ch. 3A, pars. 7 and 8 (AC B05.108 and .109); SFAS 78, par.
5 (AC B05.109A)]

2.

Do current liabilities exclude short-term obligations that the provider
intends to refinance on a long-term basis, provided the provider has
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demonstrated the ability to consummate the long-term financing?
[SFAS 6, pars. 8-14 (AC B05.113-.116); FASBI 8, pars. 2-4 (AC B05.117,
.138, and .139)]
3.

In classified statements of financial position and in classified balance
sheets, are current portions of debt obligations presented as current
liabilities?
[ARB 43, Ch. 3A, pars. 7 and 8 (AC B05.108 and .109)]

Note: Current liabilities may include notes payable to banks; the current
portion of long-term debt; accounts payable; advances from and amounts
payable to third-party payors for estimated and final reimbursement
settlements; refunds to and deposits from patients and others; deferred
revenue; accrued salaries and payroll taxes; and other accruals.
[AAG, par. 7.01]
J.

Notes Payable and Other Debt

★♦1.

Is there adequate disclosure of interest rates, maturities, and other
terms and conditions provided in loan agreements and bond inden
tures (such as assets pledged as collateral, and covenants to reduce
debt, and maintain working capital)?
[SFAS 5, par. 18 (AC C59.120)]

2.

Are the combined aggregate amounts of maturities and sinking fund
requirements for all long-term borrowings disclosed for each of the
five years following the date of the latest balance sheet presented?
[SFAS 47, par. 10b (AC C32.105b)]

3.

For unconditional purchase obligations that have been recorded in
accordance with SFAS 47, paragraph 6, is the amount of payments
due in the aggregate and for every year during the five years following
the date of the latest statement of financial position/ balance sheet
presented disclosed?
[SFAS 47, par. 10a (AC C32.105a)]

4.

If a note is non-interest-bearing or has an inappropriate stated interest
rate:
a. Is the discount or premium presented as a deduction from or
addition to the face amount of the note?
b. Does the disclosure include the effective interest rate and face
amount of the note?
c. Is amortization of the discount or premium reported as interest?

d. Are issue costs reported in the balance sheet/statement of finan
cial position as deferred charges?
[APB 21, par. 16 (AC I69.109)]

★♦5.

Are debt conversion features (such as rates and pertinent dates)
disclosed?
[APB 14 (AC D10)]

6.

If a short-term obligation is to be excluded from current liabilities in
a classified balance sheet/statement of financial position, do disclo
sures include:
a. General description of the financing agreement?
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b. Terms of any new obligation incurred or expected to be incurred,
or equity securities issued or expected to be issued as a result of
the refinancing?
[SFAS 6, par. 15 (AC B05.118)]

7.

For a troubled debt restructuring occurring during the current period,
do disclosures include:

a. Description of the principle changes in terms and/or the major
features of settlement?
b. Aggregate gain on restructuring of payables?
c. Aggregate net gain or loss on transfers of assets recognized during
the period?

d. Per-share amount, if applicable, of the aggregate gain on restruc
turing of payables?
[SFAS 15, par. 25, as amended by SFAS 145 (AC D22.121)]
8.

For periods after a troubled debt restructuring, do disclosures include:
a. Extent to which amounts contingently payable are included in the
carrying amount of restructured payables?
b. Total amounts contingently payable, if applicable, and conditions
under which those amounts would become payable or forgiven?
[SFAS 15, par. 26 (AC D22.122)]

★♦9.

If debt was considered to be extinguished under the provisions of
SFAS 76 prior to the effective date of SFAS 125, do disclosures include:

a. A general description of the transaction?

b. The amount of debt that is considered extinguished at the end of
the period as long as the debt remains outstanding?
[SFAS 140, par. 17b (AC L35.109)]
10. If assets are set aside after the effective date of SFAS 125 solely for
satisfying scheduled payments of a specific obligation, is disclosure
made describing the nature of restrictions placed on those assets?
[SFAS 140, par. 17c (AC L35.109)]
Note: SOP 02-2, Accounting for Derivative Instruments and Hedging Activi
ties by Not-for-Profit Health Care Organizations, and Clarification of the Per
formance Indicator, addresses the reporting by not-for-profit health care
organizations of gains or losses on hedging derivative instruments under
SFAS 133, as amended, and requires that not-for-profit health care organi
zations apply the provisions of SFAS 133, including the provisions per
taining to cash flow hedge accounting, in the same manner as for-profit
enterprises. The provisions of SOP 02-2 are effective for fiscal years
beginning after June 15, 2003. Earlier application is encouraged but per
mitted only as of the beginning of any fiscal quarter that begins after
issuance of SOP 02-2. See paragraphs 10 and 11 of SOP 02-2 for additional
effect date and transition information.

♦ 11. If the reclassification to earnings of the amount in accumulated com
prehensive income resulting from a cash flow hedge of debt is re
quired under SFAS 133 when the debt is extinguished, is the
reclassified amount not classified as extraordinary?
[EITF 00-9]
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★♦ 12. Are long-term obligations that are or will be callable by the creditor,
either because the debtor's violation of the debt agreement at the
balance-sheet/statement-of-financial-position date makes the obliga
tion callable, or because the violation (if not cured within a specified
grace period) will make the obligation callable, classified as current
unless one of the following conditions is met:
a.

The creditor waives or subsequently loses the right to demand
repayment for more than one year (or operating cycle, if longer)
from the balance-sheet date?

____

___

____

___

____

___

____

___

____

___

____

___

____

___

____

___

____

___

____

___

b. The obligation contains a grace period within which the debtor

may cure the violation and it is probable that the violation will be
cured within that period, thus preventing the violation from be
coming callable?
[SFAS 78, par. 5 (AC B05.109A)]
13. If an obligation under Question 12b above is included in long-term
liabilities (or in the case of an unclassified balance sheet is included as
a long-term liability in the disclosure of debt maturities), are the
circumstances disclosed?
[SFAS 78, par. 5 (AC B05.118); see also EITF 86-301

★ 14. Does the not-for-profit provider report tax-exempt obligations that
were issued for its benefit as liabilities if the provider is responsible
for repayment?
[AAG, par. 7.17]
★♦15. Are disclosures appropriate regarding the provider's tax-exempt
status and any other significant tax matters?
[AAG, par. 7.12]
K. Other Liabilities and Deferred Credits

★♦ 1.

★♦ 2.

L.

If the reporting entity has not accrued compensated absences (SFAS
43) because the amount cannot be reasonably estimated, is that fact
disclosed?
[SFAS 43, par. 6 (AC C44.104)]
If an obligation for postemployment benefits is not accrued in accord
ance with SFAS 5 or SFAS 43 only because the amount cannot be
reasonably estimated, is the fact that the benefits have not been
accrued disclosed in the financial statements?
[SFAS 112, par. 7 (AC P32.105)]

Net Assets/Shareholders' Equity
★ 1.

★♦ 2.
★ 3.

Are the equity accounts of investor-owned providers presented in a
similar fashion as other investor-owned businesses?
[AAG, par. 9.01]
Is the nature of restrictions on donor-restricted resources disclosed?
[AAG, par. 9.06]

Are limits on the use of unrestricted net assets (such as loan covenants
and board-designated endowments) and information about the na
ture and amounts of different types of permanent and temporary
restrictions disclosed?
[SFAS 117, par. 16 (AC No5.114); AAG, pars. 9.03 and 9.04]
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★ 4.

Are net assets released from restriction, such as those related to the
fufillment of time or purpose restrictions, reported separately in the
financial statements or disclosed in the notes?
[AAG, par. 10.08]

♦ 5.

Shareholders' equity (corporations):

a. For each class of stock, do disclosures include the number of shares
authorized, issued and outstanding, and par or stated value per
share and changes therein?
[Generally Accepted]
b. Are classes of capital stock presented in order of priority in liqui
dation?
[Generally Accepted]
c. Do the financial statements include a description, in summary
form, sufficient to explain the pertinent rights and privileges of the
various securities outstanding, (e.g., dividend and liquidation
preferences, participation rights, call prices and dates, conversion
or exercise prices or rates and pertinent dates, sinking fund re
quirements, unusual voting rights, significant terms of contracts
to issue additional shares)?
[SFAS 129, par. 4 (AC C24.102)]

d. Do disclosures include the number of shares issued upon conver
sion, exercise, or satisfaction of required conditions during at least
the most recent annual fiscal period and any subsequent interim
period presented?
[SFAS 129, par. 5 (AC C24.103)]
e. Are the following disclosed on the face of the statement of financial
position or in the notes:

f.

(1)

The aggregate or per-share amounts at which preferred stock
may be called or is subject to redemption through sinkingfund operations or otherwise?

(2)

The aggregate and per-share amounts of arrearages in cumu
lative preferred dividends?
[SFAS 129, par. 7 (AC C24.105)]

For preferred stock that has a preference in involuntary liquida
tion considerably in excess of par or stated value of the shares, is
the liquidation preference disclosed? (Note: Disclosure shall be
made in the equity section of the statement of financial position in
the aggregate, either parenthetically or "in short," rather than on
a per-share basis or through disclosure in the notes.)
[SFAS 129, par. 6 (AC C24.104)]

g. For redeemable stock, do disclosures include the amount of re
demption requirements, separately by issue or combined, for all
issues of capital stock that are redeemable at fixed or determinable
prices on fixed or determinable dates in each of the five years follow
ing the date of the latest statement of financial position presented?
[SFAS 129, par. 8 (AC C24.106)]
h. Are significant terms of the conversion features of contingently
convertible securities disclosed to enable users of financial state
ments to understand the circumstances of the contingency and the
potential impact of conversion?
[FSP FAS 129-1, par. 3 (AC C24.804)]
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Do disclosures indicate whether the shares that would be issued
if the contingently convertible securities were converted are in
cluded in the calculation of diluted earnings per share, and the
reasons why or why not?
[FSP FAS 129-1, par. 4 (AC C24.805)]

Note: Disclosures of information about derivative transactions entered
into in connection with the issuance of the contingently convertible secu
rities may be useful in terms of fully explaining the potential impact of the
contingently convertible securities.
[FSP FAS 129-1, par. 5 (AC C24.806)]
j. Are applicable disclosures required by SFAS 129 made for instru
ments within the scope of EITF 05-2?
[EITF 05-2, par. 10]

Note: EITF 05-2, The Meaning of "Conventional Convertible Debt Instrument"
in EITF Issue No. 00-19, "Accounting for Derivative Financial Instruments
Indexed to, and Potentially Settled in, a Company's Own Stock," should be
applied to new instruments entered into and instruments modified in
periods beginning after June 29,2005.
[EITF 05-2, pars. 11-12]

k. Are any appropriations of retained earnings for loss contingencies
clearly identified and included in stockholders' equity?
[SFAS 5, par. 15 (AC R70.103)]

l.

Are restrictions on payment of dividends disclosed?
[SFAS 5, pars. 18 and 19 (AC C59.120)]

m. Are receivables for stock issued or subscribed appropriately iden
tified and presented as a deduction from capital or, if presented as
an asset, stated separately, clearly labeled, and their status clearly
described to distinguish them from any other type of assets?
n. Are the carrying basis, the cost and the number of shares disclosed
for treasury stock?
[Generally Accepted]
o. After completion of a quasi-reorganization, is a new retained
earnings account established and dated with the date being dis
closed in subsequent financial statements until it is no longer
deemed significant?
[ARB 43, Ch. 7A, par. 10; ARB 46, par. 2 (AC Q15.111)]

p. If state laws relating to acquisition of stock restrict the availability
of retained earnings for payment of dividends or other significant
effects, is appropriate disclosure made?
[APB 6, par. 13 (AC C23.104)]
♦ 6.

If interim financial reports contain an adjustment related to prior
interim periods of the current fiscal year, do disclosures include:

a. The effect on income from continuing operations, net income, and
related per share amounts for each prior interim period of the
current fiscal year?

b. Income from continuing operations, net income, and related per
share amounts for each prior interim period restated?
[SFAS 16, par. 15 (AC A35.111)]
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♦ 7.

If the reporting entity is a publicly traded company and if interim
financial data and disclosures are not separately reported for the
fourth quarter, are accounting changes made during the fourth quar
ter, disposals of components of an entity, extraordinary, unusual or
infrequently occurring items recognized in the fourth quarter, and the
aggregate effect of year-end adjustments that are material to the
results of the quarter disclosed in a note to the annual financial
statements?
[APB 28, par. 31 (AC I73.147)1

Note: If the provisions of SFAS 154, Accounting Changes and Error Correc
tions, are in effect or are applied, delete Question 8 and refer to "Other
Financial Statement Disclosures, Section A—Accounting Changes and
Error Corrections." SFAS 154 supersedes SFAS 3. SFAS 154 is effective
for accounting changes made in fiscal years beginning after December
15, 2005. Early adoption is permitted for accounting changes made in
fiscal years beginning after the date SFAS 154 is issued (May 2005).
[SFAS 154, par. 27]

♦ 8.

9.

If the reporting entity is a publicly traded company, is disclosure
about the effect of accounting changes on interim periods that are
required by paragraphs 23-26 of APB 28 or by paragraphs 9-13 of
SFAS 3 included in a note to the financial statements for the fiscal year
in which the change is made?
[SFAS 3, par. 14]
Changes in net assets/shareholders' equity:

a. When both financial position and results of operations are presented:
(1)

Are changes in the separate accounts of equity disclosed?
[APB 12, par. 10 (AC C08.102)]

(2)

Are changes in the number of shares of equity securities
disclosed for at least the latest year and any subsequent
interim periods presented (for-profit only)?
[APB 12, par. 10 (AC C08.102)]

b. If prior-period adjustments have been recorded during the current
year, are their resulting effects (both gross and net of applicable
income taxes and including the amounts of income tax applicable
to the prior period adjustments) appropriately disclosed?
(1)

For single-period statements, does the disclosure indicate the
effects of such restatement on the balance of retained earn
ings/net assets at the beginning of the period and on the net
income/change in net assets of the immediately preceding
period?

(2)

If financial statements of more than one period are presented,
does disclosure include the effects for each of the periods
presented in the statements?
[APB 9, par. 26 (AC A35.107)]

Note: If the provisions of SFAS 154, Accounting Changes and Error Correc
tions, are in effect or are applied, delete Question 9c and refer to "Other
Financial Statement Disclosures, Section A—Accounting Changes and
(continued)
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Error Corrections." SFAS 154 supersedes APB 20. SFAS 154 is effective for
corrections of errors made in fiscal years beginning after December 15,
2005. Early adoption is permitted for corrections of errors made in fiscal
years beginning after the date SFAS 154 is issued (May 2005).
[SFAS 154, par. 271

c. Is the correction of an error in the financial statements of a prior
period discovered subsequent to their issuance reported as a prior
period adjustment, with disclosure of the following in the period
in which the error was discovered and corrected:
(1)

Nature of the error in previously issued financial statements?

____

(2)

Effect of its correction on income before extraordinary items,
net income, and related per-share amounts, if applicable?
[APB 20, par. 37 (AC A35.105)]

____

M. Restricted Resources

★ 1.

★ 2.

★ 3.

Are cash or other assets received with a donor-imposed restriction
that limits their use to long-term purposes reported separately from
assets that are unrestricted and available for current use?
[SFAS 117, par. 11 (AC No5.109)]
Does the entity provide information about the nature and amounts of
different types of permanent restrictions and temporary restrictions
by reporting their amounts on the face of the statement of financial
position or by including relevant details in notes to financial statements?
[SFAS 117, par. 14 (AC No5.112)]
Is property and equipment that is donor-restricted reported as tem
porarily or permanently restricted assets?
[SFAS 116, par. 14 (AC No5.143)]

____

____

____

Statement of Activities/Income Statement/Statement of
Operations/Statement of Changes in Net Assets
A. General

★ 1.

★ 2.

★ 3.

Does the statement of activities/operations or statement of changes
in net assets report the amount of change in net assets for the period
for the provider as a whole (using a descriptive term such as "change
in net assets" or "change in equity"), and does that amount articulate
to the net assets reported in the statement of financial position?
[SFAS 117, par. 18 (AC No5.116)]

Does the statement of activities/operations or the statement of
changes in net assets report the amount of change in permanently
restricted net assets, temporarily restricted net assets, and unre
stricted net assets for the period?
[SFAS 117, par. 19 (AC No5.117)]

____

____

Does the statement of activities/operations report the following:

a. Revenues as increases in unrestricted net assets unless the use of
the assets received is limited by donor-imposed restrictions?

____

b. Expenses as decreases in unrestricted net assets?

____
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c. Events that simultaneously increase one class of net assets and
decrease another (reclassifications), including expiration of donorimposed restrictions, separately from revenues, expenses, gains,
and losses?

d. Gains and losses as increases or decreases in unrestricted net assets
unless a donor or law temporarily or permanently restrict their use?
[SFAS 117, pars. 19,20, and 22 (AC No5.117, .118, and .119); SFAS
116, par. 17 (AC No5.147)]

★ 4.

Are revenues and expenses (arising from ongoing activities associated
with health care services) displayed as gross amounts?
[SFAS 117, par. 24 (AC No5.121)]

★ 5.

If the provider elects to report investment revenues net of related
expenses, does the provider disclose the amount of expenses, either
on the face of the statement of activities or in the notes to the financial
statements?
[SFAS 117, par. 24 (AC No5.121)]

★ 6.

If the entity reports an intermediate measure of operations (for exam
ple, excess or deficit of operating revenues over expenses), is this
intermediate measure reported only in a financial statement that, at a
minimum, reports the change in unrestricted net assets for the period?
[SFAS 117, par. 23 (AC No5.120)]

★ 7.

If the entity's use of the term operations is not apparent from the details
provided on the face of the statement of activities, does a note to
financial statements describe the nature of the reported measure of
operations or the items excluded from operations?
[SFAS 117, par. 23 (AC No5.120)]

★ 8.

If the entity reports net gains and losses on its statement of activi
ties/ operations, do these net amounts result from peripheral or inci
dental transactions or from events largely beyond the control of the
entity and its management?
[SFAS 117, pars. 25 and 138 (AC No5.122)]

9.

Is management's policy for providing charity care, as well as the level
of charity care provided, disclosed?
[AAG, par. 10.28]

★ 10. Does the statement of activities/operations include a performance
indicator that reports results of operations and that is clearly labeled
with a descriptive term such as revenues over expenses, revenues and
gains over expenses and losses, earned income, or performance earnings?
[AAG, par. 10.20]
★ 11. Do the notes to the financial statements include a description of the
nature and composition of the performance indicator?
[AAG, par. 10.20]

★ 12. Does the not-for-profit provider report the performance indicator in
a statement that also presents the total changes in unrestricted net
assets? (Note: Other changes in net assets may be presented sepa
rately or in the same statement.)
[AAG, par. 10.20]

★ 13. Does the organization report the following items separately from the
performance indicator:
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a. Transactions with owners acting in that capacity?
b. Equity transfers involving other entities that control the reporting
entity, are controlled by the reporting entity, or are under common
control with the reporting entity?
c. Receipt of restricted contributions, including temporary restric
tions (such as time or purpose) or permanent restrictions?

d. Contributions of (and assets released from donor restrictions re
lated to) long-lived assets?
e. Items that are required to be reported in or reclassified from other
comprehensive income, such as minimum pension liabilities in
accordance with paragraph 37 of SFAS 87; foreign currency trans
lation adjustments and the effective portion of the gain or loss on
derivative instruments designated and qualifying as cash flow
hedging instruments?
f.

Items that are required to be reported separately under specialized
not-for-profit standards. These include extraordinary items, the effect
of discontinued operations, and the cumulative effect of accounting
changes pursuant to the provisions of SFAS 117; and unrealized
gains and losses on investments not restricted by donors or by law
(except for those investments classified as trading securities) and
investment returns restricted by donors or by law, as required by
paragraphs 4.07 through 4.10 of this Guide?
[SOP 02-2; AAG, par. 10.211

Note: SFAS 154, Accounting Changes and Error Corrections, changes the
requirements for reporting changes in accounting principle. SFAS 154 is
effective for accounting changes made in fiscal years beginning after
December 15, 2005. Early adoption is permitted for accounting changes
made in fiscal years beginning after the date SFAS 154 was issued (May
2005).
[SFAS 154, pars. 1,7, and 27]

★♦14. For investments in common stock accounted for by the equity
method, is the investor's share of earnings shown as a single amount
except for investee extraordinary items and prior-period adjustments
that are material to the investor?
[APB 18, pars. 19c and d (AC I82.109c and d)]

★♦ 15. Are total research and development costs charged to expenses dis
closed for each period for which a statement of activities/income
statement is presented?
[SFAS 2, pars. 12 and 13 (AC R50.108 and .109); FASBI4, par. 5 (AC
B50.152) (AC B51.145); FASBI 6, par. 8 (AC R50.117); SFAS 86, par. 3
(AC Co2.102)]

★♦ 16. If the provider accounts for its obligation under a research and devel
opment arrangement as a contract to perform research and develop
ment for others, is there disclosure of:
a. The terms of significant agreements under the research and develop
ment arrangement as of the date of each balance sheet presented?
b. The amount of compensation earned or costs incurred under such
contracts for each period for which a statement of revenues and
expenses (statement of operations) is presented?
[SFAS 68, par. 14 (AC R55.112)]
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a. Adjustments or charges or credits resulting from transactions in
the provider's own capital stock?

____

___

b. Transfers to and from accounts properly designated as appropri
ated retained earnings?

____

___

____

___

____

___

____

___

____

___

____

___

____

___

____

___

____

___

a. Current tax expense or benefit?

____

___

b. Deferred tax expense or benefit (exclusive of the effects of other
components listed below)?

____

___

c. Investment tax credits?

____

___

d. Government grants (to the extent recognized as a reduction of
income tax expense)?

____

___

e. The benefits of operating loss carryforwards?

____

___

____

___

♦ 17. Are the following excluded from the determination of net income or
results of operations under all circumstances:

c. Adjustments made pursuant to a quasi-reorganization?
[APB 9, par. 28 (AC C08.101)]

♦ 18. Are net assets released from restriction, such as those related to the
fulfillment of time or purpose restrictions, reported separately in the
financial statements or disclosed in the notes?
[AAG, par. 10.08]
B. Revenue
1.

Is revenue classified based on the type of service (such as patient or
resident) rendered or contracted to be rendered?
[AAG, par. 10.04]

★♦2.

Are gains, losses, and interest earned properly classified and reported?
[AAG, par. 10.08]

3.

Is patient service revenue reported net of provisions for contractual
and other adjustments?
[AAG, par. 10.26]

4.

Do disclosures include methods of revenue recognition?
[AAG, par. 10.26]

5.

With regard to contractual adjustments and third-party settlements,
does the provider identify and explain the estimated amounts payable
or receivable?
[AAG, par. 10.26]

6.

Is significant revenue earned under capitation arrangements reported
separately?
[AAG, par. 10.26]

C. Income Taxes

♦ 1.

Are the following significant components of income tax expense
attributable to continuing operations for each year presented dis
closed in the financial statements or notes thereto:

f.

Tax expense that results from allocating certain benefits, either
directly to contributed capital or to reduce goodwill or other
noncurrent intangible assets of an acquired entity?
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g. Adjustments of a deferred tax liability or asset for enacted changes
in tax laws or rates or a change in the tax status of the provider?

h. Adjustments of the beginning-of-the-year balance of a valuation
allowance because of a change in circumstances that causes a
change in judgment about the realizability of the related deferred
tax asset in future years?
[SFAS 109, par. 45 (AC I27.144)]
♦ 2.

Is the amount of income tax expense or benefit allocated to continuing
operations and the amounts separately allocated to other items dis
closed for each year for which those items are presented?
[SFAS 109, pars. 35-39 and 46 (AC I27.134-.138 and .145)]

♦ 3.

If the reporting entity is a public enterprise, is a reconciliation in both
percentages and dollars of the reported amount of income tax expense
attributable to continuing operations for the year to the amount of
income tax expense that would result from applying domestic federal
statutory rates to pretax income from continuing operations?
[SFAS 109, par. 47 (AC I27.146)]

♦ 4.

If the reporting entity is a nonpublic enterprise, is there disclosure of
the nature of significant items required to reconcile the reported
amount of income tax expense attributable to continuing operations
for the year to the amount of income tax expense that would result
from applying domestic federal statutory tax rates to pretax income
from continuing operations?
[SFAS 109, par. 47 (AC I27.146)]

♦ 5.

Are the amounts and expiration dates of operating loss and tax credit
carryforwards for tax purposes disclosed?
[SFAS 109, par. 48 (AC I27.147)]

♦ 6.

Is the amount of any portion of the valuation allowance for deferred
tax assets for which subsequently recognized tax benefits will be
allocated to reduce goodwill or other noncurrent intangible assets of
an acquired entity or directly to contributed capital disclosed?
[SFAS 109, par. 48 (AC I27.147)]

♦ 7.

If the provider is a member of a group that files a consolidated tax
return, are the following items disclosed in its separately-issued finan
cial statements:

a. The aggregate amount of current and deferred tax expense for
each statement of earnings presented, and the amount of any
tax-related balances due to or from affiliates as of the date of each
balance sheet presented?
b. The principal provisions of the method by which the consolidated
amount of current and deferred tax expense is allocated to mem
bers of the group and the nature and effect of any changes in that
method (and in determining related balances to or from affiliates)
during the years for which the disclosures in Question 7a above
are presented?
[SFAS 109, par. 49 (AC I27.148)]
♦ 8.

Are the income taxes applicable to extraordinary events disclosed on
the face of the income statement or in related notes?
[APB 30, par. 11 (AC I17.102)]
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____

___

____

___

____

___

____

___

____

___

____

___

____

___

a. The accounting policy selected from the two alternatives in the
beginning of paragraph 26 of SOP 93-7 for reporting advertising,
indicating whether such costs are expensed as incurred or the first
time the advertising takes place?

____

___

b. A description of the direct-response advertising reported as assets
(if any), the accounting policy for it, and the amortization period?

____

___

c. The total amount charged to advertising expense for each state
ment of activities/income statement presented, with separate dis
closure of amounts, if any, representing a write-down of the
capitalized advertising costs to net realizable value?

____

___

____

___

D. Extraordinary Items

1.

2.

3.

4.

Are extraordinary items segregated and shown (including applicable
income taxes) following income before extraordinary items and be
fore net income?
[APB 30, par. 11 (AC I17.102)]
Are descriptive captions and amounts (including applicable income
taxes) presented for individual extraordinary events or transactions,
preferably on the face of the statement of operations/income state
ment, if practicable?
[APB 30, par. 11 (AC I17.102)]

Do disclosures include descriptions of extraordinary events or trans
actions and the principal items entering into determination of extraor
dinary gains or losses?
[APB 30, par. 11 (AC I17.102)]
For an adjustment of an extraordinary item reported in a prior period
(except for correction of an error):

a. Is the adjustment classified separately as an extraordinary item in
the current period?
b. Are the nature, year of origin, and amount of the item disclosed?
[SFAS 16, par. 16(c) (AC I17.119)]
E.

Unusual or Infrequent Items

1.

Are material events or transactions that are either unusual in nature
or of infrequent occurrence, but not both (and therefore not meeting
criteria for extraordinary items):

a. Reported as a separate component of income from continuing
operations?
b. Accompanied by disclosure of the nature and financial effects of
each event?
[APB 30, par. 26 (AC I22.101)]

F.

Advertising Costs
1.

Do disclosures for advertising costs include:

d. The total amount of advertising reported as assets in each balance
sheet/statement of financial position presented?
[SOP 93-7, par. 49]

FSP §11,200.03

N/A

37

Financial Statements and Notes Checklist
Yes

No

N/A

G. Donated or Contributed Services

★ 1.

If the provider receives contributed services, does it disclose the
following:

a. A description of the programs or activities for which those services
were used, including the nature and extent of contributed services
received for the period and the amount recognized as revenues for
the period?
b. The fair value of contributed services received but not recognized,
if practicable (optional)?

c. Nonmonetary information such as the number and trends of
donated hours received or service outputs provided by volunteer
efforts (optional)?

d. Dollar amount of contributions raised by volunteers (optional)?
[SFAS 116, pars. 10 and 123 (AC C67.110)]
H. Donated Materials and Facilities

★ 1.

I.

If donated materials merely pass through the organization to its
charitable beneficiaries, and the organization is only an agent or
intermediary for the donors, has that donation been excluded from
contribution revenues?
[SFAS 116, pars. 52 and 53; SFAS 136, pars. 8 and 11 (AC C67.161 and
.164)]

Fund Raising

★ 1.

Do financial statement disclosures include:
a. The types of activities for which joint costs have been incurred?
b. A statement that such costs have been allocated?

c. The total amount allocated during the period and the portion
allocated to each functional expense category?
[SOP 98-2, par. 18]
Note: SOP 98-2 encourages, but does not require, that the amount of joint
costs for each kind of joint activity be disclosed, if practical. [SOP 98-2,
par. 19]

★ 2.

J.

If the organization includes within its financial statements a ratio of
fundraising expenses to amounts raised, has it disclosed how that
ratio was computed?
[SFAS 136, par. 20 (AC No5.125A)]

____

Contributions/Pledges

★ 1.

★ 2.

Does the provider distinguish between contributions received with per
manent restrictions, those received with temporary restrictions, and
those received without donor-imposed restrictions, so that they are
reported as support increasing permanently restricted net assets, tempo
rarily restricted net assets, or unrestricted net assets, respectively?
[SFAS 116, par. 14 (AC No5.143)]

If donor-restricted contributions whose restrictions are met in the
same reporting period are reported as unrestricted support, is such
treatment consistent from period to period and is the policy disclosed?
[SFAS 117, par. 21; SFAS 116, par. 14 (AC No5.143)]

____

____
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★ 3.

Does the provider report receipt of unconditional promises to give
with payments due in future periods as restricted support, unless
explicit donor stipulations or circumstances surrounding the receipt
of the promise make clear that the donor intended the contribution to
be used to support activities of the current period?
[SFAS 116, par. 15 (AC No5.144)]

★ 4.

Does an entity that receives gifts of long-lived assets without donor
stipulation about how long the donated asset must be used:

a. Disclose its accounting policy of implying or not implying a time
restriction that expires over the useful life of the asset?
b. Report such support as restricted if it is the provider's policy to
imply a time restriction that expires over the useful life of the
donated asset?
c. Report such support as unrestricted in the absence of such a
policy?
[SFAS 116, par. 16 (AC No5.145)]

★ 5.

Does a provider that receives unconditional promises to give, in
which cash promised will be received in future periods, measure the
fair value of the contribution as the present value of estimated future
cash flows, using a discount rate commensurate with the risks in
volved, and report subsequent accruals of the interest element as
contribution income increasing either the temporarily or permanently
restricted class of net assets if the underlying promise to give is donor
restricted?
[SFAS 116, par. 20 (AC C67.116)]

6.

Are unrestricted pledges/contributions reported in the statement of
operations?
[AAG, par. 10.09]

K.

Expenses

★ 1.

Does the provider provide information about expenses reported by
their functional classification (such as major classes of program serv
ices and supporting services) either in the statement of activities or in
notes to financial statements?
[SFAS 117, par. 26 (AC No5.123)]

2.

For deferred compensation agreements, are estimated amounts to be
paid properly accrued?
[APB 12, pars. 6 and 7 (AC C38.101A and .102)]

3.

At a minimum, is the following information disclosed in the notes to
the financial statements in all periods affected by the September 11,
2001 attacks:

a. A description of the nature and amounts of losses and costs
recognized as a result of the September 11 events and the amount
of related insurance recoveries (if any) recognized?
b. A description of contingencies resulting from the September 11
events that have not yet been recognized in the financial state
ments but that are reasonably expected to impact the entity's
financial statements in the near term?
c. Applicable disclosures pursuant to SOP 94-6?
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★♦4.

★♦5.

★♦6.

d. Applicable disclosures about environmental obligations (and re
coveries) pursuant to SOP 96-1?
[EITF 01-10]

____

___

Are losses and costs incurred as a result of the September 11, 2001
attacks classified as part of income from continuing operations?
[EITF 01-10]

____

___

____

___

____

___

____

___

____

___

____

___

____

___

If the losses and costs incurred as a result of the September 11, 2001
attacks meet the criteria for disclosure of unusual or infrequently
occurring items, are they reported as a separate component of income
from continuing operations, either on the face of the statement of
operations or in the notes to the financial statements?
[EITF 01-10]

N/A

Is the following information disclosed in the notes to the financial
statements in the period(s) in which business interruption insurance
recoveries are recognized:

a. Nature of the event resulting in business interruption losses?

b. Aggregate amount of business interruption insurance recoveries
recognized during the period and the line item(s) in the statement
of operations in which those recoveries are classified (including
amounts reported as extraordinary pursuant to APB 30)?
[EITF 01-13]
L.

No

Wills

★♦1.

If the entity receives a promise to give conditioned on a future
uncertain event that is contained in a will and the will has been
declared valid by the probate court, has the provider disclosed the
conditional promise to give?
[SFAS 116, par. 208 (AC C67.160)]

M. Endowments

★ 1.

★ 2.

If the governing board determines that the relevant law requires the
organization to retain permanently some portion of gains on invest
ment assets of endowment funds, is that amount reported as an
increase in permanently restricted net assets?
[SFAS 117, par. 22 (AC No5.119)]

In the absence of such a law or a donor's explicit or clear implicit
permanent restriction is net appreciation reported as unrestricted if
the endowment's income is unrestricted or temporarily restricted if
the endowment's income is temporarily restricted by the donor?
[SFAS 117, par. 129 (AC No5.119)]

N. Earnings Per Share

Note: SFAS 128, Earnings per Share, applies only to entities with publicly
held common stock or potential common stock.
♦ 1.

Are earnings per share (EPS) data presented for all periods for which
an income statement or summary of earnings is presented?
[SFAS 128, par. 38 (AC E11.133)]
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♦ 2.

If diluted EPS data are reported for at least one period, are they
reported for all periods presented, even if they are the same amounts
as basic EPS?
[SFAS 128, par. 38 (AC E11.133)]

♦ 3.

For entities with only common stock outstanding, are basic EPS
amounts for income from continuing operations and for net income
presented on the face of the income statement?
[SFAS 128, par. 36 (AC E11.131)]

♦ 4.

For entities with other than a simple capital structure, are basic and
diluted EPS amounts for income from continuing operations and for
net income presented on the face of the income statement with equal
prominence?
[SFAS 128, par. 36 (AC E11.131)]

♦ 5.

If discontinued operations, extraordinary items, or the cumulative
effect of accounting changes are reported in a period, are the basic and
diluted per share amounts for those line items presented on the face
of the income statement or in the notes?
[SFAS 128, par. 37 (AC E11.132)]

Note: SFAS 154, Accounting Changes and Error Corrections, is effective for
accounting changes made in fiscal years beginning after December 15,
2005. Early adoption is permitted for accounting changes made in fiscal
years beginning after the date SFAS 154 is issued (May 2005). After the
effective date of SFAS 154, voluntary changes in accounting principle will
no longer be reported as a cumulative-effect adjustment through the
income statement of the period of change.
[SFAS 154, pars. 27 and C19 (AC E11.132, fn. 24a)]

♦ 6.

If per share amounts not required to be presented by SFAS 128 are
disclosed, are they disclosed only in the notes and do the disclosures
indicate whether the per share amounts are pretax or net of tax?
[SFAS 128, par. 37 (AC E11.132)]

♦ 7.

Are the following disclosed for each period for which an income
statement is presented:

a. A reconciliation of the numerators and denominators of the basic
and diluted per share computations for income from continuing
operations?
b. The effect that has been given to preferred dividends in arriving at
income available to common stockholders in computing basic EPS?

c. Securities (including those issuable pursuant to contingent stock
agreements) that could potentially dilute basic EPS in the future
that were not included in the computation of diluted EPS because
to do so would have been antidilutive for the period(s) presented?
[SFAS 128, par. 40 (AC E11.135)]
♦ 8.

For the latest period for which an income statement is presented, do
disclosures include a description of any transaction that occurs after
the end of the most recent period but before issuance of the financial
statements that would have changed materially the number of com
mon shares or potential common shares outstanding at the end of the
period if the transaction had occurred before the end of the period?
[SFAS 128, par. 41 (AC E11.136)]
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Notes: EITF 03-6, Participating Securities and the Two-Class Method under
FASB Statement No. 128, Earnings per Share, has transition guidance
stating prior period earnings per share amounts presented for compara
tive purposes should be restated to conform to consensus guidance. EITF
03-6 is effective for fiscal periods beginning after March 31,2004.
[EITF 03-6, pars. 23-24]
EITF 04-8, The Effect of Contingently Convertible Instruments on Diluted
Earnings per Share, has transition guidance requiring restatement of prior
period diluted earnings per share to conform to consensus guidance for
comparative purposes. EITF 04-8 is effective for reporting periods ending
after December 15, 2004.
[EITF 04-8, pars. 6-11]
O.

Comprehensive Income

Practice Tip

A listing of items of other comprehensive income under current accounting standards can be found in section
C49.106 of the FASB Current Text.
♦ 1.

Are all components of comprehensive income reported in the finan
cial statements in the period in which they are recognized?
[SFAS 130, par. 14 (AC C49.108)]

♦ 2.

Is a total for comprehensive income displayed in the financial statement
where the components of other comprehensive income are reported?
[SFAS 130, par. 14 (AC C49.108)]

♦ 3.

Is an amount for net income displayed and included as a component
of comprehensive income?
[SFAS 130, pars. 15 and 22 (AC C49.109 and .116)]

♦ 4.

Are items included in other comprehensive income classified sepa
rately into foreign currency items, minimum pension liability adjust
ments, and unrealized gains and losses on certain investments in debt
and equity securities?
[SFAS 130, par. 17 (AC C49.111)]

♦ 5.

Are reclassification adjustments presented on the face of the financial
statement in which comprehensive income is reported or disclosed in
the notes?
[SFAS 130, par. 20 (AC C49.114)]

♦ 6.

Are the components of other comprehensive income and total
comprehensive income displayed below the total for net income?
(Encouraged, but not required.)
[SFAS 130, par. 23 (AC C49.117)]

♦ 7.

Are the components of other comprehensive income displayed either
net of related tax effects, or before related tax effects with one amount
shown for the aggregate tax effect related to the total of other compre
hensive income items?
[SFAS 130, par. 24 (AC C49.118)]

♦ 8.

Is the amount of income tax expense or benefit allocated to each
component of other comprehensive income (including reclassification
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adjustments) disclosed either on the face of the statement in which
those components are displayed or in the notes?
[SFAS 130, par. 25 (AC C49.119)]
♦ 9.

Is the total of other comprehensive income for a period transferred to
a component of equity that is displayed separately from retained
earnings and additional paid-in-capital in a statement of financial
position with a descriptive title such as accumulated other comprehensive
income?
[SFAS 130, par. 26 (AC C49.120)]

♦ 10. Are accumulated balances for each classification within accumulated
other comprehensive income disclosed on the face of the statement of
financial position, in a statement of changes in equity, or in the notes?
[SFAS 130, par. 26 (AC C49.120)]
♦ 11. Has the enterprise reported a total for comprehensive income in
condensed financial statements of interim periods?
[SFAS 130, par. 27 (AC C49.121)]
♦ 12. Are unrealized holding gains and losses for available-for-sale securi
ties, including those classified as current assets, reported in other
comprehensive income until realized except as indicated in para
graph 13 of SFAS 115?
[SFAS 115, par. 13, as amended by SFAS 130 and SFAS 133 (AC
I80.110)]
♦ 13. If an additional pension liability is required to be recognized and
exceeds unrecognized prior service cost, is the excess (which would
represent a net loss not yet recognized as net periodic pension cost)
reported in other comprehensive income net of any tax benefits that
result from considering such losses as temporary differences?
[SFAS 87, par. 37, as amended by SFAS 130 (AC P16.131)]

♦ 14. Has the entity displayed as a separate classification within other
comprehensive income the net gain or loss on derivative instruments
designated and qualifying as cash flow hedging instruments that are
reported in comprehensive income pursuant to paragraphs 30 and 41
of SFAS 133?
[SFAS 133, par. 46 (AC D50.143)]
♦ 15. As part of the disclosures of accumulated other comprehensive in
come, pursuant to paragraph 26 of SFAS 130, Reporting Comprehensive
Income, has the entity separately disclosed the beginning and ending
accumulated derivative gain or loss, the related net change associated
with current period hedging transactions, and the net amount of any
reclassification into earnings?
[SFAS 133, par. 47 (AC D50.144)]

Statement of Cash Flows
1.

Is a statement of cash flows presented as a basic financial statement for
each period for which both a statement of financial position/balance
sheet and a statement of activities/income statement is presented?
[SFAS 95, par. 3, as amended by SFAS 117, par. 30a (AC C25.101);
AAG, par. 1.07]

2.

Does the statement of cash flows show the change in cash and cash
equivalents?
[SFAS 95, par. 7 (AC C25.105)]
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Is the policy for defining cash equivalents disclosed?
[SFAS 95, par. 10 (AC C25.108)]

Note: Any change in policy for determining which items are treated as cash
equivalents is a change in accounting principle.
[SFAS 95, par. 10 (AC C25.108)]

4.

If the direct method is used, is a separate schedule provided to reconcile
net income of an investor-owned provider or change in net assets of a
not-for-profit provider to net cash flow from operating activities?
[SFAS 95, par. 30, as amended by SFAS 117, par. 30f (AC C25.128)]

5.

If the indirect method is used:

a. Is the same amount for net cash flow from operating activities
reported indirectly by adjusting net income of an investor-owned
provider or change in net assets of a not-for-profit provider to
reconcile it to net cash flow from operating activities?
[SFAS 95, par. 28, as amended by SFAS 117, par. 30f (AC C25.126)]
b. Is the reconciliation of net income of an investor-owned provider
or change in net assets of a not-for-profit provider to net cash flows
from operating activities reported, either within the statement of
cash flows or provided in a separate schedule, with the statement
of cash flows reporting only the net cash flow from operating
activities?
[SFAS 95, par. 30, as amended by SFAS 117, par. 30f (AC C25.128)]
6.

Are cash receipts and cash payments from operating activities shown
separately on the statement of cash flows?
[SFAS 95, par. 27 (AC C25.125)]

Note: If the provisions of SFAS 123(R), Share-Based Payment, are in effect
or are applied, replace Question 7e with Question 7i. SFAS 123(R) amends
SFAS 95. The provisions of SFAS 123(R) are effective (a) for public entities
that do not file as small business issuers—as of the beginning of the first
interim or annual reporting period that begins after June 15,2005; (b) for
public entities that file as small business issuers—as of the beginning of
the first interim or annual reporting period that begins after December 15,
2005; and (c) for nonpublic entities—as of the beginning of the first annual
reporting period that begins after December 15, 2005. See paragraphs 69
through 85 of SFAS 123(R) for further effective date and transition infor
mation. Early adoption for interim or annual periods for which financial
statements or interim reports have not been issued is encouraged.
[SFAS 123(R), pars. 68-85]

7.

Are cash receipts and cash payments for the following transactions
classified as cash flows from operating activities:

a. Interest received on loans?
b. Insurance proceeds except those directly related to investing or
financing activities?
c. Interest paid to creditors?

d. Payments to suppliers and employees?
e. Payments to governments for taxes, duties, fines, and other fees
or penalties?

FSP §11,200.03

44

Health Care Organizations
Yes

f.

Payments to settle lawsuits?

g. Contributions to charities?
[SFAS 95, pars. 22 and 23 (AC C25.120 and .121)]
h. Cash flows from purchases, sales, and maturities of trading
securities?
[SFAS 115, par. 18 (AC I80.117); AAG, par. 4.17; SFAS 95, pars. 22
and 23 (AC C25.120 and .121)]
i.

8.

Payments to governments for taxes, duties, fines, and other fees
or penalties and the cash that would have been paid for income
taxes if increases in the value of equity instruments issued under
share-based payment arrangements that are not included in the
cost of goods or services recognizable for financial reporting pur
poses also had not been deductible in determining taxable in
come?
[SFAS 95, par. 23, as amended by SFAS 123(R) (AC C25.121)]

Are cash receipts and cash payments for the following transactions
classified as cash flows from investing activities:

a. Receipts from collections or sales of loans?
b. Receipts from sales of property?
c. Loans to others?

d. Payments to acquire property?
e. Purchases of and proceeds from sales of available-for-sale securities?
f.

Receipts from sales of equity instruments of other enterprises
exclusive of those carried in the trading account and from returns
of investment in those instruments?

g. Payments to acquire equity instruments of other enterprises, ex
clusive of those carried in the trading account?

h. Proceeds from maturities of available for sale and held-to-maturity
securities?

i.

★♦9.

Purchases of held-to-maturity securities?
[SFAS 95, pars. 16 and 17 (AC C25.114 and .115); SFAS 115, par. 18
(AC I80.117)]

Except for items described in paragraphs 12 and 13 of SFAS 95, are
cash receipts and cash payments from investing and financing activi
ties shown separately on the statement of cash flows?
[SFAS 95, pars. 12,13, and 31 (AC C25.110, .111, and .129)]

Note: If the provisions of SFAS 123(R), Share-Based Payment, are in effect
or are applied, also see Question 10/. SFAS 123(R) amends SFAS 95. The
provisions of SFAS 123(R) are effective (a) for public entities that do not
file as small business issuers—as of the beginning of the first interim or
annual reporting period that begins after June 15, 2005; (b) for public
entities that file as small business issuers—as of the beginning of the first
interim or annual reporting period that begins after December 15, 2005;
and (c) for nonpublic entities—as of the beginning of the first annual
reporting period that begins after December 15,2005. See paragraphs 69
through 85 of SFAS 123(R) for further effective date and transition infor
mation. Early adoption for interim or annual periods for which financial
statements or interim reports have not been issued is encouraged.
[SFAS 123(R), pars. 68-85]
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10. Are cash receipts and cash payments for the following transactions
classified as cash flows from financing activities:
a. Proceeds from issuing debt?

b. Repayments for amounts borrowed?
c. Proceeds from issuing equity instruments?

d. Payment of dividends or other distributions to owners?
e. Other principal payments to creditors who have extended long-term
debt?
[SFAS 95, pars. 19 and 20 (AC C25.117 and .118]
f. Cash payments for debt issue costs?
[EITF 95-13]

g. Proceeds received (whether at inception or over the term of the
derivative instrument) from derivative instruments that include
financing elements (other than a financing element inherently
included in an at-the-market derivative instrument with no pre
payments) at inception?
h. Distributions (whether at inception or over the term of the deriva
tive instrument) to counterparties of derivative instruments that
include financing elements (other than a financing element inher
ently included in an at-the-market derivative instrument with no
prepayments) at inception?
[SFAS 95, pars. 19 and 20 (C25.117-118), as amended by SFAS 149]
i. Cash retained as a result of the tax deductibility of increases in the
value of equity instruments issued under share-based payment
arrangements that are not included in the cost of goods or services
that is recognizable for financial reporting purposes? (Note: For
this purpose, excess tax benefits shall be determined on an indi
vidual award (or a portion thereof) basis.)
[SFAS 95, par. 19, as amended by SFAS 123(R) (AC C25.117)]

★♦11. Are investing and financing activities that affect recognized assets or
liabilities but that do not result in cash receipts or cash payments in
the period disclosed?
[SFAS 95, par. 32, as amended by SFAS 117, par. 30g (AC C25.134)]

★ 12. In its statement of cash flows, does the organization include in cash
flows from financing activities any amounts received with donorimposed stipulations that they must be used for long-term purposes?
[SFAS 117, par. 30c (AC C25.116)]
Note: If the provisions of SFAS 123(R), Share-Based Payment, are in effect
or are applied, replace Question 13k with Question 13k. SFAS 123(R)
amends SFAS 95. The provisions of SFAS 123(R) are effective (a) for public
entities that do not file as small business issuers—as of the beginning of
the first interim or annual reporting period that begins after June 15,2005;
(b) for public entities that file as small business issuers—as of the begin
ning of the first interim or annual reporting period that begins after
December 15, 2005; and (c) for nonpublic entities—as of the beginning of
the first annual reporting period that begins after December 15,2005. See
paragraphs 69 through 85 of SFAS 123(R) for further effective date and
transition information. Early adoption for interim or annual periods for
which financial statements or interim reports have not been issued is
encouraged.
[SFAS 123(R), pars. 68-85]
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13. Are the following classes of operating cash receipts and payments for
providers using the direct method, at a minimum, separately disclosed:
a. Cash received from service recipients?

b. Cash received from contributors?
c. Interest and dividends received?

d. Cash collected on contributions receivable?
e. Other operating cash receipts, if any?

f.

Cash paid to employees and suppliers?

g. Interest paid?

h. Income taxes paid?
i.

Grants paid?

j.

Other operating cash payments, if any?
[SFAS 95, par. 27, as amended by SFAS 117, par. 30e (AC C25.125)]

k. Income taxes paid and, separately, the cash that would have been
paid for income taxes if increases in the value of equity instru
ments issued under share-based payment arrangements that are
not recognizable as a cost of goods or services for accounting
purposes also had not been deductible in determining taxable
income?
[SFAS 95, par. 27, as amended by SFAS 123(R) (AC C25.125)]
Note: SFAS 95 encourages enterprises to provide further breakdowns of
operating cash receipts and payments that they consider meaningful and
feasible.
[SFAS 95, par. 27 (AC C25.125)]

14. Is the reconciliation of net income or change in net assets to net cash
flow from operating activities, including separate reporting of all
major classes of reconciling items, presented?
[SFAS 95, par. 29, as amended by SFAS 117, par. 30 (AC C25.127)]

★♦15. If the indirect method of reporting net cash flow from operating
activities is used, are amounts of interest paid (net of amounts capi
talized) and income taxes paid during the period provided in related
disclosures?
[SFAS 95, par. 29 (AC C25.127)]

★♦ 16. Does the statement of cash flows report net cash provided or used by
operating, investing, and financing activities and the net effect of those
flows on cash and cash equivalents during the period in a manner that
reconciles beginning and ending cash and cash equivalents?
[SFAS 95, par. 26 (AC C25.124)]
★ 17. Are cash receipts from contributions and investment income that by
donor stipulation are restricted for the purposes of acquiring, con
structing, or improving property, plant, equipment, or other longlived assets or establishing or increasing a permanent endowment or
term endowment classified as cash flows from financing activities?
[SFAS 117, par. 30(d) (AC C25.117)]

★♦18. Are cash payments made to settle an asset retirement obligation
classified in the statement of cash flows as an operating activity?
[EITF 02-6]
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Other Financial Statement Disclosures
A. Accounting Changes and Error Corrections

Note: If the provisions of SFAS 154, Accounting Changes and Error Correc
tions, are in effect or are applied, replace Questions 1 through 9 with
Questions 10 through 25. SFAS 154 supersedes APB 20 and SFAS 3, and
supersedes or amends other pronouncements. SFAS 154 is effective for
accounting changes and corrections of errors made in fiscal years begin
ning after December 15,2005. Early adoption is permitted for accounting
changes and corrections of errors made in fiscal years beginning after the
date SFAS 154 is issued (May 2005).
[SFAS 154, par. 27]
1.

For changes in accounting principle, does disclosure in the period of
the change include:

a. Nature of the change?
b. Justification for the change, including a clear explanation of why
the newly adopted principle is preferable?
c. Effect on income?
[APB 20, par. 17 (AC A06.113)]

2.

For all changes in accounting principle except those described in para
graphs 27 through 30,34, and 35 of APB 20 regarding a change in entity:

a. Are financial statements for prior periods included for compara
tive purposes presented as previously reported?
b. Is the cumulative effect of changing to a new accounting principle
on the amount of retained earnings/net assets at the beginning of the
period in which the change is made included in net income/change
in net assets of the period of change, between the captions "extraor
dinary items" and "net income/change in net assets"?

c. Is the effect on income/change in net assets before extraordinary
items and on net income/change in net assets (and the related per
share amounts, if applicable) of the period of change disclosed?

d. Is income/change in net assets before extraordinary items and net
income/change in net assets computed on a pro forma basis
shown on the face of the income statement/statement of opera
tions for all periods presented as if the newly adopted accounting
principle had been applied during all periods affected?
[APB 20, par. 19 (AC A06.115)]
♦ 3.

For the cumulative effect of a change in accounting principle, are
per-share amounts presented either on the face of the income state
ment or in the related notes?
[APB 20, par. 20, as amended by SFAS 128, par. 163(a) (AC A06.116)]

4.

If pro forma amounts cannot be computed or reasonably estimated
for individual prior periods, although the cumulative effect on re
tained earnings/net assets at the beginning of the period of change
can be determined, is the reason for not showing the pro forma
amounts by periods explained?
[APB 20, par. 25 (AC A06.121)]
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5.

If computing the effect on retained earnings/net assets at the begin
ning of the period of change is considered impossible, are disclosures
limited to showing the effect of the change on results of net in
come/ operations of the period of change (including per share data if
applicable) and explaining the reason for omitting accounting for the
cumulative effect and disclosure of pro forma amounts for prior years?
[APB 20, par. 26 (AC A06.122)]

6.

For changes in accounting principle that are required to be accounted
for by restating prior period financial statements:

a. Are all financial statements of prior periods presented restated?
[APB 20, par. 27 (AC A06.123)]
b. Is the nature and justification for a change in accounting principle
disclosed in the financial statements for the period the change was
adopted?
[APB 20, par. 28 (AC A06.124)]

c. Is the effect on income/change in net assets before extraordinary
items and net income/change in net assets (and related per share
amounts if applicable) for all prior periods presented disclosed?
[APB 20, par. 28 (AC A06.124)]

★♦7.

For accounting changes that are changes in estimates that affect
several future periods that are not ordinary course of business ac
counting, is the effect on income/change in net assets before extraor
dinary items, net income/change in net assets, and related per share
amounts, if applicable, of the current period disclosed? (Note: Disclo
sure of the effect of a change in estimate that is in the ordinary course
of business is recommended if the effect of such changes is material.)
[APB 20, par. 33 (AC A06.132)]

★♦8.

For changes in accounting principles that are in effect changes in
reporting entity, are the following disclosed:

a. Nature of the change?

b. The reason for the change?
c. The effect of the change on income/change in net assets before
extraordinary items, net income/change in net assets, and related
per share amounts, if applicable, for all periods presented?
[APB 20, par. 35]

9.

Is the correction of an error in the financial statements of a prior period
discovered subsequent to their issuance reported as a prior period
adjustment, with disclosure of the following in the period in which
the error was discovered and corrected:

a. Nature of the error in previously issued financial statements?
b. Effect of its correction on revenue and gains in excess of expenses
and losses (income) before extraordinary items and net revenue
and gains in excess of expenses and losses (net income) (and
related per share amounts if applicable)?
[APB 20, par. 37]
Change in Accounting Principle

10. Are changes in accounting principle reported through retrospective
application of the new principle to all prior periods unless impracti
cable?
[SFAS 154, par. 7 (AC A07.106)]
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★♦11. Does retrospective application include any direct effects of the change
in accounting principle, including any related income tax effects?
[SFAS 154, par. 10 (AC A07.109)]

No

____

___

____

___

____

___

____

___

____

___

____

___

____

___

A description of the prior-period information that has been
retrospectively adjusted if any?

____

___

The effect of the change on income from continuing opera
tions, net income (or other appropriate captions of changes in
the applicable net assets or performance indicator), any other
affected financial statement line item, and any affected per
share amounts for the current period and any prior periods
retrospectively adjusted? (Note: Presentation of the effect on
financial statement subtotals and totals other than income
from continuing operations and net income (or other appro
priate captions of changes in the applicable net assets or
performance indicator) is not required.)

____

___

★♦ 12. In the retrospective application, are the indirect effects of a change in
accounting principle actually incurred and recognized not included
in retrospective application but reported in the period in which the
accounting change is made?
[SFAS 154, par. 10 (AC A07.109)]

N/A

★♦13. If it is impracticable to determine the period-specific effects of a
change in accounting principle on all prior periods presented, but the
cumulative effect of applying the change to the new principle to all
prior periods can be determined:
a.

b.

Is the cumulative effect of the change applied to the carrying
amounts of assets and liabilities as of the beginning of the earliest
period to which the new accounting principle can be applied?

Is any offsetting adjustment made to the opening balance of re
tained earnings or other appropriate components of equity/net
assets for that period?
[SFAS 154, par. 8 (AC A07.107)]

★♦ 14. If it is impracticable to determine the cumulative effect of applying a
change in accounting principle to any prior period, is the new account
ing principle applied as if the change was made prospectively as of
the earliest date practicable?
[SFAS 154, par. 9 (AC A07.108)]
♦ 15. Are changes in accounting principle made in an interim period re
ported by retrospective application in accordance with paragraphs 7
through 10 of SFAS 154? (Note: The impracticability exception in
paragraph 11 of SFAS 154 may not be applied to prechange interim
periods of the fiscal year in which the change is made.)
[SFAS 154, par. 15 (AC A07.115)]

★♦16. For changes in accounting principle, are the following disclosed in the
fiscal period in which a change in accounting principle is made:
a.

The nature of and reason for the change in accounting principle,
including an explanation of why the newly adopted accounting
principle is preferable?

b. The method of applying the change and:

(1)
(2)
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The cumulative effect of the change on retained earnings or
other components of equity or net assets in the statement of
financial position as of the beginning of the earliest period
presented?

____

___

If retrospective application to all periods is impracticable, the
reasons therefor, and a description of the alternative method
used to report the change?

____

___

A description of the indirect effects including amounts recog
nized in the current period and related per share amounts, if
applicable?

____

___

Unless impracticable, the amount of the total recognized
indirect effects of the accounting change and the related pershare amounts, if applicable, attributable to each prior period
presented?

____

___

____

___

____

___

c. If indirect effects of a change in accounting principle are recog
nized:
(1)

(2)

d. If a change in accounting principle has no material effect in the
period of change but is reasonably certain to have material effect
in later periods are the disclosures in Question 16a provided
whenever the financial statements of the period of change are
presented?
[SFAS 154, par. 17 (AC A07.117)]

♦ 17. If interim financial statements are issued, are the required disclosures
provided in the financial statements of both the interim period of the
change and the annual period of the change?
[SFAS 154, par. 17, fn. 5 (AC A07.117, fn. 4)]

Note: Financial statements of subsequent periods do not have to repeat
the disclosures required in paragraph 17 of SFAS 154.
[SFAS 154, par. 17 (AC A07.117)]
♦ 18. If a public company that regularly reports interim information makes
an accounting change during the fiscal year fourth quarter and does
not report data specified in paragraph 30 of APB 28, in a separate
fourth-quarter report or its annual report, do the notes to the annual
financial statements in the fiscal year in which the change is made
disclose the effects of the change on interim-period results as required
by paragraph 17 of SFAS 154?
[SFAS 154, par. 16 (AC A07.116)]
19. In the fiscal year in which a new accounting principle is adopted does
the financial information reported for interim periods after the date
of adoption disclose the effect of the change on income from continu
ing operations, net income (or other appropriate captions of changes
in applicable net assets or performance indicator) and related pershare amounts, if applicable, for those post-change interim periods?
[SFAS 154, par. 18 (AC A07.118)]

Change in Accounting Estimate
20. For changes in accounting estimate:

a. Is the effect on income from continuing operations, net income (or
other appropriate captions of changes in the applicable net assets
or performance indicator), and any related per-share amounts of
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the current period disclosed for a change in estimate that effects
several future periods? (Note: Not necessary for estimates made
in ordinary course of accounting for items such as uncollectible
accounts, inventory obsolescence.)
b. Are material effects of changes in estimate disclosed?
c. If an entity effects a change in accounting estimate by changing an
accounting principle, are the disclosures in Questions 16,17, and
19 presented?

d. If a change in estimate does not have a material effect in the period
of change but is reasonably certain to have material effect in later
periods is a description of that change in estimate disclosed when
ever the financial statements of the period of change are pre
sented?
[SFAS 154, par. 22 (AC A07.122)]
♦ e. For reporting of interim financial information, do disclosures for
the effects of changes in accounting estimate conform with para
graph 22 of SFAS 154?
[APB 28, par. 26, as amended by SFAS 154 (AC I73.133)]
Change in the Reporting Entity

21. For accounting changes that in effect result in financial statements of
a different reporting entity, are changes applied retrospectively to the
financial statements of all prior periods presented, and is previously
issued interim financial information presented on a retrospective
basis?
[SFAS 154, par. 23 (AC A07.123)]
22. For changes in reporting entity:

a. Do the financial statements of the period of change describe the
nature of the change and the reason for it?
b. Is the effect of the change on income before extraordinary items,
net income (or other appropriate captions of changes in the appli
cable net assets or performance indicator), other comprehensive
income, and any related per-share amounts disclosed for all peri
ods presented?

c. If a change in reporting entity does not have a material effect in
the period of change but is reasonably certain to have material
effect in later periods is the nature of and reason for the change
disclosed whenever the financial statements of the period of
change are presented?
[SFAS 154, par. 24 (AC A07.124)]
Correction of an Error in Previously Issued Financial Statements

★♦23. Are corrections of errors in previously issued financial statements
reported as prior period adjustments by restating prior-period finan
cial statements?
[SFAS 154, par. 25 (AC A07.125)]

24. For corrections of errors in previously issued financial statements:

a. Does the entity disclose that its previously issued financial state
ments have been restated along with a description of the nature of
the error?

FSP §11,200.03

52

Health Care Organizations

Yes

b. Is the effect of the correction on each financial statement line item
and any per-share amounts affected for each prior period pre
sented disclosed?
c. Is the cumulative effect of the change on retained earnings or other
appropriate components of equity or net assets in the statement of
financial position as of the beginning of the earliest period pre
sented disclosed?

d. Are disclosures of prior-period adjustments and restatements re
quired by paragraph 26 of APB 9 presented?
[SFAS 154, par. 26 (AC A07.126)]

♦ 25. If interim financial statements are issued, are the required disclosures
provided in the financial statements of both the interim period of the
change and the annual period of the change?
[SFAS 154, par. 26, fn. 8 (AC A07.126, fn. 7)]

Note: Financial statements of subsequent periods do not have to repeat
the disclosures required in paragraph 26 of SFAS 154.
[SFAS 154, par. 26 (AC A07.126)]
B. Accounting Policies
1.

Is a description of all significant accounting policies of the provider
presented as an integral part of the financial statements?
[APB 22, pars. 8 and 9 (AC A10.102 and .103)]

★♦2.

Does the disclosure of accounting policies identify and describe all
significant accounting principles followed by the reporting entity and the
methods of applying those principles that materially affect the determi
nation of financial position, cash flows, and results of operations?
[APB 22, par. 12 (AC A10.105)]

3.

Does disclosure of significant accounting policies encompass impor
tant judgments as to the appropriateness of principles concerning
recognition of revenue and allocation of asset costs to current and
future periods?
[APB 22, par. 12 (AC A10.105)]

4.

Does the disclosure of accounting policies encompass those account
ing principles and methods that involve either:

a. A selection from existing acceptable alternatives?
b. Principles and methods peculiar to the industry in which the
reporting entity operates, even if such principles and methods are
predominantly following in that industry?

c. Unusual or innovative applications of GAAP?
[APB 22, par. 12 (AC A10.105)]
5.

Does disclosure of significant accounting policies include appropriate
reference to details presented elsewhere (in the statements and notes
thereto) so duplication of details is avoided?
[APB 22, par. 14 (AC A10.107)]

C. Business Combinations

Notes: Questions 4 through 13 in this section apply to business combina
tions that are accounted for following the provisions of SFAS 141, Business
(continued)
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Combinations. SFAS 141 does not apply to combinations between not-forprofit organizations, nor does it apply to the acquisition of a for-profit
business entity by a not-for-profit organization. If the provisions of SFAS
141 are not applicable, refer to Questions 1 through 3 in this section.

EITF 97-2, Application of FASB Statement No. 94 and APB Opinion No. 16 to
Physician Practice Management Entities and Certain Other Entities with Con
tractual Management Arrangements, provides guidance to assist PPMs in
applying APB 16 when PPMs acquire a physician practice.

★ 1.

If a business combination occurred during the period and met the
specified conditions for a pooling-of-interests, do the statements and
notes include the required disclosures?
[APB 16, pars. 63-65 (AC B50.122-.124)]

Note: Not-for-profit organizations are, under certain circumstances, per
mitted to use the pooling-of-interests method, even though they generally
do not issue common stock.
[AAG, pars. 1.49 and 1.50]

★ 2.

If a business combination occurred during the period and is to be
accounted for under the purchase method, do the statements and
notes include the required disclosures?
[APB 16, par. 95 (AC B50.164); SFAS 38, par. 10 (AC B50.166)]

★ 3.

If, as part of a business combination accounted for as a purchase, a
material liability is recognized by the combined company for costs
incurred to (a) exit an activity, (b) involuntarily terminate employees of
an acquired company, or (c) relocate employees of an acquired company:
a. Are the following disclosures made for the period in which a
purchase business combination occurs:
(1)

If the plans to exit an activity or involuntarily terminate
(relocate) employees of the acquired company are not final as
of the balance sheet date, a description of any unresolved
issues, the types of additional liabilities that may result in an
adjustment to the purchase price allocation, and how any
adjustment will be reported?

(2)

A description of the type and amount of liabilities assumed
in the purchase price allocation for costs to exit an activity or
involuntary terminate (relocate) employees?

(3)

A description of the major actions comprising the plan to exit
an activity or involuntarily terminate (relocate) employees of
an acquired company?

(4)

A description of activities of the acquired company that will
not be continued, including the method of disposition, and
the anticipated date of completion and description of em
ployee group(s) to be terminated (relocated)?

b. Are the following disclosures made for all periods presented
subsequent to the acquisition date in which a purchase business
combination occurred, until a plan to exit an activity or involun
tarily terminate or relocate employees of an acquired company is
fully executed:
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♦ 4.

(1)

A description of the type and amount of exit costs, involun
tary employee termination costs, and relocation costs paid
and charged against the liability?

(2)

The amount of any adjustment to the liability account and
whether the corresponding entry was an adjustment of the
costs of the acquired company or included in the determina
tion of net income for the period?
[EITF 95-31

Do the notes to the financial statements of a combined entity disclose
the following information in the period in which a material business
combination is completed:
a. The name and a brief description of the acquired entity and the
percentage of voting equity interests acquired?

b. The primary reasons for the acquisition, including a description of
the factors that contributed to a purchase price that results in
recognition of goodwill?
c. The period for which the results of operations of the acquired entity
are included in the income statement of the combined entity?

d. The cost of the acquired entity and, if applicable, the number of
shares of equity interests (such as common shares, preferred
shares, or partnership interests) issued or issuable, the value as
signed to those interests, and the basis for determining that value?
e. A condensed balance sheet disclosing the amount assigned to each
major asset and liability caption of the acquired entity at the
acquisition date?
f.

Contingent payments, options, or commitments specified in the
acquisition agreement and the accounting treatment that will be
followed should any such contingency occur?

g. The amount of purchased research and development assets ac
quired and written off in the period (refer to paragraph 42 of SFAS
141) and the line item in the income statement in which the
amounts written off are aggregated?
h. For any purchase price allocation that has not been finalized, that
fact and the reasons therefore?

i.

♦ 5.

In subsequent periods, the nature and amount of any material
adjustments made to the initial allocation of the purchase price?
[SFAS 141, par. 51 (AC B51.164)]

Is the following information disclosed in the notes to the financial
statements in the period in which a material business combination is
completed if the amounts assigned to goodwill or to other intangible
assets acquired are significant in relation to the total cost of the
acquired entity:

a. For intangible assets subject to amortization:
(1)

The total amount assigned and the amount assigned to any
major intangible asset class?

(2)

The amount of any significant residual value, in total and by
major intangible asset class?

(3)

The weighted-average amortization period, in total and by
major intangible asset class?
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b. For intangible assets not subject to amortization the total amount
assigned and the amount assigned to any major intangible asset class?
c. For goodwill:

♦ 6.

(1)

The total amount of goodwill and the amount that is expected
to be deductible for tax purposes?

(2)

The amount of goodwill by reportable segment (if the com
bined entity is required to disclose segment information in
accordance with SFAS 131), unless not practicable?
[SFAS 141, par. 52 (AC B51.165)]

If a series of individually immaterial business combinations completed
during the period are material in the aggregate, is the following disclosed:
a. The number of entities acquired and a brief description of those
entities?
b. The aggregate cost of the acquired entities, the number of equity
interests, (such as common shares, preferred shares, or partnership
interests) issued or issuable, and the value assigned to those interests?
c. The aggregate amount of any contingent payments, options, or
commitments and the accounting treatment that will be followed
should any such contingency occur (if potentially significant in
relation to the aggregate cost of the acquired entities)?

d. The information described in Question 5 above, if the aggregate
amount assigned to goodwill or to other intangible assets acquired is
significant in relation to the aggregate cost of the acquired entities?
[SFAS 141, par. 53 (AC B51.166)]
♦ 7.

If the combined entity is a public business enterprise, is the following
supplemental information on a pro forma basis for the period in
which a material business combination occurs (or for the period in
which a series of individually immaterial business combinations oc
cur that are material in the aggregate) disclosed:
a. Results of operations for the current period as though the business
combination or combinations had been completed at the begin
ning of the period unless the acquisition was at or near the begin
ning of the period?
b. Results of operations for the comparable prior period as though the
business combination or combinations had been completed at the
beginning of that period if comparative financial statements are
presented?
[SFAS 141, par. 54 (AC B51.167)]

♦ 8.

Does the supplemental pro forma information display revenue, in
come before extraordinary items and the cumulative effect of account
ing changes, net income, and earnings per share at a minimum? (Note:
In determining the pro forma amounts, income taxes, interest ex
pense, preferred share dividends, and depreciation and amortization
of assets shall be adjusted to the accounting base recognized for each
in recording the combination. Pro forma information related to results
of operations of periods prior to the combination shall be limited to
the results of operations for the immediately preceding period.)
[SFAS 141, par. 55 (AC B51.168)]
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Note: SFAS 154, Accounting Changes and Error Corrections, is effective for
accounting changes made in fiscal years beginning after December 15,
2005. Early adoption is permitted for accounting changes made in fiscal
years beginning after the date SFAS 154 is issued (May 2005). After the
effective date of SFAS 154, voluntary changes in accounting principle will
no longer be reported as a cumulative-effect adjustment through the
income statement of the period of change.
[SFAS 154, pars. 27 and C19 (AC B51.168, fn. 25a)]

♦ 9.

Does the supplemental pro forma information disclose the nature and
amount of material, nonrecurring items included in the reported pro
forma results of operations, if any?
[SFAS 141, par. 55 (AC B51.168)]

♦ 10. In the period in which an extraordinary gain is recognized related to
a business combination, do the notes to the financial statements
disclose the information required by paragraph 11 of APB 30?
[SFAS 141, par. 56 (AC B51.169)]
♦ 11. If a material business combination is completed after the balance sheet
date but before the financial statements are issued, is the information
required by Questions 4 and 5 above disclosed if practicable?
[SFAS 141, par. 57 (AC B51.170)]

Interim Financial Information
♦ 12. For summarized interim financial information of a public business
enterprise is the following information disclosed if a material business
combination is completed during the current year up to the date of
the most recent interim statement of financial position presented:

a. The name and a brief description of the acquired entity and the
percentage of voting equity interests acquired?

b. The primary reasons for the acquisition, including a brief descrip
tion of the factors that contributed to a purchase price that results
in recognition of goodwill?

c. The period for which the results of operations of the acquired entity
are included in the income statement of the combined entity?
d. The cost of the acquired entity and, if applicable, the number of
shares of equity interests (such as common shares, preferred
shares, or partnership interests) issued or issuable, the value as
signed to those interests, and the basis for determining that value?

e. Supplemental pro forma information that discloses the results of
operations for the current interim period and the current year up
to the date of the most recent interim statement of financial posi
tion presented (and for the corresponding periods in the preceding
year) as though the business combination had been completed as
of the beginning of the period reported on?
f.

The nature and amount of any material, nonrecurring items in
cluded in the reported pro forma results of operations?

g. Do the pro forma information disclosures in Question e above
display at a minimum, revenue, income before extraordinary
items and the cumulative effect of accounting changes (including
those on an interim basis), net income and earnings per share?
[SFAS 141, par. 58 (AC B51.171)]
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Note: SFAS 154, Accounting Changes and Error Corrections, is effective for
accounting changes made in fiscal years beginning after December 15,
2005. Early adoption is permitted for accounting changes made in fiscal
years beginning after the date SFAS 154 is issued (May 2005). After the
effective date of SFAS 154, voluntary changes in accounting principle will
no longer be reported as a cumulative-effect adjustment through the
income statement of the period of change.
[SFAS 154, pars. 27 and C19 (AC B51.171, fn. 25b)]
♦ 13. If, as part of a business combination accounted for as a purchase, a
material liability is recognized by the combined company for costs
incurred to (a) exit an activity, (b) involuntarily terminate employees of
an acquired company, or (c) relocate employees of an acquired company:
a. Are the following disclosures made for the period in which a
purchase business combination occurs:
(1)

If the plans to exit an activity or involuntarily terminate
(relocate) employees of the acquired company are not final as
of the balance sheet date, a description of any unresolved
issues, the types of additional liabilities that may result in an
adjustment to the purchase price allocation, and how any
adjustment will be reported?

(2)

A description of the type and amount of liabilities assumed
in the purchase price allocation for costs to exit an activity or
involuntarily terminate (relocate) employees?

(3)

A description of the major actions comprising the plan to exit
an activity or involuntarily terminate (relocate) employees of
an acquired company?

(4)

A description of activities of the acquired company that will
not be continued, including the method of disposition, and
the anticipated date of completion and description of em
ployee group(s) to be terminated (relocated)?

b. Are the following disclosures made for all periods presented
subsequent to the acquisition date in which a purchase business
combination occurred, until a plan to exit an activity or involun
tarily terminate or relocate employees of an acquired company is
fully executed:

(1)

A description of the type and amount of exit costs, involun
tary employee termination costs, and relocation costs paid
and charged against the liability?

(2)

The amount of any adjustment to the liability account and
whether the corresponding entry was an adjustment of the
costs of the acquired company or included in the determina
tion of net income for the period?
[EITF 95-3]

♦ 14. Are the following disclosures made for business combinations be
tween parties with a preexisting relationship:

a. The nature of the preexisting relationship?
b. The measurement of the amount of the settlement of the preexist
ing relationship, if any, and the valuation method used to deter
mine the settlement amount?
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c. The amount of any settlement gain or loss recognized and its
classification in the statement of operations?
[EITF 04-1, par. 8]

Note: EITF 04-1, Accounting for Preexisting Relationships between the Parties
to a Business Combination, should be applied to business combinations
consummated in reporting periods beginning after October 13,2004. Early
application permitted in periods for which financial statements have not
been issued.
[EITF 04-1, pars. 9-10]
D. Commitments and Contingencies
1.

Uninsured medical malpractice claims:

★♦a. If a minimum amount of a probable loss (usually associated with
litigating or settling malpractice claims) is accrued, is there disclo
sure as to a reasonable possibility of an additional potential loss
in excess of the amount accrued?
[AAG, par. 8.07; SFAS 5 (AC C59)]
b. If a range of loss cannot be reasonably estimated, is a contingency
disclosed?
[AAG, par. 8.11; SFAS 5 (AC C59)]
c. Is the program of medical malpractice coverage and basis for loss
accruals disclosed?
[AAG, par. 8.11]

d. If the provider discounts accrued malpractice claims, are the fol
lowing disclosed:

2.

(1)

The carrying amount of the claims?

(2)

The interest rates or other rates used to discount the claims?
[AAG, par. 8.12]

Retrospectively rated premiums:

a. If the provider cannot estimate losses from asserted or unasserted
malpractice claims, is the existing contingency disclosed?
[AAG, par. 8.14; SFAS 5 (AC C59)]
b. Does the provider disclose that it is insured under a retrospec
tively rated policy?
[AAG, par. 8.15]
c. Does the provider disclose that premiums are accrued based on
the ultimate cost of the experience to date of a group of entities?
[AAG, par. 8.15]
3.

Medical malpractice claims insured with captive insurance compa
nies (controlled by a parent entity for the main purpose of providing
insurance for the parent):
a. Does the provider disclose that it is insured under a retrospec
tively rated policy of a multiprovider captive?
[AAG, par. 8.18]
b. Does the provider disclose that premiums are accrued based on
the captive's experience to date?
[AAG, par. 8.18]
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c. Is the provider's ownership percentage in the captive disclosed?
[AAG, par. 8.19]

d. Is the method of accounting for its investment in and the opera
tions of the captive disclosed?
[AAG, par. 8.19]
e. If the provider cannot make the necessary estimates of losses
from asserted or unasserted claims, does it disclose the existing
contingency?
[AAG, par. 8.19; SFAS 5 (AC C59)]

4.

Trust funds:
a. If trust funds (revocable or irrevocable) are included in the
provider's financial statements:

5.

(1)

Is a portion of the funds (the amount of assets expected to be
liquidated to pay malpractice claims classified as current
Eabilities) classified as a current asset in a classified balance
sheet/statement of financial position?
[AAG, par. 8.20]

(2)

Is the balance of the funds, if any, classified as a noncurrent
asset in a classified balance sheet/statement of financial
position?
[AAG, par. 8.20]

(3)

Are trust fund revenue and administrative expenses included
in the statement of activities (statement of operations)?
[AAG, par. 8.20]

(4)

Are estimated losses from asserted and unasserted claims
reported?
[AAG, par. 8.21]

(5)

Is the existence of trust funds and whether they are irrevoca
ble disclosed?
[AAG, par. 8.22]

Prepaid health care services:
a. Health care costs:
(1)

Is the basis for accruing health care costs disclosed?

(2)

Are significant business and contractual arrangements
with hospitals, physicians, and other associated entities
disclosed?
[AAG, par. 13.04]

b. Stop-loss insurance:
(1)

Are receivables representing amounts recoverable from in
surers reported as assets net of any valuation allowance?

(2)

Are the nature, amounts, and effects of significant stop-loss
insurance contracts disclosed?
[AAG, par. 13.08]

c. Loss contracts:

(1)

Are losses recognized, in accordance with SFAS 5, when it is
probable that expected future health care costs and mainte
nance costs under a group of existing contracts will exceed
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anticipated future premiums and stop-loss insurance on
those contracts?
[AAG, par. 13.06]
d. Contract acquisition costs:
(1)

6.

Are acquisition costs of providers of prepaid health care serv
ices, other than costs of advertising, expensed as incurred?
[AAG, par. 13.11]

Guarantees:
a. Are the nature and amount of guarantees disclosed (for example,
of indebtedness of others)?
[SFAS 5, par. 12 (AC C59.113); FASBI 45, pars. 17 and 18 (AC
C59.114)]

b. Is the following information disclosed by a guarantor about each
guarantee, or each group of similar guarantees, even if the likeli
hood of the guarantor's having to make any payments under the
guarantee is remote:

(1)

The nature of the guarantee, including the approximate term,
how the guarantee arose, and the events or circumstances that
would require the guarantor to perform under the guarantee?

(2)

The maximum potential amount of future payments (undis
counted) the guarantor could be required to make under the
guarantee?

(3) If the terms of the guarantee provide for no limitation to the
maximum potential future payments under the guarantee, is
that fact disclosed?

(4)

The reasons why the guarantor cannot estimate the maxi
mum potential amount of future payments under its guaran
tee, if the guarantor is unable to develop an estimate?

(5)

The current carrying amount of the liability, if any, for the
guarantor's obligations under the guarantee, including the
amount, if any, recognized under SFAS 5, paragraph 8, re
gardless of whether the guarantee is freestanding or embed
ded in another contract?

(6)

The nature of—
(i)

Any recourse provisions that would enable the guaran
tor to recover from third parties any of the amounts paid
under the guarantee?

(ii) Any assets held either as collateral or by third parties
that, upon the occurrence of any triggering event or
condition under the guarantee, the guarantor can obtain
and liquidate to recover all or a portion of the amounts
paid under the guarantee?
(7)

If estimable, the approximate extent to which the proceeds
from liquidation of those assets would be expected to cover
the maximum potential amount of future payments under
the guarantee?
[FASBI 45, par. 13 (AC G80.112)]

c. For product warranties and other guarantee contracts, collectively
referred to as product warranties, is the following information
disclosed if the guarantor is not required to disclose the maximum
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potential amount of future payments, as provided in FASBI 45,
paragraph 14:

(1)

The guarantor's accounting policy and methodology used in
determining its liability for product warranties?

(2)

A tabular reconciliation of the changes in the guarantor's aggre
gate product warranty liability for the reporting period?

(3) Does the tabular reconciliation present—
(i)

The beginning balance of the aggregate product war
ranty liability?

(ii) The aggregate reductions in that liability for payments
made in cash or in kind under the warranty?

(iii) The aggregate changes in the liability for accruals related
to product warranties issued during the reporting period,
and the aggregate changes in the liability for accruals
related to preexisting warranties, including adjustments
related to changes in estimates?
(iv) The ending balance of the aggregate product warranty
liability?
[FASBI 45, par. 14 (AC G80.113)]

7. Other disclosures:
a. Is disclosure made of the nature of estimated loss contingencies
accrued when (a) information available prior to issuance of the
financial statements indicates that it is probable that an asset has
been impaired or liability incurred at the date of the financial
statements and (b) the amount of the loss can be reasonably
estimated?
[SFAS 5, pars. 8 and 9 (AC C59.105 and .108)]
b. If necessary to keep the financial statements from being mislead
ing, are the amounts of contingencies accrued as described in
Question 7a above disclosed?
[SFAS 5, pars. 8 and 9 (AC C59.105 and .108)]
c. For loss contingencies not accrued because one or both of the
conditions in paragraph 8 of SFAS 5 are not met, or if an exposure
to loss exists in excess of the amount accrued, when there is at least
a reasonable possibility that a loss or an additional loss may have
been incurred, do disclosures indicate the:

(1)

Nature of the contingency?

(2)

Estimate of the possible loss or range of loss (or a statement
that such an estimate cannot be made)?
[SFAS 5, par. 10 (AC C59.109)]

d. Are gain contingencies adequately disclosed with care to avoid
any misleading implications about likelihood of realization?
[SFAS 5, par. 17 (AC C59.118)]
e. Is there adequate disclosure of commitments such as those for
plant acquisition or an obligation to reduce debts, maintain work
ing capital, or restrict dividends?
[SFAS 5, pars. 18 and 19 (AC C59.120)]

f.

For long-term unconditional purchase obligations that are not
recorded in the purchaser's balance sheet, are the following
disclosed:
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8.

(1)

Nature and term of the obligations?

(2)

Amount of the fixed and determinable portion of the obliga
tions as of the date of the latest balance sheet presented in the
aggregate and, if determinable, for each of the next five years?

(3)

Nature of any variable components of the obligation?

(4)

Amounts purchased under the obligations for each period
for which an income statement/statement of operations is
presented?
[SFAS 47, par. 7 (AC C32.102)]

Postemployment benefits:

★♦a. If an obligation for postemployment benefits (for example, sal
ary continuation, supplemental unemployment benefits, sever
ance benefits, disability-related benefits, job training and
counseling, and continuation of health and insurance coverage) is
not accrued in accordance with SFAS 5 (AC C59) or SFAS 43 (AC
C44) only because the amount cannot reasonably be estimated,
is the fact of nonaccrual disclosed in the financial statements?
[SFAS 112, par. 7 (AC P32.105)]
9.

Environmental remediation liabilities:

a. Are environmental remediation obligations reported and dis
closed in accordance with SOP 96-1?
[SOP 96-1]
E. Exit or Disposal Activities

Note: SFAS 146, Accounting for Costs Associated with Exit or Disposal Activi
ties, nullifies EITF 94-3. The provisions of EITF 94-3 shall continue to apply
for an exit activity initiated under an exit plan that met the criteria of EITF
94-3 prior to SFAS 146's initial application. For the purposes of applying
SFAS 146, an exit or disposal activity is initiated when management,
having the authority to approve the action, commits to an exit or disposal
plan or otherwise disposes of a long-lived asset (disposal group) and, if
the activity involves the termination of employees, the criteria for a plan
of termination in paragraph 8 of SFAS 146 are met.
1.

If a material liability is recognized for certain employee termination
benefits in accordance with Section A of EITF 94-3, Liability Recognition
for Certain Employee Termination Benefits and Other Costs to Exit an
Activity (including Certain Costs Incurred in a Restructuring), are the
following disclosures made in all periods until the plan of termination
is completed:

a. The amount of termination benefits accrued and charged to ex
pense and the classification of those costs in the income statement/
statement of activities?

b. The number of employees to be terminated?
c. A description of the employee group(s) to be terminated?

d. The amount of actual termination benefits paid and charged
against the liability and the number of employees actually termi
nated as a result of the plan to terminate employees?
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e. The amount of any adjustment(s) to the liability?
[EITF 94-3, Section A]

★♦2.

If management commits to an exit plan that meets the criteria in
Section B of EITF 94-3, are the following reporting requirements
followed:

a. Reporting the income statement effect of recognizing a liability at
the commitment date in income from continuing operations and
not on the face of the income statement net of taxes?
b. No disclosure made on the face of the income statement for
earnings per share effect?
c. Revenue and related costs and expenses of activities that will not
be continued should not be combined and reported as a separate
component of income?
[EITF 94-3, Section B]

3.

If the activities that will not be continued are significant to the enter
prise's revenue or operating results, or if the exit costs recognized at
the commitment date are material, are the following disclosures made
in all periods until the exit plan is completed:
a. A description of the major actions comprising the exit plan, activi
ties that will not be continued, including the method of disposi
tion, and the anticipated date of completion?
b. A description of the type and amount of exit costs recognized as
liabilities and the classification of those costs in the income
statement/statement of activities?
c. A description of the type and amount of exit costs paid and
charged against the liability?

d. The amount of any adjustment(s) to the liability?
e. For all periods presented, the revenue and net operating income
or losses from activities that will not be continued if those activities
have separately identifiable operations?
[EITF 94-3, Section B]

4.

Is the following information disclosed in notes to the financial state
ments that include the period in which an exit or disposal activity is
initiated and any subsequent period until the activity is completed:

a. A description of the exit or disposal activity, including the facts
and circumstances leading to the expected activity and the ex
pected completion date?
b. For each major type of cost associated with the activity (for exam
ple, one-time termination benefits, contract termination costs, and
other associated costs):
(1)

The total amount expected to be incurred in connection with
the activity, the amount incurred in the period, and the cu
mulative amount incurred to date?

(2)

A reconciliation of the beginning and ending liability bal
ances showing separately the changes during the period at
tributable to costs incurred and charged to expense, costs
paid or otherwise settled, and any adjustments to the liability
with an explanation of the reason(s) therefor?
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c. The line item(s) in the income statement or the statement of
activities in which the costs in Question 4b are aggregated?
d. For each reportable segment:

(1)

The total amount of costs expected to be incurred in connec
tion with the activity?

(2)

The amount incurred in the period?

(3)

The cumulative amount incurred to date, net of any adjust
ments to the liability with an explanation of the reason(s)
therefor?

e. If a liability for a cost associated with the activity is not recognized
because fair value cannot be reasonably estimated, that fact and
the reasons therefor?
[SFAS 146, par. 20 (AC L32.120)]

♦ 5.

Are costs associated with an exit or disposal activity that does not
involve a discontinued operation included in income from continuing
operations before income taxes in the income statement?
[SFAS 146, par. 18 (AC L32.118)]

★ 6.

Are costs associated with an exit or disposal activity that does not
involve a discontinued operation included in income from continuing
operations in the statement of activities?
[SFAS 146, par. 18 (AC L32.118)]

7.

Are costs associated with an exit or disposal activity that involves a
discontinued operation included in the results of discontinued opera
tions?
[SFAS 146, par. 18 (AC L32.118)]

8.

If an event or circumstance occurs that discharges or removes an entity's
responsibility to settle a liability for a cost associated with an exit or
disposal activity recognized in a prior period, is the liability reversed?
[SFAS 146, par. 19 (AC L32.119)]

★♦9.

Are the related costs reversed through the same line item(s) in the
income statement (statement of activities) used when those costs were
recognized initially?
[SFAS 146, par. 19 (AC L32.119)]

F.

Derivative Instruments and Hedging Activities
1.

If an entity holds or issues derivative instruments (or nonderivative
instruments that are designated and qualify as hedging instruments
pursuant to paragraphs 37 and 42 of SFAS 133) has disclosure been
made of its objectives for holding or issuing those instruments, the
context needed to understand those objectives, and its strategies for
achieving those objectives?
[SFAS 133, par. 44 (AC D50.141)]

★♦2.

Does the description distinguish between derivative instruments
(and nonderivative instruments) designated as fair value hedging
instruments, derivative instruments designated as cash flow hedg
ing instruments, derivative instruments (and nonderivative instru
ments) designated as hedging instruments for hedges of the foreign
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currency exposure of a net investment in a foreign operation, and all
other derivatives?
[SFAS 133, par. 44 (AC D50.141)]
3.

Does the description also indicate the entity's risk management policy
for each of those types of hedges, including a description of the items
or transactions for which risks are hedged?
[SFAS 133, par. 44 (AC D50.141)]

★♦4.

For derivative instruments not designated as hedging instruments,
does the description indicate the purpose of the derivative activity?
[SFAS 133, par. 44 (AC D50.141)]

5.

Qualitative disclosures about an entity's objectives and strategies for
using derivative instruments may be more meaningful if such objec
tives and strategies are described in the context of an entity's overall
risk management profile. If appropriate, an entity is encouraged, but
not required, to provide such additional qualitative disclosures. Have
such disclosures been made?
[SFAS 133, par. 44 (AC D50.141)]

Note: SOP 02-2, Accounting for Derivative Instruments and Hedging Activi
ties by Not-for-Profit Health Care Organizations, and Clarification of the Per
formance Indicator, paragraph 8, requires not-for-profit health care
organizations to provide disclosures that are analogous to those required
by paragraph 45 of SFAS 133, Accounting for Derivative Financial Instru
ments and Hedging Activities, for for-profit enterprises, including the dis
closure of anticipated reclassifications into the performance indicator of
gains and losses that have been excluded from that measure and reported
in accumulated derivative gain or loss as of the reporting date. The provisions
of SOP 02-2 are effective for fiscal years beginning after June 15,2003. Earlier
application is encouraged but permitted only as of the beginning of any fiscal
quarter that begins after issuance of SOP 02-2. See paragraphs 10 and 11 of
SOP 02-2 for additional effect date and transition information. If the provi
sions of SOP 02-2 are applied, see Questions 8, 9 and 10 for disclosures
required for the transition to the provisions of SOP 02-2.
6.

Do the entity's disclosures for every reporting period for which a com
plete set of financial statements is presented also include the following:
Fair Value Hedges

a. For derivative instruments, as well as nonderivative instruments
that may give rise to foreign currency transaction gains or losses
under SFAS 52, that have been designated and have qualified as
fair value hedging instruments and for the related hedged items:
(1)

The net gain or loss recognized in earnings during the report
ing period representing (a) the amount of the hedges' ineffec
tiveness and (b) the component of the derivative instruments'
gain or loss, if any, excluded from the assessment of hedge
effectiveness, and a description of where the net gain or loss
is reported in the statement of income or other statement of
financial performance?

(2)

The amount of net gain or loss recognized in earnings when
a hedged firm commitment no longer qualifies as a fair value
hedge?
[SFAS 133, par. 45a (AC D50.142)]
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Cash Flow Hedges

b. For derivative instruments that have been designated and have
qualified as cash flow hedging instruments and for the related
hedged transactions:

(1)

The net gain or loss recognized in earnings during the report
ing period representing (a) the amount of the hedges' ineffec
tiveness and (b) the component of the derivative instruments'
gain or loss, if any, excluded from the assessment of hedge
effectiveness, and a description of where the net gain or loss
is reported in the statement of income or other statement of
financial performance?

(2)

A description of the transactions or other events that will
result in the reclassification into earnings of gains and losses
that are reported in accumulated other comprehensive in
come, and the estimated net amount of the existing gains or
losses at the reporting date that is expected to be reclassified
into earnings within the next 12 months?

(3)

The maximum length of time over which the entity is hedging
its exposure to the variability in future cash flows for fore
casted transactions excluding those forecasted transactions
related to the payment of variable interest on existing finan
cial instruments?

(4)

The amount of gains and losses reclassified into earnings as
a result of the discontinuance of cash flow hedges because it
is probable that the original forecasted transactions will not
occur by the end of the originally specified time period (as
documented at the inception of the hedging relationship) or
within additional two-month period of time thereafter?
[SFAS 133, par. 45b, as amended by SFAS 138, par. 4r (AC
D50.142)]

Hedges of the Net Investment in a Foreign Operation

c. For derivative instruments, as well as nonderivative instruments
that may give rise to foreign currency transaction gains or losses
under SFAS 52, that have been designated and have qualified
as hedging instruments for hedges of the foreign currency ex
posure of a net investment in a foreign operation, the net amount
of gains or losses included in the cumulative translation adjust
ment during the reporting period?
[SFAS 133, par. 45c (AC D50.142)]

★♦7.

The quantitative disclosures about derivative instruments may be
more useful, and less likely to be perceived to be out of context or
otherwise misunderstood, if similar information is disclosed about
other financial instruments or nonfinancial assets and liabilities to
which the derivative instruments are related by activity. Accordingly, in
such situations, has the entity presented a more complete picture of its
activities by disclosing that information? (Encouraged, but not required.)
[SFAS 133, par. 45 (AC D50.142)]

★ 8.

Are any derivative gains and losses excluded from the performance
indicator in the financial statements issued for periods ended before
the initial date of application of SOP 02-2 that did not meet the cash
flow hedging criteria of SFAS 133:
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a. Not reclassified and included as a component of the performance
indicator in any period subsequent to the initial date of application
of SOP 02-2?
b. Not included in the disclosure of the accumulated derivative gain
or loss as described in paragraph 8 of SOP 02-2?
[SOP 02-2, par. 10]

★ 9.

To the extent that derivative gains or losses on cash flow hedges
qualifying under SFAS 133 had been reported in a manner consistent
with the provisions of SOP 02-2 in financial statements for periods
prior to the initial date of application of SOP 02-2, are such amounts
included in the disclosure of derivative gain or loss as described in
paragraph 8 of SOP 02-2 and reclassified and included in the perform
ance indicator when the hedged transaction affects the performance
indicator?
[SOP 02-2, par. 10]

★ 10. When the financial statements of the year of adoption are presented
separately or included in comparative financial statements do the
notes to the financial statements disclose:
a. The fact that SOP 02-2 has been adopted and the effective date of
the adoption?
b. The nature of any differences in accounting principles or financial
statement presentation applicable to the financial statements pre
sented that resulted from adoption of SOP 02-2 (disclosure of pro
forma amounts is not required)?
[SOP 02-2, par. 10]

G.

Financial Instruments

Disclosures About Fair Value of Financial Instruments
1.

Has the entity disclosed, either in the body of the financial statements
or in the accompanying notes, the fair value of financial instruments
(except for those excluded in paragraphs 8 and 13 of SFAS 107) for
which it is practicable to estimate fair value?
[SFAS 107, par. 10 (AC F25.115C)]

Note: If disclosed in more than a single note, one of the notes shall include
a summary table. The summary table shall contain the fair value and
related carrying amounts and cross-references to the location(s) of the
remaining disclosures required by SFAS 107 as amended.
[SFAS 107, par. 10, fn. * (AC F25.115C fn. 16a)]
2.

Has the fair value disclosed in the notes been presented together with
the related carrying amount in a form that makes it clear whether the
fair value and carrying amount represent assets or liabilities and how
the carrying amounts relate to what is reported in the statement of
financial position?
[SFAS 107, par. 10 (AC F25.115C)]

3.

Are the methods and significant assumptions used to estimate the fair
value of financial instruments disclosed?
[SFAS 107, par. 10 (AC F25.115C)]

4.

In disclosing the fair value of a financial instrument, has the entity
taken care not to net that fair value with the fair value of other
financial instruments—even if those financial instruments are of
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the same class or are otherwise considered to be related, for example,
by a risk management strategy—except to the extent that the offset
ting of carrying amounts in the statement of financial position is
permitted under the general principle in paragraphs 5 and 6 of FASBI
39, Offsetting of Amounts Related to Certain Contracts, or the exceptions
for master netting arrangements in paragraph 10 of FASBI 39 and
for amounts related to certain repurchase and reverse repurchase
agreements in paragraphs 3 and 4 of FASBI 41, Offsetting of Amounts
Related to Certain Repurchase and Reverse Repurchase Agreements?
[SFAS 107, par. 14 (AC F25.115I)]
5.

If it is not practicable to estimate the fair value of a financial instru
ment or a class of financial instruments, are the following dis
closed:

a. Information pertinent to estimating the fair value of that financial
instrument or class of financial instruments, such as the carrying
amount, effective interest rate, and maturity?
b. The reasons why it is not practicable to estimate fair value?
[SFAS 107, par. 14 (AC F25.115J)]
Note: SFAS 126, Exemption from Certain Required Disclosures about Financial
Instruments for Certain Nonpublic Entities, makes the disclosures about fair
values of financial instruments prescribed in SFAS 107 optional for report
ing entities that:
• Are nonpublic entities,
Have total assets of less than $100 million on the date of the financial
statements, and
Have no instrument that, in whole or in part, is accounted for as a
derivative instrument under SFAS 133, Accounting for Derivative In
struments and Hedging Activities, other than commitments related to
the origination of mortgage loans to be held for sale during the report
ing period.
[SFAS 126, par. 2, as amended by SFAS 149 (AC F25.105J)]
Disclosure About Concentrations of Credit Risk ofAU Financial Instruments

6.

Except as indicated in paragraph 15B of SFAS 107, has the entity
disclosed all significant concentrations of credit risk arising from
all financial instruments, whether from an individual counter
party or groups of counterparties (Group concentrations of credit risk
exist if a number of counterparties are engaged in similar economic
characteristics that would cause their ability to meet contractual
obligations to be similarly affected by changes in economic or other
conditions)?
[SFAS 107, par. 15A (AC F25.116A)]

Note: SFAS 107, paragraph 15B provides that these disclosure require
ments do not apply to the following financial instruments, whether writ
ten or held:
a. Financial instruments of a pension plan, including plan assets, when
subject to the accounting and reporting requirements of SFAS 87
(Financial instruments of a pension plan, other than the obligations
for pension benefits, when subject to the accounting and reporting
requirements of SFAS 35, Accounting and Reporting by Defined Benefit
Pension Plans, are subject to the reporting of paragraph 15A).
(continued)
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b. The financial instruments described in paragraphs 8(a), 8(c), 8(e),
and 8(f) of SFAS 107, as amended by SFAS 112, Employers' Accounting
for Postemployment Benefits, SFAS 123, Accounting for Stock-Based
Compensation, except for reinsurance receivables and prepaid rein
surance premiums.
[SFAS 107, par. 15B (AC F25.116B)]

7.

Has the entity made the following disclosures about each significant
concentration:

a. Information about the (shared) activity, region, or economic char
acteristic that identifies the concentration?
b. The maximum amount of loss due to credit risk that, based on the
gross fair value of the financial instrument, the entity would incur
if parties to the financial instruments that make up the concentra
tion failed completely to perform according to the terms of the
contracts and the collateral or other security, if any, for the amount
due proved to be of no value to the entity?

c. The entity's policy of requiring collateral or other security to
support financial instruments subject to credit risk, information
about the entity's access to that collateral or other security, and the
nature and a brief description of the collateral or other security
supporting those financial instruments?

d. The entity's policy of entering into master netting arrangements
to mitigate the credit risk of financial instruments, information
about the arrangements for which the entity is a party, and a brief
description of the terms of those arrangements, including the
extent to which they would reduce the entity's maximum amount
of loss due to credit risk?
[SFAS 107, par. 15A (AC F25.116A)]

8.

Has the entity disclosed quantitative information about the market
risks of financial instruments that is consistent with the way it man
ages or adjusts those risks? (Encouraged, but not required.)
[SFAS 107, par. 15C (AC F25.116C)]

Note: Appropriate ways of reporting the quantitative information en
couraged will differ for different entities and will likely evolve over
time as management approaches and measurement techniques evolve.
Possibilities include disclosing (a) more details about current positions
and perhaps activity during the period, (b) the hypothetical effects on
comprehensive income (or net assets), or annual income, of several
possible changes in market prices, (c) a gap analysis of interest rate
repricing or maturity dates, (d) the duration of the financial instru
ments, or (e) the entity's value at risk from derivatives and from other
positions at the end of the reporting period and the average value at
risk during the year. This list is not exhaustive, and an entity is encour
aged to develop other ways of reporting quantitative information.
[SFAS 107, par. 15D (AC F25.116D)]
9.

Are the classification guidelines and disclosures under EITF 00-19,
Accounting for Derivative Financial Instruments Indexed to, and Potentially
Settled in, a Company's Own Stock, followed for freestanding contracts
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that are indexed to, and potentially settled in, the company's own
stock?
[EITF 00-191

10. Is disclosure made of the primary geographic sources of patients?
[AAG, par. 5.24]

♦ Disclosures About Certain Financial Instruments With Characteristics of
Both Liabilities and Equity
Note: Depending upon whether an entity is a nonpublic entity, a public
entity, or an SEC registrant, FSP FAS 150-3 defers the effective date for
applying the provisions of SFAS 150. Refer to SFAS 150 and FSP FAS 150-3
for effective date information on applying the provisions of SFAS 150.

11. For items within the scope of SFAS 150, are they presented as liabilities
(or assets in some circumstances), and not between the liabilities
section and the equity section of the statement of financial position?
[SFAS 150, par. 18 (AC F41.116)]
12. If the entity has no equity instruments outstanding but has financial
instruments in the form of shares, all of which are mandatorily re
deemable financial instruments required to be classified as liabilities:

a. Are they described in statements of financial position as "shares
subject to mandatory redemption"?
b. Are payments to holders of such instruments and related accruals
presented separately from payments to and interest due to other
creditors in statements of cash flows and income?
[SFAS 150, pars. 19 and 28 (AC F41.117 and .126)]
13. Do the entities referred to in Question 12 above disclose the compo
nents of the liability that would otherwise be related to shareholders'
interest and other comprehensive income, if any, subject to the re
demption feature? (For example, par value and other paid-in amounts
of mandatorily redeemable instruments should be disclosed sepa
rately from the amount of retained earnings or accumulated deficit.)
[SFAS 150, par. 28 (AC F41.126)]

14. For issuers of financial instruments within the scope of SFAS 150:

a. Are the nature and terms of the financial instruments and the
rights and obligations embodied in those instruments disclosed?
b. Does that disclosure include information about settlement alter
natives, if any, in the contract and identify the entity that controls
the settlement alternatives?
[SFAS 150, par. 26 (AC F41.124)]
15. For all outstanding financial instruments within the scope of SFAS 150
and for each settlement alternative, do issuers disclose:

a. The amount that would be paid, or the number of shares that
would be issued and their fair value, determined under the con
ditions specified in the contract if the settlement were to occur at
the reporting date?
b. How changes in the fair value of the issuer's equity shares would
affect those settlement amounts?
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c. The maximum amount that the issuer could be required to pay to
redeem the instrument by physical settlement, if applicable?

d. The maximum number of shares that could be required to be
issued, if applicable?
e. That a contract does not limit the amount that the issuer could be
required to pay or the number of shares that the issuer could be
required to issue, if applicable?
f.

For a forward contract or an option indexed to the issuer's equity
shares, the forward price or option strike price, the number of
issuer's shares to which the contract is indexed, and the settlement
date or dates of the contract, as applicable?
[SFAS 150, par. 27 (AC F41.125)]

16. Are mandatorily redeemable financial instruments classified as li
abilities unless the redemption is required to occur only upon the
liquidation or termination of the reporting entity?
[SFAS 150, par. 9 (AC F41.107)]
17. Are financial instruments, other than an outstanding share, that at
inception, (a) embodies an obligation to repurchase the issuer's equity
shares or is indexed to such an obligation, and (b) requires or may
require the issuer to settle the obligation by transferring assets, clas
sified as liabilities (or assets in some circumstances)?
[SFAS 150, par. 11 (AC F41.109)]
18. Are financial instruments that embody an unconditional obligation,
or financial instruments other than an outstanding share that embod
ies a conditional obligation, that the issuer must or may settle by
issuing a variable number of its equity shares, classified as liabilities
(or assets in some circumstances) if, at inception, the monetary value
of the obligation is based solely or predominantly on any one of the
items indicated in paragraph 12 of SFAS 150?
[SFAS 150, par. 12 (AC F41.110)]

Mandatorily Redeemable Shares Requiring Redemption by Payment of
an Amount That Differs from Book Value
19. Are the cumulative transition adjustment and any subsequent adjust
ments reported as an excess of liabilities over assets (a deficit) and
changes thereto even though the mandatorily redeemable shares are
reported as a liability?
[FSP FAS 150-2 (AC F41.810)]

20. If the redemption price of mandatorily redeemable shares is less than
the book value of those shares, is the excess of that book value over
the liability reported for the mandatorily redeemable shares as an
excess of assets over liabilities (equity)?
[FSP FAS 150-2 (AC F41.811)]

SFAS 150 Effective Date Deferral
21. Although the disclosure requirements of SFAS 150 do not apply for
those mandatorily redeemable instruments of certain nonpublic com
panies while application of the provisions of SFAS 150 to those
instruments is deferred, are the capital structure disclosure require
ments in SFAS 129 still provided, in particular:
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a. Information required in paragraph 4 about the pertinent rights
and privileges of the various securities outstanding, including
mandatory redemption requirements?
b. Disclosure required in paragraph 8 of the amount of redemption
requirements for all issues of stock that are redeemable at fixed or
determinable prices on fixed or determinable dates in each of the
next five years?
[FSP FAS 150-3 (AC F41.819)]

22. During the deferral period, if the entity is a public entity or a nonpub
lic entity that is an SEC registrant, are the disclosure requirements in
paragraphs 26 and 27 of SFAS 150 as well as disclosures required by
other applicable guidance complied with?
[FSP FAS 150-3 (AC F41.822)]
H. Nonmonetary Transactions
1.

Do disclosures include:
a. Nature of the transactions?

b. Basis of accounting for the assets transferred?

c. Gains or losses recognized on the transfers?
[APB 29, par. 28 (AC C11.102 and N35.120)]

♦ 2.

I.

Is the amount of gross operating revenue recognized as a result of
nonmonetary transactions addressed by EITF 00-8, Accounting by a
Grantee for an Equity Instrument to Be Received in Conjunction with
Providing Goods or Services, disclosed in each period's financial state
ments?
[EITF 00-8]

Pension and Other Postretirement Benefit Plans

★♦1.

If an employer sponsors one or more defined benefit pension plans or
one or more defined benefit postretirement plans, do disclosures
include (separately for pension plans and other postretirement benefit
plans):

a. A reconciliation of beginning and ending balances of the benefit
obligation showing separately, if applicable, the effects during the
period attributable to each of the following: service cost, interest
cost, contributions by plan participants, actuarial gains and losses,
foreign currency exchange rate changes, benefits paid, plan
amendments, business combinations, divestitures, curtailments,
settlements, and special termination benefits?
b. A reconciliation of beginning and ending balances of the fair value
of plan assets showing separately, if applicable, the effects during
the period attributable to each of the following: actual return on
plan assets, foreign currency exchange rate changes, contributions
by the employer, contributions by plan participants, benefits paid,
business combinations, divestitures, and settlements?

c. The funded status of the plans, the amounts not recognized in the
statement of financial position, and the amounts recognized in the
statement of financial position, including:
(1)
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(2)

The amount of any unrecognized net gain or loss (including
asset gains and losses not yet reflected in market-related
value)?

(3)

The amount of any remaining unamortized, unrecognized
net obligation or net asset existing at the initial date of appli
cation of SFAS 87 or SFAS 106?

(4)

The net pension or other postretirement benefit prepaid as
sets or accrued liabilities?

(5)

Any intangible asset and the amount of accumulated other
comprehensive income (net assets) recognized pursuant to
paragraph 37 of SFAS 87, as amended?

No

N/A

d. Information about plan assets:

(1)

For each major category of plan assets, which shall include,
but is not limited to, equity securities, debt securities, real
estate, and all other assets, the percentage of the fair value of
total plan assets held as of the measurement date used for
each statement of financial position presented?

(2)

A narrative description of investment policies and strategies,
including target allocation percentages or range of percent
ages for each major category of plan assets presented on a
weighted-average basis as of the measurement date(s) of the
latest statement of financial position presented, if applicable,
and other factors that are pertinent to an understanding of the
policies or strategies such as investment goals, risk manage
ment practices, permitted and prohibited investments in
cluding the use of derivatives, diversification, and the
relationship between plan assets and benefit obligations?

(3)

A narrative description of the basis used to determine the
overall expected long-term rate-of-return-on-assets assump
tion, such as the general approach used, the extent to which
the overall rate-of-return-on-assets assumption was based on
historical returns, the extent to which adjustments were made
to those historical returns in order to reflect expectations of
future returns, and how those adjustments were determined?

(4)

Disclosure of additional asset categories and additional infor
mation about specific assets within a category? (Note: En
couraged if that information is expected to be useful in
understanding the risks associated with each asset category
and the overall expected long-term rate of return on assets.)

e. For defined benefit pension plans, the accumulated benefit obli
gation?
f.

The benefits (as of the date of the latest statement of financial
position presented) expected to be paid in each of the next five
fiscal years, and in the aggregate for the five fiscal years thereafter?
(Note: The expected benefits should be estimated based on the
same assumptions used to measure the company's benefit obliga
tion at the end of the year and should include benefits attributable
to estimated future employee service.)

g. The employer's best estimate, as soon as it can reasonably be
determined, of contributions expected to be paid to the plan
during the next fiscal year beginning after the date of the latest
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statement of financial position presented? (Note: Estimated con
tributions may be presented in the aggregate combining (1) con
tributions required by funding regulations or laws, (2)
discretionary contributions, and (3) noncash contributions.)

h. The amount of net periodic benefit cost recognized, showing
separately the service cost component, the interest cost compo
nent, the expected return on plan assets for the period, the amor
tization of the unrecognized transition obligation or transition
asset, the amount of recognized gains or losses, the amount of
prior service cost recognized, and the amount of gains or losses
recognized due to a settlement or curtailment?

i.

The amount included within other comprehensive income
(change in net assets) for the period arising from a change in the
additional minimum pension liability recognized pursuant to
paragraph 37 of SFAS 87, as amended?

j.

On a weighted-average basis, the following assumptions used in
the accounting for the plans: assumed discount rates, rates of
compensation increase (for pay-related plans), and expected long
term rates of return on plan assets specifying, in a tabular format,
the assumptions used to determine the benefit obligation and the
assumptions used to determine net benefit cost?

k. The measurement date(s) used to determine pension and other
postretirement benefit measurements for the pension plans and
other postretirement benefit plans that make up at least the major
ity of plan assets and benefit obligations?
l.

The assumed health care cost trend rate(s) for the next year used
to measure the expected cost of benefits covered by the plan (gross
eligible charges) and a general description of the direction and
pattern of change in the assumed trend rates thereafter, together
with the ultimate trend rate(s) and when that rate is expected to
be achieved?

m. The effect of a one-percentage-point increase and the effect of a
one-percentage-point decrease in the assumed health care cost trend
rates on (1) the aggregate of the service and interest cost components
of net periodic postretirement health care benefit costs and (2) the
accumulated postretirement benefit obligation for health care bene
fits? (For purposes of this disclosure, all other assumptions shall be
held constant, and the effects shall be measured based on the sub
stantive plan that is the basis for the accounting.)

n. If applicable, the amounts and types of securities of the employer
and related parties included in plan assets, the approximate
amount of future annual benefits of plan participants covered by
insurance contracts issued by the employer or related parties, and
any significant transactions between the employer or related par
ties and the plan during the period?
o. If applicable, any alternative method used to amortize prior serv
ice amounts or unrecognized net gains and losses pursuant to
paragraphs 26 and 33 of SFAS 87 or paragraphs 53 and 60 of SFAS
106?

p. If applicable, any substantive commitment, such as past practice
or a history of regular benefit increases, used as the basis for
accounting for the benefit obligation?
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q. If applicable, the cost of providing special or contractual termina
tion benefits recognized during the period and a description of the
nature of the event?

r. An explanation of any significant change in the benefit obligation
or plan assets not otherwise apparent in the other disclosures
required by SFAS 132?
[SFAS 132(R), par. 5 (AC P16.150 and P40.169)]
2.

Are amounts related to the employer's results of operations disclosed
for each period for which an income statement/statement of opera
tions is presented?
[SFAS 132(R), par. 5 (AC P16.150 and P40.169)]

3.

Are amounts related to the employer's statement of financial position,
unless otherwise stated, disclosed as of the measurement date used
for each statement of financial position presented?
[SFAS 132(R), par. 5 (AC P16.150 and P40.169)]

Employers With Two or More Plans

★♦4.

Are the disclosures required by SFAS 132 (revised 2003) aggregated
for all of an employer's defined benefit pension plans and for all of an
employer's other defined benefit postretirement plans unless disag
gregating in groups is considered to provide useful information or is
otherwise required by paragraphs 6 and 7 of SFAS 132 (revised 2003)?
[SFAS 132(R), par. 6 (AC P16.153 and P40.172)]

5.

Unless otherwise stated, are disclosures as of the measurement date
for each statement of financial position presented?
[SFAS 132(R), par. 6 (AC P16.153 and P40.172)]

6.

Does the disclosure of amounts recognized in the statement of finan
cial position present prepaid benefit costs and accrued benefit liabili
ties separately?
[SFAS 132(R), par. 6 (AC P16.153 and P40.172)]

Note: Disclosures about pension plans with assets in excess of the accu
mulated benefit obligation generally may be aggregated with disclosures
about pension plans with accumulated benefit obligations in excess of
assets. The same aggregation is permitted for other postretirement benefit
plans.
[SFAS 132(R), par. 6 (AC P16.153 and P40.172)]
7.

If aggregate disclosures are presented, does the employer disclose:

a. The aggregate benefit obligation and aggregate fair value of plan
assets for plans with benefit obligations in excess of plan assets as
of the measurement date of each statement of financial position
presented?
b. The aggregate pension accumulated benefit obligation and aggre
gate fair value of plan assets for pension plans with accumulated
benefit obligations in excess of plan assets?
[SFAS 132(R), par. 6 (AC P16.153 and P40.172)]

8.

Are disclosures about pension or other postretirement benefit plans
outside the United States separate from those for U.S. plans when the
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plans outside the United States have benefit obligations that are
significant relevant to the total benefit obligation and use significantly
different assumptions?
[SFAS 132(R), par. 7 (AC P16.153A and P40.173)]

Reduced Disclosure Requirements for Nonpublic Entities
9.

A nonpublic entity is not required to disclose the information required
by paragraphs 5(a)-(c), 5(h), 5(m), and 5(o)-(r) of SFAS 132 (revised
2003). If a nonpublic entity that sponsors one or more defined benefit
pension plans or one or more other defined benefit postretirement
plans elects the reduced disclosure requirements, has the following
information been disclosed, separately for pension plans and other
postretirement benefit plans:
a. The benefit obligation, fair value of plan assets, and funded status
of the plan?

b. Employer contributions, participant contributions, and benefits
paid?

c. Information about plan assets:
(1)

For each major category of plan assets which shall include,
but is not limited to, equity securities, debt securities, real
estate, and all other assets, the percentage of the fair value of
total plan assets held as of the measurement date used for
each statement of financial position presented?

(2)

A narrative description of investment policies and strategies,
including target allocation percentages or range of percent
ages for each major category of plan assets presented on a
weighted-average basis as of the measurement date(s) of the
latest statement of financial position presented, if applicable,
and other factors that are pertinent to an understanding of the
policies or strategies such as investment goals, risk manage
ment practices, permitted and prohibited investments in
cluding the use of derivatives, diversification, and the
relationship between plan assets and benefit obligations?

(3)

A narrative description of the basis used to determine the
overall expected long-term rate-of-return-on-assets assump
tion, such as the general approach used, the extent to which
the overall rate-of-return-on-assets assumption was based on
historical returns, the extent to which adjustments were made
to those historical returns in order to reflect expectations of
future returns, and how those adjustments were determined?

Note: Disclosure of additional asset categories and additional informa
tion about specific assets within a category is encouraged if that informa
tion is expected to be useful in understanding the risks associated with
each asset category and the overall expected long-term rate of return on
assets.
[SFAS 132(R), par. 8 (AC P16.150A and P40.169A)]

d. For defined benefit pension plans, the accumulated benefit obli
gation?
e. The benefits (as of the date of the latest statement of financial
position presented) expected to be paid in each of the next five
fiscal years, and in the aggregate for the five fiscal years thereafter?
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(The expected benefits should be estimated based on the same
assumptions used to measure the company's benefit obligation at
the end of the year and should include benefits attributable to
estimated future employee service.)
f.

The employer's best estimate, as soon as it can reasonably be
determined, of contributions expected to be paid to the plan
during the next fiscal year beginning after the date of the latest
statement of financial position presented? (Estimated contribu
tions may be presented in the aggregate combining (1) contribu
tions required by funding regulations or laws, (2) discretionary
contributions, and (3) noncash contributions.)

g. The amounts recognized in the statements of financial position,
including net pension and other postretirement benefit prepaid
assets or accrued liabilities and any intangible asset and the
amount of accumulated other comprehensive income (net assets)
recognized pursuant to paragraph 37 of SFAS 87, as amended?
h. The amount of net periodic benefit cost recognized and the
amount included within other comprehensive income (change in
net assets) arising from a change in the minimum pension liability
recognized pursuant to paragraph 37 of SFAS 87, as amended?

i.

On a weighted-average basis, the following assumptions used in
the accounting for the plans: assumed discount rates, rates of
compensation increase (for pay-related plans), and expected long
term rates of return on plan assets specifying, in a tabular format,
the assumptions used to determine the benefit obligation and the
assumptions used to determine net benefit cost?

j.

The measurement date(s) used to determine pension and other
postretirement benefit measurements for the pension plans and
other postretirement benefit plans that make up at least the major
ity of plan assets and benefit obligations?

k. The assumed health care cost trend rate(s) for the next year used
to measure the expected cost of benefits covered by the plan (gross
eligible charges) and a general description of the direction and
pattern of change in the assumed trend rates thereafter, together
with the ultimate trend rate(s) and when that rate is expected to
be achieved?
l.

If applicable, the amounts and types of securities of the employer
and related parties included in plan assets, the approximate
amount of future annual benefits of plan participants covered by
insurance contracts issued by the employer or related parties, and
any significant transactions between the employer or related par
ties and the plan during the period?

m. The nature and effect of significant nonroutine events, such as
amendments, combinations, divestitures, curtailments, and
settlements?
[SFAS 132(R), par. 8 (AC P16.150A and P40.169A)]
10. Are amounts related to the employer's results of operations disclosed
for each period for which a statement of income/statement of opera
tions is presented?
[SFAS 132(R), par. 8 (AC P16.150A and P40.169A)]
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11. Are amounts related to the employer's statement of financial position
disclosed as of the measurement date used for each statement of
financial position presented?
[SFAS 132(R), par. 8 (AC P16.150A and P40.169A)]
Disclosures in Interim Financial Reports

12. If the entity is a publicly traded entity, does it disclose the following
information in its interim financial statements that include a statement
of income:

a. The amount of net periodic benefit cost recognized, for each period
for which a statement of income/operations is presented, showing
separately the service cost component, the interest cost compo
nent, the expected return on plan assets for the period, the amor
tization of the unrecognized transition obligation or transition
asset, the amount of recognized gains or losses, the amount of
prior service cost recognized, and the amount of gain or loss
recognized due to a settlement or curtailment?

b. The total amount of the employer's contributions paid, and ex
pected to be paid, during the current fiscal year, if significantly
different from amounts previously disclosed pursuant to para
graph 5(g) of SFAS 132 (revised 2003)? (Estimated contributions
may be presented in the aggregate combining (1) contributions
required by funding regulations or laws, (2) discretionary contri
butions, and (3) noncash contributions.)
[SFAS 132(R), par. 9; APB 28, par. 30, as amended by SFAS 132(R),
par. 15 (AC I73.146)]
13. If the entity is a nonpublic entity, does it disclose in interim periods,
for which a complete set of financial statements is presented, the total
amount of the employer's contributions paid, and expected to be paid,
during the current fiscal year, if significantly different from amounts
previously disclosed pursuant to paragraph 8(f) of SFAS 132 (revised
2003)? (Estimated contributions may be presented in the aggregate
combining (a) contributions required by funding regulations or laws,
(b) discretionary contributions, and (c) noncash contributions.)
[SFAS 132(R), par. 10 (AC P16.150B and P40.169B)]

Defined Contribution Plans
14. Does the employer disclose the amount of cost recognized for defined
contribution pension plans and for other defined contribution postre
tirement benefit plans for all periods presented separately from the
amount of cost recognized for defined benefit plans?
[SFAS 132(R), par. 11 (AC P16.162 and P40.198)]
15. Do disclosures include a description of the nature and effect of any
significant changes during the period affecting comparability, such as
a change in the rate of employer contributions, a business combina
tion, or a divestiture?
[SFAS 132(R), par. 11 (AC P16.162 and P40.198)]

Multiemployer Plans
16. Has the employer disclosed the amount of contributions to multiem
ployer plans for each annual period for which a statement of income/
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statement of operations is presented? (An employer may disclose total
contributions to multiemployer plans without disaggregating the
amounts attributable to pension plans and other postretirement bene
fit plans.)
[SFAS 132(R), par. 12 (AC P16.166 and P40.178)]

★♦17. Is a description of the nature and effect of any changes affecting
comparability, such as a change in the rate of employer contributions,
a business combination, or a divesture, disclosed?
[SFAS 132(R), par. 12 (AC P16.166 and P40.178)]
★♦18. In some situations, withdrawal from a multiemployer plan may result
in an employer having an obligation to the plan for a portion of the
unfunded benefit obligation of the pension plans and other postretire
ment benefit plans:

a. If withdrawal under circumstances that would give rise to an
obligation is either probable or reasonably possible, have the
provisions of SFAS 5 been applied? (See also Question 7 in "Other
Financial Statement Disclosures, Section D—Commitments and
Contingencies.")
[SFAS 132(R), par. 13; SFAS 87, par. 70 (AC P16.167)]
b. If it is either probable or reasonably possible that (a) an employer
would withdraw from the plan under circumstances that would
give rise to an obligation or (b) an employer's contribution to the
fund would be increased during the remainder of the contract
period to make up a shortfall in the funds necessary to maintain
the negotiated level of benefit coverage (a "maintenance of bene
fits" clause), has the employer applied the provisions of SFAS 5?
(See also Question 7 in "Other Financial Statement Disclosures,
Section D—Commitments and Contingencies.")
[SFAS 132(R), par. 13; SFAS 106, par. 83 (AC P40.179)]
Disclosure Requirements Related to the Medicare Prescription Drug,
Improvement and Modernization Act of 2003

Note: FSP FAS 106-1 permits a sponsor of a postretirement health care
plan that provides a prescription drug benefit to make a one-time election
to defer recognizing the effects of the Act in accounting for its plan under
SFAS 106 and providing disclosures related to the plan required by SFAS
132 (revised 2003) until authoritative guidance on the accounting for the
federal subsidy is issued, or certain other events occur. See Questions 22
through 24 for disclosures required by FSP FAS 106-2.

★♦19. If the entity that sponsors a postretirement health care plan that
provides prescription drug benefits and elects the deferral provided
by FSP FAS 106-1, is the following disclosed in annual or interim
financial statements:
a. The existence of the Act and the fact that, in accordance with FSP
FAS 106-1, any measures of the accumulated postretirement bene
fit obligation or net periodic postretirement benefit cost in the
financial statements or accompanying notes do not reflect the
effects of the Act on the plan?
b. The fact that specific authoritative guidance on the accounting for
the federal subsidy is pending and that guidance, when effective,
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____

___

Note: A plan sponsor that elects the deferral is also encouraged to disclose
additional information that it believes is appropriate for the reader to
understand the Act's possible economic consequences including whether
the sponsor would need to amend the plan (regardless of whether the
sponsor intends to do so) in order to benefit from the new legislation.
[FSP FAS 106-1, par. 10 (AC P40.863)]

20. If a plan sponsor does not elect the deferral provided by FSP 106-1,
do the annual or interim financial statements disclose:

a. The effects, if any, of the Act on the reported measure of the
accumulated postretirement benefit obligation?

____

b. How that effect has been, or will be reflected, in the net postretire
ment benefit costs of current or subsequent periods?

____

c. The effects of any changes in estimates of participation rates or per
capita claims costs as a result of the Act?

____

d. The fact that specific authoritative guidance on the accounting for
the federal subsidy is pending and that guidance, when effective,
could require the sponsor to change previously reported informa
tion?

____

e. To the extent a plan sponsor's accounting recognizes the effect of
the federal subsidy, the basis for concluding that its plan is at least
"actuarially equivalent" (as defined in the Act) to Medicare Part D?
[FSP FAS 106-1, par. 11 (AC P40.864)]

★♦21. If a plan sponsor does not elect the deferral provided by FSP FAS
106-1, and the sponsor concludes that some or all of the federal
subsidy related to prescription drug costs included in the accumu
lated postretirement benefit obligation should be recognized imme
diately as a component of income from continuing operations, is any
amount recognized reported as a separate line item on the face of the
income statement or statement of activities?
[FSP FAS 106-1, par. 11 (AC P40.864)]
Note: FSP FAS 106-2 superseded FSP FAS 106-1. Except for certain non
public entities, FSP FAS 106-2 is effective for the first interim or annual
period beginning after June 15,2004. For a nonpublic entity, as defined in
SFAS 87, that sponsors one or more defined benefit postretirement health
care plans that provide prescription drug coverage but of which no plan
has more than 100 participants, FSP FAS 106-2 is effective for fiscal years
beginning after December 15, 2004. Earlier application is encouraged in
financial statements for any period including or following enactment of
the Act that have not yet been issued as of May 19,2004.
[FSP FAS 106-2 (AC P40.880)]

★♦ 22. Until an employer is able to determine whether benefits provided by
its plan are actuarially equivalent, do the financial statements for
interim or annual periods disclose:
a. The existence of the Act?
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____

___

a. The reduction in the accumulated postretirement benefit obliga
tion for the subsidy related to benefits attributed to past service?

____

___

b. The effect of the subsidy on the measurement of net periodic
postretirement benefit cost for the current period?

____

___

____

___

____

___

Identification of the other entity and the nature of its relation
ship with the reporting entity that results in control?

____

___

Summarized financial data of the other entity, including total
assets, liabilities, net assets, revenue, and expenses; and re
sources that are held for the benefit of the reporting entity or
that are under its control?

____

___

____

___

____

___

b. The fact that measures of the accumulated postretirement benefit
obligation or net periodic postretirement benefit cost do not reflect
any amount associated with the subsidy because the employer is
unable to conclude whether the benefits provided by the plan are
actuarially equivalent to Medicare Part D under the Act?
[FSP FAS 106-2, par. 20 (AC P40.877)]

N/A

23. In interim and annual financial statements for the first period in which
an employer includes the effects of the subsidy in measuring the
accumulated postretirement benefit obligation and the first period in
which an employer includes the effects of the subsidy in measuring
net periodic postretirement benefit cost, do disclosures include:

c. Any other disclosures required by paragraph 5(r) of SFAS 132
(revised 2003)?
[FSP FAS 106-2, par. 21 (AC P40.878)]

24. For purposes of the disclosures required by paragraphs 5(a) and 5(f)
of SFAS 132 (revised 2003), are the gross benefit payments (paid and
expected, respectively), including prescription drug benefits, and
separately the gross amount of the subsidy receipts (received and
expected, respectively) disclosed?
[FSP FAS 106-2, par. 22 (AC P40.879)]

J.

Related Organizations and Economic Dependency
1.

Related parties and economic dependency:
a. If the reporting entity controls a separate not-for-profit entity
through a form other than majority ownership or voting interest,
has an economic interest in that other entity, and consolidated
financial statements are not presented, do the notes to the financial
statements include the following disclosures:
(1)

(2)

(3)

Disclosures set forth in SFAS 57 (see Question 2g below)?
[AAG, par. 11.12]

b. In cases where the entity has control (other than through owner
ship or sole corporate membership) or an economic interest in
another entity, but not both, has the entity made the required
disclosures set forth in SFAS 57 (see Question 2g below)?
[AAG, par. 11.13]

\

c. If consolidated financial statements are presented and they in
clude a controlled not-for-profit organization, are the following
disclosed:
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____

___

____

___

____

___

____

___

____

___

____

___

A description of the transaction, including transac
tions to which no amounts or nominal amounts were
ascribed?

____

___

(ii) Other information deemed necessary to an under
standing of the effects of the transaction on the financial
statements?

____

___

(iii) The dollar amount of transactions?

____

___

(iv) The effect of any changes in the method of establishing
the terms from that used in the preceding period?

____

___

____

___

____

___

a. A description of the principal services performed by the health
care provider and the revenue sources for the entity's services?

____

___

b. The fact that financial statements prepared in accordance with
GAAP require the use of management's estimates?

____

___

(1)

(2)

Restrictions made by entities outside of the reporting entity
on distributions from the controlled not-for-profit organiza
tion to the reporting entity? and

Any resulting unavailability of the net assets of the controlled
not-for-profit organization for use by the reporting entity?
[AAG, par. 11.15]

d. Are significant relationships and transactions not in the ordinary
course of business with directors, management, medical staff, etc.
disclosed in the financial statements?
[AAG, par. 11.35]
e. If representations about transactions with related parties are
made, do they avoid the implication that the related party trans
actions were consummated at arm's length, or if such implications
are made, can they be substantiated?
[SFAS 57, par. 3 (AC R36.103)]

f.

If (d) the reporting entity and one or more other enterprises are
under common ownership or management control and (b) the
existence of the control could result in operating results or finan
cial position of the reporting entity being significantly different
from that if the enterprise were autonomous, is the nature of the
controlled relationships disclosed (even if there are no transac
tions between the enterprises)?
[SFAS 57, pars. 2 and 4 (AC R36.102 and .104)]

g. For related-party transactions, do disclosures include:

(1)

The nature of the relationships involved?

(2)

For each period for which an income statement/statement of
operations is presented:
(i)

(3)

(4)

Amounts due from or to related parties as of the date of each
balance sheet presented and, if not otherwise apparent, the
terms and manner of settlement?
[SFAS 57, par. 2 (AC R36.102)]
The information required by paragraph 49 of SFAS 109?
[SFAS 109, par. 288(s) (AC R36.102)]

K. Risks and Uncertainties
1.

Are the following disclosed:

FSP §11,200.03

N/A

83

Financial Statements and Notes Checklist
Yes

No

N/A

____

____

____

____

____

____

____

____

____

____

____

____

a. Concentrations in the volume of the business transacted with
a particular customer (patient), supplier, lender, grantor, or
contributor?

____

____

____

b. Concentrations in revenue from particular services provided or
fund-raising events?

____

____

____

c. Concentrations in the available sources of supply of labor, serv
ices, or of applicable licenses necessary to provide services?

____

____

____

d. Concentrations in the market or geographical area in which an
entity conducts its operations, including the carrying amounts of
net assets and their locations?

____

____

____

e. Concentrations of labor subject to collective bargaining agree
ments, including the percentage of the labor force covered by a
collective bargaining agreement and the percentage of the labor
force covered by a collective bargaining agreement that will expire
within one year?

____

____

____

____

____

____

c. If the reporting entity operates in more than one business, is the
relative importance of its operations in each business and the basis
for the determination (for example, assets, revenues, or earnings)
disclosed?
[SOP 94-6, pars. 10 and 11]

★♦2.

If known information available before the financial statements are
issued indicates (1) it is at least reasonably possible that the estimate(s)
used in preparing the financial statements will change in the near
term, and (2) the effect(s) of the change will be material, are the
following disclosed:

a. The nature of uncertainties inherent in estimates used to deter
mine the carrying amounts of assets and liabilities, or used to
disclose gain or loss contingencies?
b. That a material change in the estimate could occur in the near term?
[SOP 94-6, pars. 12-14]

3.

4.

If the estimate in Question 2 above involves a loss contingency cov
ered by SFAS 5, Accounting for Contingencies, do disclosures include
an estimate of the possible loss or range of loss, or state that such an
estimate cannot be made?2
[SOP 94-6, par. 14]
If, based on information known to management before the financial
statements are issued, (1) the concentration existed at the date of the
financial statements, (2) the concentration made the enterprise vulner
able to the risk of near-term severe impact, and (3) it is at least
reasonably possible that the events that could cause the severe impact
will occur in the near term, are the following disclosed:

f.

Information adequate to inform users of the general nature of the
risk associated with the concentration?
[SOP 94-6, pars. 21-24]

2 If risk reduction techniques are used to mitigate losses or the uncertainty that may result from certain events, these disclosures are
encouraged but not required. [SOP 94-6, par. 15]
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♦ L.

Segment Information
Note: Public business enterprises are required to provide the disclosures
described in SFAS 131, Disclosures about Segments of an Enterprise and
Related Information, and nonpublic business enterprises are encouraged to
do so.

1.

Are the following items disclosed for each reportable segment for each
period for which an income statement is presented:
a. General information as described in SFAS 131, paragraph 26?
b. Information about profit or loss (including certain revenues and
expenses included in profit or loss), segment assets, and the basis
of measurement, as described in SFAS 131, paragraphs 27-31?
c. Reconciliations of the totals of segment revenues, reported profit
or loss, assets, and other significant items to corresponding enter
prise amounts as described in SFAS 131, paragraph 32?

d. Interim period information as described in SFAS 131, paragraph 33?
[SFAS 131, pars. 25-33, as amended by SFAS 135, par. 4 (AC
S30.124-.132)]

Note: Reconciliations of balance sheet amounts for reportable segments
to consolidated balance sheet amounts are required only for each year for
which a balance sheet is presented.
[SFAS 131, par. 25, as amended by SFAS 135, par. 4(x) (AC S30.124)]
2.

If an enterprise changes the structure of its internal organization in a
manner that changes the composition of its reportable segments, has
it disclosed whether it has restated the corresponding items of seg
ment information for earlier periods?
[SFAS 131, par. 34 (AC S30.133)]

3.

If segment information is not restated to reflect a change in the
composition of reportable segments, is current year segment informa
tion under both the old basis and the new basis of segmentation
disclosed, unless it is impracticable to do so?
[SFAS 131, par. 35 (AC S30.134)]

4.

For all enterprises subject to SFAS 131, including those that have a
single reportable segment, are the following enterprise-wide items
disclosed:

a. Revenues from external customers for each product and service or
each group of similar products and services unless it is impracti
cable to do so?
b. Geographic information as described in paragraph 38 unless it is
impracticable to do so?
c. Information about the extent of the enterprise's reliance on its
major customers as described in paragraph 39?
[SFAS 131, pars. 36-39 (AC S30.135-.138)]

5.

If the information described in Questions 4a and 4b above has not been
disclosed because it is impracticable, is that fact disclosed?
[SFAS 131, pars. 37 and 38 (AC S30.136-.137)]
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M. Subsequent Events

★ 1.

Are subsequent events that provide evidence about conditions that
did not exist at the date of the balance sheet, but arose subsequent to
that date, adequately disclosed to keep the financial statements from
being misleading?
[SFAS 5, par. 11 (AC C59.112); APB 16 (AC B50.120); SAS 1, secs.
560.05-.07, .09, and 561.01-10, as amended by SAS 98 (AU 560.05-.07,
.09, and 561.01-.10)]

♦ 2.

Are subsequent events that provide evidence about conditions that
did not exist at the date of the balance sheet, but arose subsequent to
that date, adequately disclosed to keep the financial statements from
being misleading?
[SFAS 5, par. 11 (AC C59.112); SAS 1, secs. 560.05-.07, .09, and 561.01.10, as amended by SAS 98 (AU 560.05-.07, .09, and 561.01-.10)]

Note: Consider the appropriateness of dual dating the auditor's report if
a subsequent event is disclosed in the financial statements.
[SAS 1, sec. 530.05 (AU 530.05)]

N.

Stock-Based Compensation/Share-Based Payment

Note: If the provisions of SFAS 123(R), Share-Based Payment, are in effect
or are applied, replace Questions 1 through 9 with Questions 10 through
14. SFAS 123(R) replaces SFAS 123, Accounting for Stock-Based Compensa
tion, supersedes APB 25, Accounting for Stock Issued to Employees, and
amends APB 28, Interim Financial Reporting. The provisions of SFAS 123(R)
are effective (a) for public entities that do not file as small business
issuers—as of the beginning of the first interim or annual reporting period
that begins after June 15, 2005; (b) for public entities that file as small
business issuers—as of the beginning of the first interim or annual report
ing period that begins after December 15, 2005; and (c) for nonpublic
entities—as of the beginning of the first annual reporting period that
begins after December 15, 2005. See paragraphs 69 through 85 of SFAS
123(R) for further effective date and transition information. Early adop
tion for interim or annual periods for which financial statements or interim
reports have not been issued is encouraged.
[SFAS 123(R), pars. 3 and 69-85]
♦ 1.

If an entity continues to apply APB 25 in accounting for its stock-based
compensation arrangements, is the pro forma net income and, if
presented, earnings per share (determined as if the fair value based
method had been applied in measuring compensation cost) prominently
disclosed?
[SFAS 123, par. 11, SFAS 123, par. 45, as amended by SFAS 148, par.
2(e) (AC C36.110 and .144)]

♦ 2.

If an entity has one or more stock-based compensation plans, is a
description of the plan(s), including the general terms of awards
under the plan(s), disclosed?
[SFAS 123, par. 46 (AC C36.145)]

♦ 3.

Is the information in paragraph 47 of SFAS 123 disclosed for each year
for which an income statement is presented?
[SFAS 123, par. 47a-f (AC C36.146)]
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♦ 4.

If an entity grants options under multiple stock-based employee
compensation plans, are the items in paragraph 47 disclosed sepa
rately for different types of awards to the extent that the differences
in the characteristics of the awards make separate disclosure impor
tant to an understanding of the entity's use of stock-based compen
sation?
[SFAS 123, par. 47 (AC C36.146)]

♦ 5.

Are the following disclosed for options outstanding at the date of the
latest statement of financial position presented:
a. The range of exercise prices?
b. The weighted-average exercise price?
c. The weighted-average remaining contractual life?
[SFAS 123, par. 48 (AC C36.147)]

♦ 6.

If the range of exercise prices is wide, are they segregated into ranges?
[SFAS 123, par. 48 (AC C36.147)]

♦ 7.

Are the following disclosed for each range identified in Question 6:

a. The number, weighted-average exercise price, and weightedaverage remaining contractual life of options outstanding?

b. The number and weighted-average exercise price of options cur
rently exercisable?
[SFAS 123, par. 48 (AC C36.147)]
♦ 8.

Is the following information disclosed in the "Summary of Significant
Accounting Policies" or its equivalent:

a. The method used—either the intrinsic value method or the fair
value based method—to account for stock-based employee com
pensation in each period presented?
b. For an entity that adopts the fair value recognition provisions of
SFAS 148 for all financial statements in which the period of adop
tion is presented, a description of the method of reporting the
change in accounting principle?
c. If awards of stock-based employee compensation were outstand
ing and accounted for under the intrinsic value method of APB 25
for any period for which an income statement is presented, a
tabular presentation of the following information for all periods
presented—

(1)

Net income and basic and diluted earnings per share as
reported?

(2)

The stock-based employee compensation cost, net of related
tax effects, included in the determination of net income as
reported?

(3)

The stock-based employee compensation cost, net of related
tax effects, that would have been included in the determina
tion of net income if the fair value based method had been
applied to all awards?

(4)

Pro forma net income as if the fair value based method had
been applied to all awards?
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(5)

♦ 9.

No

N/A

Pro forma basic and diluted earnings per share as if the fair
value based method had been applied to all awards?
[SFAS 123, par. 45, as amended by SFAS 148, par. 2(e) (AC
C36.144)]

Is the following information about stock-based employee compensa
tion costs disclosed prominently and in tabular form for all periods
presented if awards of stock-based employee compensation were
outstanding and accounted for under the intrinsic value method of
APB 25 for any period for which an income statement is presented:

a. Net income and basic and diluted earnings per share as reported?
b. The stock-based employee compensation cost, net of related tax
effects, included in the determination of net income as reported?

c. The stock-based employee compensation cost, net of related tax
effects, that would have been included in the determination of net
income if the fair value based method had been applied to all awards?

d. Pro forma net income as if the fair value based method had been
applied to all awards?
e. Pro forma basic and diluted earnings per share as if the fair value
based method had been applied to all awards?
[APB 28, par. 30, as amended by SFAS 148, par. 3 (AC I73.146)]
♦ 10. If the entity has one or more share-based payment arrangements, does
it disclose information that enables users of the financial statements
to understand:

a. The nature and terms of such arrangements that existed during
the period and the potential effects of those arrangements on
shareholders?
b. The effect of compensation cost arising from share-based payment
arrangements on the income statement?
c. The method of estimating the fair value of the goods or services
received, or the fair value of the equity instruments granted (or
offered to grant), during the period?

d. The cash flow effects resulting from share-based payment arrange
ments?
[SFAS 123(R), par. 64 (AC C35.164)]

Note: Paragraph A240 of SFAS 123(R) includes minimum information
needed to achieve the disclosure objectives in Question 10. The minimum
information disclosures in paragraph A240 are presented in Question 11.
In some circumstances, an entity may need to disclose information beyond
that listed in paragraph A240 to achieve the disclosure objectives.
[SFAS 123(R), pars. 64 and A240 (AC C35.164)]
♦ 11. Does the entity disclose:

a. A description of the share-based payment arrangement(s), includ
ing the general terms of awards under the arrangement(s)?
b. The method used for measuring compensation cost from share
based payment arrangements with employees?
c. For the most recent year for which an income statement is provided,
the number and weighted-average exercise prices (or conversion
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ratios) for each of the following groups of share options (or share
units):

(1)

Those outstanding at the beginning of the year?

(2)

Those outstanding at the end of the year?

(3)

Those exercisable or convertible at the end of the year?

(4)

Those granted during the year?

(5)

Those exercised or converted during the year?

(6)

Those forfeited during the year?

(7)

Those expired during the year?

d. For the most recent year for which an income statement is pro
vided, the number and weighted-average grant-date fair value
(calculated value for a nonpublic entity that uses that method;
intrinsic value if a reasonable estimate of fair value is not possible)
of equity instruments not specified in Question 11c for each of the
following groups of equity instruments:
(1)

Those nonvested at the beginning of the year?

(2)

Those nonvested at the end of the year?

(3)

Those granted during the year?

(4)

Those vested during the year?

(5)

Those forfeited during the year?

e. For each year an income statement is provided:

f.

(1)

Weighted-average grant-date fair value (calculated value for
a nonpublic entity that uses that method; intrinsic value if
reasonable estimate of fair value is not possible) of equity
options or other equity instruments granted during the year?

(2)

Total intrinsic value of options exercised (or share units con
verted), share-based liabilities paid, and total fair value of
shares vested during the year?

For fully vested share options (or share units) and share options
expected to vest at the date of the latest statement of financial
position:

(1)

Number, weighted-average exercise price (or conversion ra
tio), aggregate intrinsic value, and weighted-average remain
ing contractual term of options (or share units) outstanding?

(2)

Number, weighted-average exercise price (or conversion ra
tio), aggregate intrinsic value (except for nonpublic entities)
and weighted-average remaining contractual term of options
(or share units) currently exercisable (or convertible)?

g. For each year an income statement is presented, a description of
the method used during the year to estimate fair value (or calcu
lated value) of awards under share-based payment arrangements?
(Note: Not required if intrinsic value is used pursuant to para
graphs 24 and 25 of SFAS 123(R).)
h. For each year an income statement is presented, a description of
significant assumptions used during the year to estimate fair value
(or calculated value) of share-based compensation awards, includ
ing, if applicable: (Note: Not required if intrinsic value is used
pursuant to paragraphs 24 and 25 of SFAS 123(R).)
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(1)

Expected term of share options and similar instruments, in
cluding discussion of the method used to incorporate the
contractual term of the instruments and employees' expected
exercise and post-vesting employment termination behavior
into the fair value (or calculated value) of the instrument?

(2)

Expected volatility of the entity's shares and the method used
to estimate it?

(3)

The range of expected volatilities used and weighted-average
expected volatility if a method that employs different vola
tilities during the contractual term is used?

(4)

For a nonpublic entity that uses the calculated value method,
the reasons why it is not practicable to estimate expected
volatility of its share price, the appropriate industry sector
index selected, reasons for selecting the particular index, and
how historical volatility was calculated using that index?

(5)

Expected dividends?

(6)

If a method that employs different dividend rates during the
contractual term is used, the range of expected dividends
used and weighted-average expected dividends?

(7)

Risk free rates?

(8)

If a method that employs different risk-free rates is used, the
range of risk-free rates used?

(9)

Discount for post-vesting restrictions and method for esti
mating it?

No

N/A

Note: If an entity grants equity or liability instruments under multiple
share-based payment arrangements with employees, the information in
Questions 11a through 11h is presented separately for different types of
awards to the extent the differences in the characteristics of the awards
make separate disclosure important to understanding the use of share
based compensation.
[SFAS 123(R), pars. 65 and A240 (AC C35.399A)]

i.

j.

For each year an income statement is presented:
(1)

Total compensation cost for share-based payment arrange
ments (a) recognized in income as well as total recognized tax
benefit related thereto and (b) total compensation cost capi
talized as part of asset cost?

(2)

Description of significant modifications?

As of the latest balance sheet date presented, total compensation
cost related to nonvested awards not yet recognized and the
weighted-average period over which is it expected to be recog
nized?

k. If not separately disclosed elsewhere, amount of cash received
from exercise of share options and similar instruments granted
under share-based payment arrangements and the tax benefit
realized from stock options exercised during the annual period?
l.

If not separately disclosed elsewhere, amount of cash used to
settle equity instruments granted under share-based payment
arrangements?
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m. Description of policy, if any, for issuing shares (including the
source) upon share option exercise (or share unit conversion)?

n. If the entity expects to repurchase shares in the following annual
period, an estimate of the amount (or range if more appropriate)
of shares to be repurchased during that period?
[SFAS 123(R), par. A240 (AC C35.399A)]
♦ 12. If the entity acquires goods or services other than employee services
in share-based payment transactions, does it provide disclosures
similar to those required by paragraph 64 of SFAS 123(R) (Question
10 above) to the extent that those disclosures are important to an
understanding of the effects of those transactions on the financial
statements?
[SFAS 123(R), par. 65 (AC C35.165)]
♦ 13. In the period that SFAS 123(R) is adopted, does the entity disclose the
effect of the change from applying the original provisions of SFAS
123 on income from continuing operations, income before income
taxes, net income, cash flow from operations, cash flow from financ
ing activities, and basic and diluted earnings per share?
[SFAS 123(R), par. 84]

♦ 14. In the period that SFAS 123(R) is adopted, if awards under share
based payment arrangements with employees are accounted for un
der the intrinsic value method of APB 25 for any reporting period for
which an income statement is presented, and if the entity is a public
entity, does it continue to provide the tabular presentation of the
following information that was required by paragraph 45 of SFAS 123
for all those periods:
a. Net income and basic and diluted earnings per share as reported?
b. The share-based employee compensation cost, net of related tax
effects, included in net income as reported?

c. The share-based employee compensation cost, net of related tax
effects, that would have been included in net income if the fair
value-based method had been applied to all awards?

d. Pro forma net income as if the fair-value-based method had been
applied to all awards?
e. Pro forma basic and diluted earnings per share as if the fair-value
based method had been applied to all awards?
[SFAS 123(R), par. 84]

Note: Entities may disclose supplemental information believed useful to
investors and creditors, in addition to the information required by SFAS
123(R), provided the supplemental information is reasonable and does not
lessen the prominence and credibility of required information.
[SFAS 123(R), par. A242 (AC C35.399C)]
O.

Transfers of Financial Assets

★♦1.

If it is not practicable to estimate the fair value of certain assets
obtained or liabilities incurred in transfers of financial assets during
the period, are those items and the reasons why it is not practicable to
estimate fair value described in the notes to the financial statements?
[SFAS 140, par. 17d (AC F39.110)]
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2.

Is the policy for requiring collateral or other security disclosed if the
reporting entity has entered into securities lending transactions?
[SFAS 140, par. 17a(1) (AC F39.110)]

3.

If the entity has pledged any of its assets as collateral that are not
reclassified and separately reported in the statement of financial
position pursuant to paragraph 15a of SFAS 140, is the carrying
amount and classification of those assets as of the date of the latest
statement of financial position presented?
[SFAS 140, par. 17a(2) (AC F39.110)]

4.

If the entity has accepted collateral that it is permitted by contract or
custom to sell or repledge, is the fair value, as of the date of each
statement of financial position presented, of that collateral and of the
portion of that collateral that it has sold or repledged disclosed?
[SFAS 140, par. 17a(3) (AC F39.110)]

5.

Is information about the sources and uses of that collateral, as of the
date of each statement of financial position presented, disclosed?
[SFAS 140, par. 17a(3) (AC F39.110)]

No

N/A

P. Long-Lived Assets and Disposal Groups to Be Disposed Of

Reporting Discontinued Operations
1.

Are the results of operations of a component of an entity (as that phrase
is defined in SFAS 144) that either has been disposed of or is classified
as held for sale reported in discontinued operations in accordance
with paragraph 43 of SFAS 144 (Questions 6,7,8, and 9 below) if both
of the following conditions are met:
a. The operations and cash flows of the component have been (or will
be) eliminated from the ongoing operations of the entity as a result
of the disposal transaction?
b. The entity will not have any significant continuing involvement in
the operations of the component after the disposal transaction?
[SFAS 144, par. 42 (AC I14.102)]

2.

If the occurrence of a significant event or circumstance at any time
during the assessment period results in an expectation that the criteria
in paragraph 42 of SFAS 144 will be met by the end of the assessment
period, are the component's operations presented as discontinued
operations?
[EITF 03-13, par. 13]

★♦3.

Is the following information disclosed in the notes to the financial
statements for each discontinued operation that generates continuing
cash flows:

a. The nature of the activities that give rise to continuing cash flows?
b. The period of time continuing cash flows are expected to be
generated?

c. The principal factors used to conclude that the expected continu
ing cash flows are not direct cash flows of the disposed compo
nent?
[EITF 03-13, par. 17]

★♦4.

For each discontinued operation in which the ongoing entity will
engage in a "continuation of activities" with the disposed component
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after its disposal and for which the amounts presented in continuing
operations after the disposal transaction include a continuation of
revenues and expenses that were intercompany transactions (elimi
nated in consolidated financial statements) before the disposal trans
action, are the intercompany amounts before the disposal transaction
disclosed for all periods presented?
[EITF 03-13, par. 17]
5.

Are the types of continuing involvement, if any, that the entity will
have after the disposal transaction disclosed and is that information
disclosed in the period in which operations are initially classified as
discontinued?
[EITF 03-13, par. 17]

Note: EITF 03-13, Applying the Conditions in Paragraph 42 of FASB State
ment No. 144, Accounting for the Impairment or Disposal of Long-Lived
Assets, in Determining Whether to Report Discontinued Operations, should be
applied to a component of an enterprise that is either disposed of or
classified as held for sale in fiscal periods beginning after December 15,
2004. Operating results related to a component that is disposed of or
classified as held for sale within an enterprise's fiscal year that includes
the date EITF 03-13 is ratified (November 30, 2004) may be classified to
reflect the consensus.
[EITF 03-13, pars. 18-19]
6.

In a period in which a component of an entity either has been disposed
of or is classified as held for sale, does the income statement of a
business enterprise or statement of activities of a not-for-profit organi
zation for current and prior periods report the results of operations of
the component, including any gain or loss recognized in accordance
with paragraph 37 of SFAS 144, in discontinued operations?
[SFAS 144, par. 43 (AC I14.103)]

7.

Are the results of operations of a component classified as held for sale
reported in discontinued operations in the period(s) in which they
occur?
[SFAS 144, par. 43 (AC I14.103)]

★♦8.

Are the results of discontinued operations, less applicable income
taxes (benefit), reported as a separate component of income before
extraordinary items and the cumulative effect of accounting changes
(if applicable)?
[SFAS 144, par. 43 (AC I14.103)]

9.

Is the gain or loss recognized on the disposal disclosed either on the
face of the income statement or in the notes to the financial statements?
[SFAS 144, par. 43 (AC I14.103)]

★♦10. Are adjustments to amounts previously reported in discontinued
operations that are directly related to the disposal of a component of
an entity in a prior period classified separately in the current period
in discontinued operations?
[SFAS 144, par. 44 (AC I14.104)]

★♦11. Are the nature and amount of such adjustments (as discussed in
Question 6 above) disclosed?
[SFAS 144, par. 44 (AC I14.104)]
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Reporting Disposal Gains or Losses in Continuing Operations

★♦ 12. Is a gain or loss, that is recognized on the sale of a long-lived asset
(disposal group) that is not a component of an entity, included in
income from continuing operations before income taxes in the income
statement of a business enterprise and in income from continuing
operations in the statement of activities of a not-for-profit organization?
[SFAS 144, par. 45 (AC D60.118)]
13. If a subtotal such as "income from operations" is presented, does it
include the amounts of those gains or losses considered in Question
8 above?
[SFAS 144, par. 45 (AC D60.118)]

Reporting a Long-Lived Asset or Disposal Group Sold or Classified as
Held for Sale

★♦14. If the criteria of paragraph 30 of SFAS 144 are met (and thus a
long-lived asset is classified as held for sale) after the balance sheet
date but before issuance of the financial statements, does the longlived asset continue to be classified as held and used in those financial
statements when issued and is the information required by paragraph
47(a) of SFAS 144 (Question 19a below) disclosed in the notes to the
financial statements?
[SFAS 144, par. 33 (AC D60.110)]

★♦15. Is a long-lived asset that is classified as held for sale presented
separately in the statement of financial position?
[SFAS 144, par. 46 (AC D60.119)]
★♦ 16. Are the assets and liabilities of a disposal group that is classified as
held for sale presented separately in the asset and liability sections,
respectively, of the statement of financial position?
[SFAS 144, par. 46 (AC D60.119)]
★♦ 17. Are those assets and liabilities considered in Question 12 above, not
offset and presented as a single amount?
[SFAS 144, par. 46 (AC D60.119)]

★♦ 18. Are the major classes of assets and liabilities that are classified as held
for sale separately disclosed either on the face of the statement of
financial position or in the notes to financial statements?
[SFAS 144, par. 46 (AC D60.119)]

★♦ 19. Is the following information disclosed in the notes to the financial
statements that cover the period in which a long-lived asset (disposal
group) either has been sold or is classified as held for sale:
a. A description of the facts and circumstances leading to the ex
pected disposal, the expected manner and timing of that disposal,
and, if not separately presented on the face of the statement, the
carrying amount(s) of the major classes of assets and liabilities
included as part of a disposal group?
b. The gain or loss recognized in accordance with paragraph 37 of
SFAS 144 and if not separately presented on the face of the income
statement, the caption in the income statement or statement of
activities that includes that gain or loss?

c. If applicable, amounts of revenue and pretax profit or loss re
ported in discontinued operations?
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d. If applicable, the segment in which the long-lived asset (disposal
group) is reported under SFAS 131?
[SFAS 144, par. 47 (AC D60.120 and 114.105)]

★♦20. If either paragraph 38 or 40 of SFAS 144 applies, is a description of the facts
and circumstances leading to the decision to change the plan to sell the
long-lived asset (disposal group) and its effect on the results of operations
for the period and any prior periods presented disclosed in the notes to the
financial statements that include the period of that decision?
[SFAS 144, par. 48 (AC D60.121 and I14.106)]
★♦21. If a long-lived asset is to be disposed of other than by sale, does it
continue to be classified as held and used until it is disposed of?
[SFAS 144, par. 27 (AC D60.104)]
Q. Asset Retirement Obligations

★♦1.

Is the following information about its asset retirement obligations
disclosed:

a. A general description of the asset retirement obligations and the
associated long-lived assets?
b. The fair value of assets that are legally restricted for purposes of
settling asset retirement obligations?
c. A reconciliation of the beginning and ending aggregate carrying
amount of asset retirement obligations showing separately the
changes attributable to (1) liabilities incurred in the current period,
(2) liabilities settled in the current period, (3) accretion expense,
and (4) revisions in estimated cash flows, whenever there is a
significant change in one or more of those four components during
the reporting period?
[SFAS 143, par. 22 (AC A50.122)]

★♦ 2.

If the fair value of an asset retirement obligation cannot be reasonably
estimated is that fact and the reasons therefore disclosed?
[SFAS 143, par. 22 (AC A50.122)]

★♦3.

In addition to the disclosures required by paragraphs 19 (c), 19 (d),
and 21 of APB 20, is the liability for the asset retirement obligation
computed on a pro forma basis disclosed in the footnotes for the
beginning of the earliest year presented and at the end of all years
presented as if SFAS 143 and FASBI 47 had been applied during all
periods affected?
[SFAS 143, par. 27; FASBI 47, par. 11]

Notes: FASBI 47, Accounting for Conditional Asset Retirement Obligations—
an interpretation of FASB Statement No. 143, is effective no later than the end
of fiscal years ending after December 15, 2005 (December 31, 2005 for
calendar-year enterprises). Early adoption is encouraged.
[FASBI 47, par. 8]
SFAS 154, Accounting Changes and Error Corrections, which supersedes APB
20, is effective for accounting changes made in fiscal years beginning after
December 15,2005. SFAS 154 does not change the transition provisions of
any existing accounting pronouncements, including those in a transition
phase as of the effective date of SFAS 154.
[SFAS 154, par. 27]
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R. Impaired Loans
1.

Is the following information about loans that meet the definition of
impaired loans in SFAS 114 disclosed as of the date of each balance
sheet presented:

a. The total recorded investment in impaired loans?

____

___

b. The amount of that recorded investment for which there is a
related allowance for credit losses determined in accordance with
SFAS 114 and the amount of that allowance?

____

___

____

___

____

___

a. The average recorded investment in the impaired loans during the
period?

____

___

b. The related amount of interest income recognized during the time
within the period that the loans were considered impaired?

____

___

c. Unless not practicable, the amount of interest income recognized
using a cash-basis method of accounting during the time within
the period that the loans were impaired?

____

___

____

___

____

___

____

___

c. The amount of that recorded investment for which there is no
related allowance for credit losses determined in accordance with
SFAS 114?
[SFAS 118, par. 6i (AC 108.118a)]

2.

★♦3.

Is the policy for recognizing interest income on impaired loans, in
cluding how cash receipts are handled, disclosed?
[SFAS 118, par. 6i (AC I08.118b)]

Are the following disclosures made for each period for which an
income statement/statement of operations is presented:

d. Activity in the total allowance for credit losses related to loans,
including the balance in the allowance for credit losses account at
the beginning and end of each period, additions charged to opera
tions, direct write-downs charged against the allowance, and re
coveries of amounts previously charged off? (Note: The total
allowance for credit losses related to loans includes those amounts
that have been determined in accordance with SFAS 5 and SFAS
114.)
[SFAS 118, par. 6i (AC I08,118c, and .118A)]
S.

Impairment of Long-Lived Assets to Be Held and Used

1.

★♦2.

Is an impairment loss recognized for a long-lived asset (asset group)
to be held and used included in income from continuing operations
before income taxes in the income statement of a business enterprise
and in income from continuing operations in the statement of activi
ties of a not-for-profit organization?
[SFAS 144, par. 25 (AC I08.160)]
Is the following information disclosed in the notes to the financial
statements that include the period in which an impairment loss is
recognized:

a. A description of the impaired long-lived asset (asset group) and
the facts and circumstances leading to the impairment?
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b. If not separately presented on the face of the statement, the amount
of the impairment loss and the caption in the income statement or
statement of activities that includes that loss?

c. The method or methods for determining fair value (whether based
on a quoted market price, prices for similar assets, or another
valuation technique)?

d. If applicable, the segment in which the impaired long-lived asset
(asset group) is reported under SFAS 131, Disclosures about Seg
ments of an Enterprise and Related Information?
[SFAS 144, par. 26 (AC I08.161)]
T. Lessor Leases
1.

For sales-type and direct financing leases, do disclosures include:

a. The components of the net investment in sales-type and direct
financing leases as of each balance-sheet date:
Future minimum lease payments to be received, with sepa
rate deductions for (a) amounts representing executory costs,
including any profit thereon, included in minimum lease
payments and (b) the accumulated allowance for uncollect
ible minimum lease payments receivable?

____

(2) The unguaranteed residual values accruing to the benefit of
the lessor?

____

(1)

(3)

For direct financing leases only, initial direct costs?

____

(4)

Unearned income?

____

b. Future minimum lease payments to be received for each of the five
succeeding fiscal years as of the latest balance sheet presented?
c. Total contingent rentals included in income for each period for
which an income statement is presented?
[SFAS 13, par. 23a, as amended by SFAS 91, par. 25 (AC L10.119a)]

2.

★♦3.

4.

____
____

For operating leases, do disclosures include:

a. Cost and carrying amount (if different) of property on lease or held
for leasing by major classes of property according to nature or
function and the amount of accumulated depreciation in total as
of the date of the latest balance sheet/statement of financial posi
tion presented?

____

b. Minimum future rentals on noncancelable leases as of the date of
the latest balance sheet presented in the aggregate and for each of
the five succeeding fiscal years?

____

c. Total contingent rentals included in income for each period for
which an income statement/ statement of operations is presented?
[SFAS 13, par. 23b (AC L10.119b)]

____

Do disclosures include a general description of the lessor's leasing
arrangements?
[SFAS 13, par. 23 (AC L10.119c)]

____

For investments in leveraged leases, do disclosures include:

a. In the balance sheet, the amount of deferred taxes presented
separately from the remainder of the net investment?
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b. In the income statement or the notes thereto, separate presentation
(from each other) of pretax income from the leveraged lease, the
tax effect of pretax income, and the amount of investment tax
credit recognized as income during the period?
c. When leveraged leasing is a significant part of the lessor's business
activities in terms of revenue, net income, or assets, the compo
nents of the net investment balance in leveraged leases in the notes
to the financial statements?
[SFAS 13, par. 47 (AC L10.149)]

5.

★♦6.

For leasing transactions with related parties, are the nature and extent
of the transaction disclosed?
[SFAS 13, par. 29 (AC L10.125)]
For contingent rental income:

a. Has disclosure been made of the lessor's accounting policy for
contingent rental income?

b. If the lessor accrues contingent rental income prior to the lessee's
achievement of the specified target (provided achievement of that
target is considered probable), has disclosure been made of the
impact on rental income as if the lessor's accounting policy was to
defer contingent rental income until the specified target is met?
[EITF 98-9]

U. Lessee Leases
1.

For capital leases do disclosures include:

a. Gross amounts of assets recorded by major classes, as of the date
of each balance sheet/statement of financial position presented?
[SFAS 13, par. 16a.i. (AC L10.112a(1))]
b. Future minimum lease payments, as of the date of the latest
balance sheet/statement of financial position presented, in total
and for each of the next five years, with separate deductions for
executory costs, including any profit thereon, included in the
minimum lease payments, and for the amount of the imputed
interest necessary to reduce net minimum lease payments to pre
sent value?
[SFAS 13, pars. 10 and 16a.ii. (AC L10.106 and .112a(2))]

c. Total future minimum sublease rentals to be received in the future
under noncancelable subleases as of the date of the latest balance
sheet/statement of financial position presented?
[SFAS 13, par. 16a.iii (AC L10.112a(3))]
d. Total contingent rentals actually incurred for each period presented?
[SFAS 13, par. 16a.iv (AC L10.112a(4))]

e. Assets recorded under capital leases and the related accumulated
amortization, and obligations under those leases identified sepa
rately in the balance sheet/statement of financial position or a note?
[SFAS 13, pars. 13 and 16 (AC L10.112a(5))]
f.

Amount of amortization of capital lease assets or the fact that the
amortization of capital lease assets is included in depreciation
expense?
[SFAS 13, par. 13 (AC L10.112a(5))]
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2.

For operating leases that have initial or remaining noncancelable lease
terms in excess of one year, do disclosures include:

a. Future minimum rental payments required as of the latest balance
sheet/statement of financial position presented in total and for
each of the next five years?

b. Total future minimum rentals under noncancelable subleases as
of the date of the latest balance sheet/statement of financial posi
tion presented?
[SFAS 13, par. 16b (AC L10.112b)]
3.

For all operating leases, do disclosures include rental expense for each
period presented, with separate amounts for minimum rentals, con
tingent rentals, and sublease rentals?
[SFAS 13, par. 16c (AC L10.112c)]

★♦4.

Do disclosures include a general description of the lessee's leasing
arrangements including, but not limited to:
a. Bases for determination of contingent rentals?
b. Existence and terms of any renewal or purchase options or escala
tion clauses?
c. Restrictive covenants?
[SFAS 13, par. 16d (AC L10.112d)]

5.

Is the nature and extent of leasing transactions with related parties
disclosed?
[SFAS 13, par. 29 (AC L10.125)]

★♦6.

If material, is the accounting policy used in recognizing amounts
related to a modification of an operating lease (that does not change
the lease classification) disclosed?
[EITF 95-17]

Continuing Care Retirement Communities (CCRCs)
A. Refundable Advance Fees
1.

Is the estimated amount of advance fees expected to be refunded to
current residents reported as a liability?
[AAG, par. 14.22]

2.

Is the remaining amount of advance fees reported in the balance sheet
as deferred revenue?
[AAG, par. 14.22]

3.

Are the following disclosed:
a. The gross amount of contractual refund obligations under existing
contracts?
b. The CCRC's refund policy?
[AAG, par. 14.22]

4.

Are amounts refunded disclosed in the statement of cash flows as a
financing transaction?
[AAG, par. 14.22]
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Is the amortization method for deferred revenue disclosed?
[AAG, par. 14.23]

B. Fees Refundable to Residents Only From Reoccupancy Proceeds of a
Contract Holder's Unit
1.

Are the following reported as deferred revenue:
a. The portion of fees to be paid to current residents or their desig
nees, only to the extent of a contract holder's unit reoccupancy
proceeds, if law and management policy and practice support the
withholding of refunds under this condition?
b. Similar amounts received from new residents in excess of the
amount to be paid to previous residents or their designees?
[AAG, par. 14.25]

C. Nonrefundable Advance Fees
1.

★♦2.

Are nonrefundable advance fees reported as deferred revenue?
[AAG, par. 14.26]
Is unamortized deferred revenue reported as revenue upon a resi
dent's death or contract termination?
[AAG, par. 14.23]

D. Obligation to Provide Future Services and Use of Facilities to Current
Residents
1.

If the obligation to provide future services and use of facilities to
current residents under continuing-care contracts results in a liability,
are the following disclosed:
a. The carrying amount of the liability that is presented at present
value in the financial statements (if not separately disclosed in the
balance sheet/statement of financial position)?
b. The interest rate used to discount that liability?
[AAG, par. 14.31]

E.

Costs of Acquiring Initial Continuing-Care Contracts

★♦1.

Are continuing-care contract acquisition costs expensed if incurred
after (a) the CCRC is substantially occupied or (b) one year following
completion?
[AAG, par. 14.33]

F. Other

★♦1.

Do the notes to the financial statements of the CCRC include a
description of the CCRC and the nature of the related continuing-care
contracts entered into by the CCRC?
[AAG, par. 14.35]

★♦2.

Do the notes to the financial statements of the CCRC include the
statutory escrow or similar requirements?
[AAG, par. 14.35]
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OMB Circular A-133 Presentation Requirements
1.

Does the schedule of expenditures of federal awards disclose the basis
of accounting and the significant accounting policies used in prepar
ing the schedule?
[AAG-SLA, par. 7.05]

2.

Did the auditee prepare a schedule of expenditures of federal awards
for the period covered by the auditee's financial statements that, at a
minimum:

a. Lists individual federal programs by federal agency?

b. Include, for federal awards received as a subrecipient, the name
of the pass-through entity and the identifying number assigned by
the pass-through entity?
c. Provide the total federal awards expended for each individual
federal program and the CFDA number or other identifying num
ber when the CFDA information is not available?

d. Include notes that describe the significant accounting policies used
in preparing the schedule?
e. For federal awards received as a pass-through entity, identify, to
the extent practical, the total amount provided to subrecipients
from each federal program?
f.

3.

Include, in either the schedule or a note to the schedule, the value
of federal awards expended in the form of noncash assistance, the
amount of insurance in effect during the year, and loans or loan
guarantees outstanding at year end?
[AAG-SLA, par. 7.06]

If nonfederal data are presented in the schedule of expenditures of
federal awards:
a. Are the nonfederal data segregated and clearly designated as
nonfederal?

b. Is the title of the schedule modified to indicate that nonfederal
awards are included?
[AAG-SLA, par. 7.09]

4.

If the auditee is unable to obtain the CFDA number, does the schedule
include:

a. A statement that the CFDA number is not available?
b. The program's name and, if available, other identifying numbers?
[AAG-SLA, par. 7.10]
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Auditors' Reports Checklist
.01 This checklist has been developed by the staff of the Accounting and Auditing Publications Team of
the AICPA as a nonauthoritative practice aid. This checklist contains the basic requirements for reporting on
an audit of the financial statements in accordance with AICPA professional standards (GAAS) and Public
Company Accounting Oversight Board (PCAOB) Auditing Standard No. 1, References in Auditors' Reports to
the Standards of the Public Company Accounting Oversight Board. It does not contain all requirements for reports
required to be issued in audits in accordance with government auditing standards ("Yellow Book"), with
the audit requirements of OMB Circular A-133 ('Single Audits'), or PCAOB professional standards.
.02 Explanation of References:

.03

SAS =

AICPA Statement on Auditing Standards

AU =

Reference to section number in AICPA Professional Standards (vol. 1)

SSARS =

AICPA Statements on Standards for Accounting and Review Services

AR =

Reference to section number in AICPA Professional Standards (vol. 2)

PCAOB AS =

PCAOB Auditing Standards

Checklist Questionnaire:
Yes

1.

Is each financial statement audited specifically identified in the intro
ductory paragraph of the auditor's report?
[SAS 58, par. 6 (AU 508.06)]

2.

Do the titles of the financial statements referred to in the introductory
paragraph of the auditor's report match the titles of the financial
statement presented?
[Generally Accepted]

3.

Do the dates of the financial statements referred to in the introductory
paragraph of the auditor's report match the dates of the financial
statements presented?
[Generally Accepted]

4.

Is the report appropriately addressed?
[SAS 58, par. 9 (AU 508.09)]

5.

Does the auditor's report include:

No

N/A

a. A title that includes the word "independent"?
[SAS 58, par. 8a (AU 508.08a)]
b. A statement that the financial statements identified in the report
were audited?
[SAS 58, par. 8b (AU 508.08b)]
c. A statement that the financial statements are the responsibility of
management and that the auditor's responsibility is to express an
opinion on the financial statements based on his or her audit?
[SAS 58, par. 8c (AU 508.08c)]
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d. For audits of nonissuers, a statement that the audit was conducted
in accordance with generally accepted auditing standards and an
identification of the United States of America as the country of
origin of those standards (for example, auditing standards gener
ally accepted in the United States of America or U.S. generally
accepted auditing standards)?
[SAS 58, par. 8d, as amended by SAS 93 (AU 508.08d)]

Note: Issuers, as defined by the Sarbanes-Oxley Act of 2002, and other
entities when prescribed by the rules of the Securities and Exchange
Commission (SEC) (collectively referred to in this section of the checklist
as "issuers" or "issuer"), and their public accounting firms are subject to
the rules and standards of the PCAOB, as appropriate.
e. For audits of issuers, a statement that the audit was conducted in
accordance with the standards of the Public Company Accounting
Oversight Board (United States)?
[PCAOB AS 1, App., par. 3]
f. A statement that those standards require that the auditor plan and
perform the audit to obtain reasonable assurance about whether
the financial statements are free of material misstatement?
[SAS 58, par. 8e, as amended by SAS 93 (AU 508.08e)]

g. A statement that an audit includes examining, on a test basis,
evidence supporting the amounts and disclosures in the financial
statements; assessing the accounting principles used and signifi
cant estimates made by management; and evaluating the overall
financial statement presentation?
[SAS 58, par. 8f (AU 508.08f)]
h. A statement that the auditor believes that his or her audit provides
a reasonable basis for his or her opinion?
[SAS 58, par. 8g (AU 508.08g)]

i.

An opinion as to whether the financial statements present fairly,
in all material respects, the financial position of the reporting
entity as of the balance sheet date and the results of its operations
and its cash flows for the period then ended in conformity with
generally accepted accounting principles? The opinion should
include an identification of the United States of America as the
country of origin of those accounting principles (for example,
accounting principles generally accepted in the United States of
America or U.S. generally accepted accounting principles).
[SAS 58, par. 8h, as amended by SAS 93 (AU 508.08h)]

j. The manual or printed signature of the auditor's firm?
[SAS 58, par. 8i (AU 508.08i)]
k. The date of the audit report?
[SAS 58, par. 8j (AU 508.08j)]
Note: Issuers, as defined by the Sarbanes-Oxley Act of 2002, and other
entities when prescribed by the rules of the SEC (collectively referred to
in this section of the checklist as "issuers" or "issuer"), and their public
accounting firms are subject to the rules and standards of the PCAOB, as
appropriate.
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l.

6.

7.

8.

For audits of issuers, the city and state (or city and country for
non-U.S. auditors) from which the auditor's report is issued?
[PCAOB AS 1, App., par. 3]

If a subsequent event disclosed in the financial statements occurs after
completion of fieldwork but before the issuance of the related finan
cial statements, has the need for dual-dating of the report been con
sidered?
[SAS 1, sec. 530, pars. 3-5, as amended (AU 530.03-.05)]
If the accountant is not independent, is a compilation report indi
cating the lack of independence issued (non-public companies
only)?
[SAS 26, par. 10 (AU 504.10); SSARS1, pars. 21 and 37 (AR 100.19 and
.44)]

No

N/A

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

If the opinion is based in part on the report of another auditor:

a. Does the introductory paragraph of the standard report disclose
the fact that the opinion is based, in part, on the report of other
auditors?
b. Does the opinion paragraph include a reference to the report of
the other auditor?
[SAS 58, pars. 11a, 12, and 13 (AU 508.11a, .12, and .13)]
9.

Yes

If, to prevent the financial statements from being misleading because
of unusual circumstances, the financial statements contain a depar
ture from an accounting principle promulgated by a body designated
by the AICPA Council to establish such principles, does the report
include, in a separate paragraph or paragraphs, the information re
quired by Rule 203 of the Code of Professional Conduct of the AICPA?
[SAS 58, pars. 11b and 15 (AU 508.111b and .15)]

10. If there is substantial doubt about the entity's ability to continue as a
going concern:

a. Does the report include an explanatory paragraph, following the
opinion paragraph, to reflect that conclusion?
b. Is that conclusion expressed through the use of the phrase "sub
stantial doubt about its (the entity's) ability to continue as a going
concern" or similar wording that includes the terms substantial
doubt and going concern?
[SAS 58, par. 11c (AU 508.11c); SAS 59, as amended by SAS 64, par.
12 (AU 341.12)]

Practice Tip

In a going concern paragraph, the auditor should not use conditional language in expressing a conclusion
concerning the existence of substantial doubt about the entity's ability to continue as a going concern. See
SAS 77 for an example.
[SAS 59, as amended by SAS 77 (AU 341.13, fn. 5)]
11. If there has been a material change between periods in accounting
principles or in the method of their application that has a material effect
on the comparability of the reporting entity's financial statements:

a. Does the report include an explanatory paragraph, following the
opinion paragraph, that refers to the change?
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b. Does the explanatory paragraph identify the nature of the change
and refer the reader to the note to the financial statements that
discusses the change in detail?
[SAS 58, as amended by SAS 79, pars. 11d and 16 (AU 508.11d and
.16)]
c. If the change in the accounting principle is a change in reporting
entity that did not result from a transaction or an event, is an
explanatory paragraph included in the auditor's report? (Note: A
change in the reporting entity resulting from a transaction or
event, such as a pooling of interests, or the creation, cessation, or
complete or partial purchase or disposition of a subsidiary or other
business unit, does not require that an explanatory paragraph
about consistency be included in the auditor's report.)
[SAS No. 88, par. 8, AU 420.08]

12. If in an updated report, the opinion is different from the opinion
previously expressed on the financial statements of a prior period:
a. Does the report include an explanatory paragraph, preceding the
opinion paragraph, that discloses all of the substantive reasons for
the different opinion?
b. Does the explanatory paragraph disclose:

(1)

The date of the auditor's previous report?

(2)

The type of opinion previously expressed?

(3)

The circumstances or events that caused the auditor to ex
press a different opinion?

(4)

That the auditor's updated opinion on the financial state
ments of the prior period is different from his or her previous
opinion on those statements?
[SAS 58, as amended by SAS 79, pars. 11e and 69 (AU 508.11e
and .69)]

13. If financial statements of a prior period (presented for comparative
purposes) have been audited by a predecessor auditor whose report
is not presented:

a. Does the introductory paragraph of the report indicate:

(1)

That the financial statements of the prior period were audited
by another auditor?

(2)

The date of the predecessor auditor's report?

(3)

The type of report issued by the predecessor auditor?

(4)

If the report was other than a standard report, the substantive
reasons therefor, including a description of the nature of and
reasons for the explanatory paragraph added to the predeces
sor's report or his or her opinion qualification?

b. If the financial statements have been restated, does the introduc
tory paragraph indicate that the predecessor auditor reported on
the financial statements of the prior period before restatement?
[SAS 58, as amended by SAS 79, pars. 11e and 74 (AU 508.11e and .74)]
14. If selected quarterly financial data required by SEC Regulation S-K
has been omitted or has not been reviewed, does the report include
an additional paragraph stating that fact?
[SAS 58, par. 11f (AU 508.11f); SAS 100, par. 50 (AU 722.50)]
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15. If supplementary information required by GAAP has been omitted,
the presentation of such information departs materially from pre
scribed guidelines, the auditor is unable to complete prescribed pro
cedures with respect to such information, or the auditor is unable to
remove substantial doubt about whether the supplementary informa
tion conforms to prescribed guidelines, does the report include an
additional paragraph stating that fact?
[SAS 58, par. 11g (AU 508.11g); SAS 52, par. 8, as amended by SAS 98
(AU 558.08)]
16. If other information in a document containing audited financial state
ments is materially inconsistent with information appearing in the
financial statements, has it been determined whether the financial
statements, the auditor's report, or both require revision?
[SAS 58, par. 11h (AU 508.11h); SAS 8, par. 4 (AU 550.04)]
17. If the auditor decides to emphasize a matter regarding the financial
statements in the report, is the explanatory information presented in
a separate paragraph that avoids use of phrases such as "with the
foregoing (following) explanation"?
[SAS 58, pars. 11 and 19, as amended by SAS 79 (AU 508.11 and .19);
Interpretation 3 of SAS 1, sec. 410 (AU 9410.18); Interpretation 1 of
SAS 57 (AU 9342.03)]
18. If it has not been possible to conduct the audit in accordance with
GAAS or to apply all of the procedures considered necessary in the
circumstances, has consideration been given to the need to issue a
qualified opinion or to disclaim an opinion?
[SAS 58, as amended by SAS 79, par. 22 (AU 508.22)]
19. If a qualified opinion is to be expressed because of a scope limitation:

a. Are all of the substantive reasons for the qualification disclosed in one
or more explanatory paragraphs preceding the opinion paragraph?
b. Does the qualified opinion include the word except or exception in
a phrase such as except for or with the exception of?

c. Is the situation described and referred to in both the scope and
opinion paragraphs?
d. Does the wording in the opinion paragraph indicate that the
qualification pertains to the possible effects on the financial state
ments and not the scope limitation itself?
[SAS 58, as amended by SAS 79, pars. 21-27 (AU 508.21-.27)]

Practice Tips
Scope limitations include situations in which the auditor is unable to obtain sufficient evidential matter to
support management's assertions about the nature of a matter involving an uncertainty and its presentation
or disclosure in the financial statements.
[SAS 58, as amended by SAS 79, par. 31 (AU 508.31)]

SOP 00-1, Auditing Health Care Third-Party Revenues and Related Receivables, discusses auditing matters to
consider in testing third-party revenues and related receivables, and provides guidance regarding the
sufficiency of evidential matter (SOP 00-1, pars. 16-21).
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Yes

Note: Consult the Topical Index to the AICPA Professional Standards
under "Scope of Audit—Limitations" for additional references to specific
types of scope limitations that could result in either a qualified or dis
claimer of opinion.

20. If an opinion is disclaimed because of a scope limitation:
a. Are all of the substantive reasons for the disclaimer stated in a
separate paragraph or paragraphs?

b. Does the report state that the scope of the audit was not sufficient
to warrant the expression of an opinion?
c. Does the report avoid identifying procedures that were performed?

d. Is the scope paragraph omitted?
e. If there are reservations about fair presentation of the financial
statements in conformity with GAAP, are they described in the
report?
[SAS 58, as amended by SAS 79, pars. 62 and 63 (AU 508.62-.63)]

21. If the financial statements are materially affected by a departure from
GAAP (including inadequate disclosure, inappropriate accounting
principles, and unreasonable accounting estimates), has considera
tion been given to the need to issue a qualified opinion or an adverse
opinion?
[SAS 58, as amended by SAS 79, par. 35 (AU 508.35)1

Note: SOP 00-1, Auditing Health Care Third-Party Revenues and Related
Receivables, discusses auditing matters to consider in testing third-party
revenues and related receivables, and provides guidance regarding the
sufficiency of evidential matter and reporting on financial statements of
health care entities exposed to material uncertainties. Paragraphs 22-37
specifically address potential departures from GAAP related to estimates
and uncertainties that fall into three categories: unreasonable accounting
estimates; inappropriate accounting principles; and inadequate disclosure.
22. If a qualified opinion is to be expressed because of a GAAP departure:
a. Are all of the substantive reasons that have led to the conclusion that
there is a departure from GAAP disclosed in one or more separate
explanatory paragraphs preceding the opinion paragraph?
b. Does the qualified opinion include the word except or exception in
a phrase such as except for or with the exception of and a reference to
the explanatory paragraph?

c. Does the explanatory paragraph disclose the principle effects of
the departure on financial position, results of operations, and cash
flows, if practicable, or state that the effects are not reasonably
determinable, if not practicable to do so?
[SAS 58, as amended by SAS 79, pars. 21, 37, and 38 (AU 508.21,
.37, and .38)]
23. If an adverse opinion is to be expressed because of a GAAP departure:

a. Are all of the substantive reasons for the adverse opinion disclosed
in one or more separate explanatory paragraphs preceding the
opinion paragraph?
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b. Does the explanatory paragraph disclose the principle effects of
the departure on financial position, results of operations, and cash
flows, if practicable, or state that the effects are not reasonably
determinable, if not practicable to do so?
c. State that the financial statements do not present fairly the finan
cial position, or results of operations or cash flows in conformity
with GAAP?
[SAS 58, as amended by SAS 79, pars. 58 and 59 (AU 508.58 and .59)]

Yes

No

N/A

____

____

____

____

____

____

Note: Consult the Topical Index to the AICPA Professional Standards
under "Departures From Established Principles," "Adverse Opinions,"
and "Qualified Opinions" for additional references to specific types of
GAAP departures that could result in either a qualified or adverse opinion.

24. If information accompanies the basic financial statements and audi
tor's report in an auditor-submitted document, is it accompanied by
a report that:

a. States that the audit was performed for the purpose of forming an
opinion on the basic financial statements taken as a whole?
b. Specifically identifies the accompanying information?

c. States that the accompanying information is presented for pur
poses of additional analysis and is not a required part of the basic
financial statements?
d. Includes either an opinion on whether the accompanying informa
tion is fairly stated in all material respects in relation to the basic
financial statements taken as a whole or a disclaimer of opinion
(depending on whether the information was subjected to the
auditing procedures applied in the audit of the basic financial
statements)?
[SAS 29, par. 6 (AU 551.06)]

Practice Tip

SAS 87, Restricting the Use of an Auditor's Report, provides guidance to auditors in determining whether an
engagement requires a restricted-use report and, if so, what elements to include in that report.

Practice Tip

PCAOB Conforming Amendments To PCAOB Interim Standards Resulting from the Adoption of PCAOB Auditing
Standard No. 2, "An Audit of Internal Control Over Financial Reporting Performed In Conjunction With An
Audit Of Financial Statements," amend SAS 58 to include reporting requirements when performing an
integrated audit of financial statements and internal control over financial reporting in accordance with
PCAOB Standards.

Note: The PCAOB establishes standards for audits of issuers, as defined
by the Sarbanes-Oxley Act of 2002, and other entities when prescribed by
the rules of the SEC, collectively referred to in this section of the checklist
as "issuers."
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Practice Tips
Auditing Interpretation 17, "Clarification in the Audit Report of the Extent of Testing of Internal Control
Over Financial Reporting in Accordance With Generally Accepted Auditing Standards," of SAS 58, provides
for audits of nonissuers an example of additional language that may be added to an auditor's standard report
to explain that an audit includes consideration of internal control over financial reporting as a basis for
designing audit procedures but not for the purpose of expressing an opinion on the effectiveness of internal
control over financial reporting.
[Interpretation 17 of SAS 58 (AU 9508.85-88)]
Auditing Interpretation 18, "Reference to PCAOB Standards in an Audit Report on a Nonissuer," of SAS 58,
provides guidance on the appropriate referencing of PCAOB auditing standards in audit reports for those
auditors who are engaged to perform an audit in accordance with PCAOB standards when auditing
nonissuers.
[Interpretation 18 of SAS 58 (AU 9508.89-92)]
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FSP Section 11,400
Auditors' Reports on Audits Performed in
Accordance With Government Auditing
Standards and Circular A-133 Checklist
.01 Government Auditing Standards (also referred to as the Yellow Book), issued by the Comptroller
General of the United States of the Government Accountability Office (GAO), applies to the audits of
governmental entities, programs, activities, and functions, and of governmental assistance administered by
contractors, not-for-profit organizations (NPOs), and other nongovernmental entities, when required by
statute or other mandates or when auditors hold themselves out as following those standards.1 The Single
Audit Act Amendments of 1996 (the Single Audit Act) and Office of Management and Budget (OMB) Circular
A-133, Audits of States, Local Governments, and Non-Profit Organizations (Circular A-133), require a single or
program-specific audit for entities that expend $500,000 or more of federal awards in a fiscal year. The Single
Audit Act requires single audits and program-specific audits of federal awards to be performed in accordance
with Government Auditing Standards. Similarly, Government Auditing Standards requires the use of its standards
when auditing compliance with regulations relating to federal award expenditures and other governmental
financial assistance in conjunction with or as a byproduct of a financial statement audit.

.02 This checklist has two parts: Part I is for auditor's reports on financial statement audits performed in
accordance with Government Auditing Standards. (This checklist does not address the performance auditing
or attestation standards of Government Auditing Standards. It also does not address types of financial audits
other than financial statement audits, except for Circular A-133 audits.) Part II contains the additional
requirements for auditor's reports on audits performed in accordance with the Single Audit Act and Circular
A-133. For audits performed in accordance with Circular A-133, both Parts I and II of this checklist must be
completed. Illustrative auditor's reports on financial statement audits performed in accordance with Govern
ment Auditing Standards and illustrative auditor's reports and an illustrative schedule of findings and
questioned costs for Circular A-133 audits are in the AICPA Audit Guide Government Auditing Standards
and Circular A-133 Audits.
.03 The OMB issues an annual Circular A-133 compliance supplement for conducting single audits. That
supplement is available from the Government Printing Office by calling (202) 512-1800 and on the OMB's
Web site at www.whitehouse.gov/omb/grants/grants_circulars.html. The AICPA issues an annual Audit
Risk Alert, Government Auditing Standards and Circular A-133 Audits, as a complement to the Audit Guide
Government Auditing Standards and Circular A-133 Audits. The AICPA also has issued a related practice aid,
Auditing Recipients of Federal Awards: Practical Guidance for Applying OMB Circular A-133, Third Edition
(product no. 006621).
.04 The Public Accounting Oversight Board (PCAOB) establishes standards for audits of "issuers," as
that term is defined by the Sarbanes-Oxley Act of 2002 (the Act) or whose audit is prescribed by the rules of
the Securities and Exchange Commission (SEC). Other entities are referred to as "nonissuers." Because health
care organizations generally are nonissuers, this section of this checklist does not address PCAOB standards.1
1 As discussed in paragraph 4.24 of the AICPA Audit Guide Government Auditing Standards and Circular A-133 Audits, paragraph
5.07 of Government Auditing Standards acknowledges that an auditee may need a financial statement audit for purposes other than to
comply with a requirement calling for an audit in accordance with Government Auditing Standards. For example, the auditee may need
a financial statement audit to issue bonds. In that case, Government Auditing Standards permits auditors to issue a separate report on the
financial statements conforming only to the requirements of generally accepted auditing standards (GAAS).
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However, the auditee may be an issuer or the auditor may be engaged to audit and report on the effectiveness
of a nonissuer's internal control over financial reporting in accordance with PCAOB auditing standards. In
those cases, the auditor should modify this checklist considering the guidance in PCAOB standards, the GAO
Internet Notice at www.gao.gov/govaud/ybk01.htm titled Guidance on Complying with Government Audit
ing Standards Reporting Requirements for the Report on Internal Control for Audits of Certain Entities Subject to
the Requirements of the Sarbanes-Oxley Act of 2002 and Government Auditing Standards, and Auditing
Interpretation 18, "Reference to PCAOB Standards in an Audit Report on a Nonissuer," of SAS 58, as
amended (AU 9508.89-92), as well as the discussion in the Notice to Readers and Appendix A to Chapter 4
of the AICPA Audit Guide Government Auditing Standards and Circular A-133 Audits.

.05 Explanation of References:
A-133 =

Office of Management and Budget (OMB) Circular A-133, Audits of States, Local
Governments, and Non-Profit Organizations (June 1997 Revision)

GAS =

General Accounting Office 1994 revision to Government Auditing Standards, as
amended through Amendment 3, Independence

SAS =

AICPA Statement on Auditing Standards

AU =

Reference to section number in AICPA Professional Standards (vol. 1)

AAG-SLA =

AICPA Audit Guide Government Auditing Standards and Circular A-133 Audits
(with conforming changes as of May 1,2005)

.06 Checklist Questionnaire:
Yes

No

N/A

____

____

____

____

____

____

____

____

____

Part I—Reports on Audits Performed in Accordance With
Government Auditing Standards
1.

In a financial statement audit performed in accordance with Govern
ment Auditing Standards, has the auditor issued the following reports:
a. A report on the entity's financial statements that provides an
opinion or disclaimer of opinion on the financial statements?
[GAS, par. 5.03; AAG-SLA, pars. 4.03 and 4.21]

b. A report on internal control over financial reporting and on com
pliance and other matters based on an audit of financial statements
performed in accordance with Government Auditing Standards?
[GAS, pars. 5.08 and 5.12; AAG-SLA, pars. 4.03,4.07, and 4.25]
Report on the Financial Statements

2.

In addition to the elements listed in the checklist for the auditor's
report on the financial statements at FSP section 11,300, does the
auditor's report on the financial statements contain:2
a. A statement that the audit was conducted in accordance with the
standards applicable to financial audits contained in Government
Auditing Standards, issued by the Comptroller General of the
United States?3
[GAS, par. 5.05; AAG-SLA, pars. 4.04a, 4.21d, and 4.23]

2 If an auditee prepares financial statements in conformity with comprehensive bases of accounting other than generally accepted
accounting principles (GAAP), known as other comprehensive bases of accounting, or OCBOA, the auditor still is required to express or
disclaim an opinion and should follow the reporting in SAS 62 (AU 623), as amended. [AAG-SLA, par. 4.21h, fn. 21]

3 When personal, external, and organizational impairments to independence exist, a government auditor who cannot decline to
perform the work because of a legislative requirement or for other reasons should report the impairment in the scope section of the
auditor's report. [GAS, par. 3.05; AAG-SLA, par. 4.21d, fn. 20]
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Yes

No

N/A

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

b. A reference to the separate report on internal control over
financial reporting and on compliance with certain provisions
of laws, regulations, contracts, and grant agreements and other
matters prepared in accordance with Government Auditing Stand
ards,4 which includes:
(1)

(2)

3.

4.

A statement that the purpose of that report is to describe the
scope of testing of internal control over financial reporting
and compliance and the results of that testing, and not to
provide an opinion on the internal control over financial
reporting or on compliance?5

A statement that the separate report is an integral part of an
audit performed in accordance with Government Auditing
Standards and should be considered in assessing the results of
the audit?
[GAS, par. 5.08; AAG-SLA, pars. 4.04b and 4.21i]

If the auditor does not follow an applicable standard of Government
Auditing Standards, does the scope section of the report disclose the
standard that was not followed, the reasons therefore, and how not
following the standard affected, or could have affected, the results of
the audit?
[GAS, par. 5.06; AAG-SLA, par. 4.23]
If a material organizational unit is not required to have an audit in
accordance with Government Auditing Standards, has the scope para
graph of the report on the financial statements been modified to
indicate the portion of the entity that was not audited in accordance
with Government Auditing Standards'?
[AAG-SLA, pars. 4.37 and 4.38]

Report on Internal Control Over Financial Reporting and On Compli
ance and Other Matters Based on an Audit Performed in Accordance
With Government Auditing Standards
5.

6.

Does the auditor's report on internal control over financial reporting
and on compliance and other matters conform to the standard report
language illustrated in AAG-SLA?
[AAG-SLA, par. 4.44, Exs. 4-3 and 4-4]

Does the auditor's report on internal control over financial reporting
and on compliance and other matters contain:
a. A statement that the auditor has audited the financial statements
of the auditee and a reference to the auditor's report on the
financial statements, including a description of any departure
from the standard report (for example, a qualified opinion, a
modification as to consistency because of a change in accounting
principle, or a reference to the report of other auditors)?
[AAG-SLA, pars. 4.26a and 4.44, Ex. 4-3, fn. 24]

4 If the reporting on internal control over financial reporting and on compliance and other matters is included in the report on the
financial statements, the reference to the separate report is not required. The Audit Guide Government Auditing Standards and Circular
A-133 Audits recommends separate reporting. [AAG-SLA, pars. 4.04b and 4.21i]
5 Paragraph 5.08 of Government Auditing Standards permits, but does not require, an opinion on internal control over financial
reporting or on compliance if sufficient work was performed. This statement should be modified if the auditor is providing an opinion
on internal control over financial reporting or on compliance in the Government Auditing Standards report. [AAG-SLA, pars. 4.04b, fn. 6
and 4.21i]
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Yes

No

N/A

b. A statement that the audit was conducted in accordance with
GAAS (with an identification of the United States of America as
the country of origin of those standards) and with the standards
applicable to financial audits contained in Government Auditing
Standards, issued by the Comptroller General of the United
States?6
c. A statement that in planning and performing the audit, the auditor
considered the auditee's internal control over financial reporting
in order to determine the auditing procedures for the purpose of
expressing an opinion on the financial statements and not to provide
an opinion on the internal control over financial reporting?7

d. If applicable, a statement that reportable conditions were noted
and the definition of a reportable condition?
e. If no reportable conditions are noted, a statement that the auditor's
consideration of the internal control over financial reporting
would not necessarily disclose all matters in the internal control
that might be material weaknesses; if reportable conditions are
noted, a statement that the auditor's consideration of the internal
control over financial reporting would not necessarily disclose all
matters in the internal control that might be reportable conditions
and, accordingly, would not necessarily disclose all reportable
conditions that are also considered to be material weaknesses?

f.

If applicable, a description of the reportable conditions noted
(including the views of responsible officials and their planned
corrective action) or a reference to a separate schedule in which
the reportable conditions, views of responsible officials, and their
planned corrective action are described?8

g. The definition of a material weakness?
h. If applicable, a statement about whether the auditor believes any
of the reportable conditions noted are material weaknesses and, if
they are, that identifies which reportable conditions are consid
ered material weaknesses?9 (If there are no reportable conditions
noted, a statement is made that no material weaknesses were
noted.)

i.

A statement that as part of obtaining reasonable assurance about
whether the auditee's financial statements are free of material
misstatement, the auditor performed tests of the auditee's compli
ance with certain provisions of laws, regulations, contracts, and
grant agreements, noncompliance with which could have a direct
and material effect on the determination of financial statement
amounts?

6 See footnote 3. [GAS, par. 3.05; AAG-SLA, par. 4.26b, fn. 27]
7 Paragraph 5.08 of Government Auditing Standards permits, but does not require, an opinion on internal control over financial
reporting or on compliance if sufficient work was performed. This statement should be modified if the auditor is providing an opinion
on internal control over financial reporting. [AAG-SLA, par. 4.26c, fn. 28]
8 For an audit in accordance with Circular A-133, all findings, including those required to be reported under Government Auditing
Standards, should be included in the schedule of findings and questioned costs. Therefore, for such audits, this report should refer to
the schedule of findings and questioned costs. See the questions about that schedule in Part II of this checklist. [AAG-SLA, pars. 4.26f,
fn. 29 and 12.17]
9 In reporting reportable conditions, the auditor should identify those that are individually or in the aggregate material weaknesses.
[GAS, par. 5.14; AAG-SLA, par. 4.08]
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A statement that providing an opinion on compliance with those
provisions was not an objective of the audit and that, accordingly,
the auditor does not express such an opinion?1011

k. A statement that notes whether the results of tests disclosed in
stances of noncompliance or other matters (certain fraud and
abuse) that are required to be reported under Government Auditing
Standards and, if they are, describes the instances of noncompli
ance and other matters (including the views of responsible officials
and their planned corrective action) or refers to the separate sched
ule in which the noncompliance and other matters, views of
responsible officials, and their planned corrective action are de
scribed?11
[AAG-SLA, par. 4.26]

l.

If applicable, a statement that additional matters were communi
cated to the auditee in a management letter?
[AAG-SLA, pars. 4.26l, 4.35, and 4.44, Ex. 4-3, fn. 30 and Ex. 4-4,
fn. 46]

m. A separate paragraph at the end of the report stating that the report
is intended solely for the information and use of the audit
committee, management and specified legislative or regulatory
bodies12 and is not intended to be and should not be used by
anyone other than these specified parties?13
n. The manual or printed signature of the auditor's firm?
o. The date of the auditor's report?
[AAG-SLA, par. 4.26]
7.

Does the report carry the same date as the report on the financial
statements?
[AAG-SLA, par. 4.26o]

8.

If a material organizational unit is not required to have an audit in
accordance with Government Auditing Standards, has the scope para
graph of the report been modified to indicate the portion of the entity
that was not audited in accordance with Government Auditing Stand
ards?
[AAG-SLA, pars. 4.37 and 4.39]

9.

If certain pertinent information is prohibited from general disclosure
(as it may be by federal, state, or local laws or regulations), does the
auditor's report state the nature of the information omitted and the
requirement that makes the omission necessary?
[GAS, par. 5.31; AAG-SLA, par. 4.04e]

10. Does the language in the compliance and other matters section of the
report refer to findings that do or may include fraud and abuse? (That
10 Paragraph 5.08 of Government Auditing Standards permits, but does not require, an opinion on internal control over financial
reporting or on compliance if sufficient work was performed. This statement should be modified if the auditor is providing an opinion
on compliance. [AAG-SLA, par. 4.26i, fn. 30]

11 See footnote 8. [AAG-SLA, par. 4.26k, fn. 32]
12 For an audit in accordance with Circular A-133, this reference should include federal awarding agencies and, if applicable,
pass-through entities. [AAG-SLA, pars. 4.26m, fn. 34 and 12.17]
13 This paragraph conforms to SAS 87, Restricting the Use of an Auditor’s Report (AU 532). See SAS 87 for additional guidance on
restricted-use reports. [AAG-SLA, par. 4.26m, fn. 35]
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language should appear in all reports, even if the report does not
describe or refer to findings of fraud or abuse or even if the only
findings of fraud or abuse are described in or referred to from the
section on internal control over financial reporting.)
[AAG-SLA, par. 4.291
11. Are findings that relate to both internal control over financial report
ing and to compliance reported in or referred to from both the section
of the report concerning internal control over financial reporting and
in the section of the report concerning compliance and other matters?
(The reporting in one section of the report or schedule may be in
summary form with a reference to a detailed reporting in the other
section.)
[AAG-SLA, par. 4.281

12. Are findings of fraud and abuse reported in or referred to from the
compliance and other matters section of the report, unless the primary
nature of the finding is a reportable condition in internal control?
(Auditors should present or refer to findings of fraud and abuse that
represent reportable conditions in internal control in the internal
control section.)
[AAG-SLA, par. 4.291
13. Do the reported findings include all identified deficiencies in internal
control over financial reporting considered to be reportable conditions
and all fraud and illegal acts (unless clearly inconsequential),1415
16
and
material violations of provisions of contracts or grant agreements and
material abuse that has occurred or is likely to have occurred?15,16
[GAS, par. 5.12; AAG-SLA, pars. 4.04c, 4.08,4.15,4.16,4.27, and 12.33]

a. Does the auditor limit the public reporting of fraud, illegal acts,
violations of provisions of contracts or grant agreements, or abuse
to matters that would not compromise investigative or legal pro
ceedings?
[GAS, par. 5.25; AAG-SLA, par. 4.20]
14. Does each finding include a reference number? (For example, findings
identified and reported in the audit of fiscal year 20X1 could be
assigned reference numbers 20X1-1,20X1-2, and so forth.)
[AAG-SLA, par. 4.32]
15. Do the reported findings place the findings in proper perspective (or
context) by describing the work performed that resulted in the find
ing? (The identified instances should be related to the population or
the number of cases examined and be quantified in terms of dollar
value, if appropriate.)
[GAS, pars. 5.14 and 5.18; AAG-SLA, par. 4.30]

Yes

No

N/A

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

14 In an audit conducted in accordance with Circular A-133, the auditor should apply a financial statement materiality consideration
in reporting in the Government Auditing Standards report fraud and illegal acts involving federal awards that are subject to Circular
A-133 reporting. [AAG-SLA, pars. 4.15,12.16, and 12.33]

15 Although Government Auditing Standards uses the term significant in its reporting standard for violations of provisions of contracts
or grant agreements and abuse, footnote 47 to paragraph 4.18 of Government Auditing Standards states that it considers the terms material
and significant to be synonymous. For consistency, the Audit Guide Government Auditing Standards and Circular A-133 Audits and this
checklist use the term material when discussing that standard. [AAG-SLA, par. 4.04c, fn. 8]

16 Government Auditing Standards requires this reporting even if the auditor disclaims an opinion on the financial statements.
Government Auditing Standards also provides reporting requirements for other findings of internal control deficiencies, fraud, illegal
acts, violations of provisions of contracts or grants agreements, and abuse; see Questions 18 and 19.
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____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

a. When reporting instances of fraud, illegal acts, violations of pro
visions of contracts or grant agreements, or abuse, are the results
projected? (If the results cannot be projected, conclusions in the
findings should be limited to the items tested.)
[GAS, par. 5.18; AAG-SLA, par. 4.30]
16. To the extent possible, do the reported findings present criteria,
condition, cause, effect, and recommendation?
[GAS, pars. 5.15 and 5.19; AAG-SLA, par. 4.31]
17. Does the auditor's report include the views of responsible officials
concerning the findings, conclusions, and recommendations, as well
as planned corrective actions?17,18
[GAS, par. 5.26; AAG-SLA, pars. 4.04d and 4.33]

a. If the auditee's views oppose the report's findings, conclusions, or
recommendations, and are not, in the auditor's opinion, valid—or
if the planned corrective actions do not adequately address the
auditor's recommendations—does the report state reasons for
disagreeing with the comments or planned corrective actions?
[GAS, par. 5.30; AAG-SLA, par. 4.33]
Other Reporting and Communication Considerations

18. Does the management letter communicate the following unless
clearly inconsequential—deficiencies in internal control that are not
reportable conditions, immaterial violations of provisions of contracts
or grant agreements, and immaterial abuse?17
19
18
[GAS, pars. 5.16 and 5.20; AAG-SLA, pars. 4.17 and 4.35]

a. Are the management letter discussions worded so that readers can
distinguish those matters that are required to be included by
GAAS or Government Auditing Standards from matters that are
recommendations for improvements or information about "best
practices"?
[AAG-SLA, par. 4.36]
b. Does the management letter not include personal identification or
other potentially sensitive matters?
[AAG-SLA, par. 4.42]
19. Has the auditor used professional judgment to determine whether
and how to communicate to auditee officials deficiencies in internal

17 In an audit in accordance with Circular A-133, the auditee is required to submit a corrective action plan. For those audits,
depending on the status of the development of the corrective action plan at the time the auditor's reports are released, the auditor may
be able to refer to the corrective action plan to satisfy as the required presentation of the auditee's views and planned corrective actions.
See the questions about the reporting of auditee views and the corrective action plan in Part II of this checklist. [AAG-SLA, par. 4.33, fn.
39]

18 The auditor is required to extend a reasonable effort to obtain and report auditee views and planned corrective actions. Government
Auditing Standards does not require the auditor to delay or withhold the release of the report if the auditee does not provide the
necessary information on a timely basis. If, however, the auditee does not provide the necessary information by the time the report is
released, the report should indicate the status of the auditee's response. [AAG-SLA, par. 4.34]
19 Generally, Government Auditing Standards requires the auditor to evaluate findings for the purpose of communication in the
management letter based on their consequence to the financial statements or other financial data significant to the audit objectives. In
an audit in accordance with Circular A-133, however, the auditor should evaluate findings involving federal awards for the purpose of
that communication based only on their consequence to the financial statements. Further, the auditor should not communicate such
findings in the management letter if they are otherwise reported as audit findings in accordance with Circular A-133. [AAG-SLA, pars.
4.35, fn. 40 and 12.25]

FSP §11,400.06

116

Health Care Organizations

Yes

No

N/A

____

____

____

____

____

____

a. The auditor's responsibilities for testing and reporting on internal
control over financial reporting and on compliance with laws,
regulations, and provisions of contracts or grant agreements?

____

____

____

b. The nature of any additional testing of internal control and com
pliance required by laws, regulations, and provisions of contracts
or grant agreements or otherwise requested, and whether the
auditor is planning on providing an opinion on internal control
over financial reporting or on compliance with laws, regulations,
and provisions of contracts or grant agreements?

____

____

____

c. A contrasting of the responsibilities in Questions a and b above
with other audits of internal control and compliance?

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

control, fraud, illegal acts, violations of provisions of contracts or
grant agreements, and abuse that are clearly inconsequential?20
[GAS, pars. 5.16 and 5.20; AAG-SLA, par. 4.35]

20. Has the auditor reported fraud, illegal acts, violations of provisions
of contracts or grant agreements, and abuse directly to parties outside
of the auditee in the situations required by Government Auditing
Standards, even if the auditor has resigned or been dismissed from the
audit?
[GAS, pars. 5.21-5.25; AAG-SLA, pars. 4.18-4.20]
21. Has the auditor communicated the following information, preferably
in a writing such as the engagement letter, to officials of the audited
entity and to the individuals contracting for or requesting the audit
during the planning stages of the audit:

d. Potential restrictions on the auditor's reports?
[GAS, pars. 4.06-4.11; AAG-SLA, pars. 2.18 and 2.19]
e. Additional relevant topics, such as the auditor's fieldwork and
reporting responsibilities for fraud and abuse?
[AAG-SLA, par. 2.18]
22. If an audit is terminated before it is complete, is the reason for
terminating the audit communicated to auditee management, the
entity requesting the audit, and other appropriate officials, preferably
in writing?
[GAS, par. 4.09; AAG-SLA, par. 2.20]
23. If the auditor is:

a. A government auditor, does the auditor submit the auditor's
reports to the appropriate officials of the audited entity, appropri
ate officials of the organizations requiring or arranging for the
audits (unless legal restrictions prevent it), and other officials who
have legal oversight authority or who may be responsible for
acting on audit findings and recommendations and to others
authorized to receive such reports?
b. A nongovernment auditor, does the auditor clarify report distri
bution responsibilities with the party contracting for the audit and
follow the agreements reached?
[GAS, par. 5.34; AAG-SLA, par. 4.04/]

20 GAAS require that whenever the auditor has determined that there is evidence that fraud may exist, the auditor should bring that
matter to the attention of an appropriate level of management, even if the matter might be considered inconsequential. [SAS 99, par. 79
(AU 316.79); AAG-SLA, pars. 4.11 and 4.35, fn. 42]
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Yes

No

N/A

____

____

____

a. A report on the supplementary schedule of expenditures of
federal awards?

____

____

____

b. A report on compliance with requirements applicable to each
major program and on internal control over compliance in accord
ance with Circular A-133?

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

24. Unless the report is restricted by law or regulation, or contains privi
leged and confidential information, does the auditor clarify that cop
ies are made available for public inspection? (That clarification should
be made in the engagement letter and may also be made in correspon
dence that transmits the reports to the auditee and other recipients.)
[GAS, par. 5.34; AAG-SLA, par. 4.04f and fn. 10]

Part II—Reports on Audits Performed in Accordance With
Circular A-133
1.

In an audit performed in accordance with Circular A-133, has the
auditor issued the following reports in addition to those in Part I of
this checklist:21

c. A schedule of findings and questioned costs?
[A-133, sec. 505; AAG-SLA, par. 12.07]
Report on the Supplementary Schedule of Expenditures of
Federal Awards
2.

3.

4.

Is the report on the schedule (a) included in the auditor's report on the
financial statements, (b) included in the report on compliance with
requirements applicable to each major program and on internal con
trol over compliance in accordance with Circular A-133, or (c) issued
as a stand-alone report?
[AAG-SLA, pars. 12.12,12.15,12.24, and 12.28]

If the report on the financial statements refers to the work of other
auditors, has the auditor considered the need to refer to the major
federal programs audited by other auditors in the report on the
schedule?
[AAG-SLA, par. 12.29]
If the report on the schedule is included in the auditor's report on the
financial statements or in the Circular A-133 report on compliance and
on internal control over compliance, does it:

a. Conform to the standard report language illustrated in AAG-SLA?
[AAG-SLA, pars. 12.14 and 12.54, Ex. 12-1, fn. 5]
b. Identify the schedule of expenditures of federal awards as accom
panying supplementary information by descriptive title or by
page number of the document?

c. Contain a statement that the audit was conducted for the purpose
of forming an opinion on the basic financial statements taken as a
whole and that the schedule is presented for purposes of additional
analysis and is not a required part of the financial statements?
[AAG-SLA, pars. 12.12 and 12.54, Ex. 12-1, fn. 5]

21 Because of the requirements of Government Auditing Standards, the auditor also has other reporting and communication responsi
bilities in a Circular A-133 audit. See the questions in the section titled "Other Reporting and Communication Considerations" in Part
I of this checklist.
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d. Contain an opinion or a disclaimer of opinion as to whether the
Schedule is fairly stated, in all material respects, in relation to the
financial statements taken as a whole?
[AAG-SLA, pars. 12.10,12.12, and 12.54, Ex. 12-1, fn. 5]
e. Carry the same date as the report on the financial statements, even
if that requires a dual date on the Circular A-133 report on com
pliance and on internal control over compliance?
[AAG-SLA, pars. 12.26 and 12.28]

f.

5.

Consider the effect of any modifications to this report?
[AAG-SLA, par. 12.14, fn. 10]

If the report on the schedule is issued as a stand-alone report, is the
guidance of SAS 58 (AU 508) followed in issuing that report?
a. Does the report carry the same date as the Circular A-133 report
on compliance and on internal control over compliance?
[AAG-SLA, par. 12.28]

Report on Compliance With Requirements Applicable to Each Major
Program and on Internal Control Over Compliance in Accordance With
Circular A-133
6.

Does the report conform to the standard report language illustrated
in AAG-SLA?
[AAG-SLA, par. 12.54, Exs. 12-1-12-4]

7.

Does the report contain the following elements:

a. A statement that the auditor has audited the compliance of the
auditee with the types of compliance requirements described in
the OMB Circular A-133 Compliance Supplement that are applicable
to each of its major programs?
b. A statement that the auditee's major programs are identified in the
summary of the auditor's results section of the accompanying
schedule of findings and questioned costs?
c. A statement that compliance with the requirements of laws, regu
lations, contracts, and grants applicable to each of the auditee's
major federal programs is the responsibility of the auditee's man
agement, and that the auditor's responsibility is to express an
opinion on the auditee's compliance based on the audit?

d. A statement that the audit of compliance was conducted in accord
ance with GAAS (with an identification of the United States of
America as the country of origin of those standards), the standards
applicable to financial audits contained in Government Auditing
Standards issued by the Comptroller General of the United States,
and Circular A-133?
e. A statement that those standards and Circular A-133 require that
the auditor plan and perform the audit to obtain reasonable assur
ance about whether noncompliance with the types of compliance
requirements that could have a direct and material effect on a
major federal program occurred?
f.

A statement that an audit includes examining, on a test basis,
evidence about the auditee's compliance with those requirements
and performing such other procedures as the auditor considered
necessary in the circumstances?
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g. A statement that the auditor believes that the audit provides a
reasonable basis for the auditor's opinion?

____

___

h. A statement that the audit does not provide a legal determination
of the auditee's compliance with those requirements?

____

___

i.

The reference number(s) of the finding(s)?

____

___

(2)

An identification of the type(s) of compliance requirements
and related major program(s)?

____

___

A statement that compliance with such requirements is nec
essary, in the auditor's opinion, for the auditee to comply
with the requirements applicable to the program(s)?

____

___

An opinion on whether the auditee complied, in all material
respects, with the types of compliance requirements that are ap
plicable to each of its major federal programs?

____

___

k. If applicable, a statement that the results of the auditing proce
dures disclosed instances of noncompliance that are required to
be reported in accordance with Circular A-133 and a reference to
the schedule of findings and questioned costs in which they are
described?

____

___

A statement that the auditee's management is responsible for
establishing and maintaining effective internal control over com
pliance with the requirements of laws, regulations, contracts, and
grants applicable to federal programs?

____

___

m. A statement that in planning and performing the audit, the auditor
considered the auditee's internal control over compliance with
requirements that could have a direct and material effect on a
major federal program, to determine the auditing procedures for
the purpose of expressing an opinion on compliance and to test
and report on the internal control over compliance in accordance
with Circular A-133?

____

___

n. If applicable, a statement that reportable conditions were noted
and the definition of a reportable condition?

____

___

o. If applicable, a reference to a description of reportable conditions
noted in the accompanying schedule of findings and questioned
costs, including the reference number of the finding(s)?

____

___

p. If no reportable conditions are noted, a statement that the auditor's
consideration of the internal control over compliance would not
necessarily disclose all matters in internal control that might be
material weaknesses; if reportable conditions are noted, a state
ment that the auditor's consideration of the internal control over
compliance would not necessarily disclose all matters in the inter
nal control that might be reportable conditions and, accordingly,
would not necessarily disclose all reportable conditions that are
also considered to be material weaknesses?

____

___

q. The definition of a material weakness?

____

___

(3)

l.

N/A

If instances of noncompliance are noted that result in an opinion
modification, a reference to a description in the accompanying
schedule of findings and questioned costs, including:

(1)

j.
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r. If applicable, a statement about whether the auditor believes any
of the reportable conditions noted are material weaknesses and, if
they are, a reference to a description of the material weaknesses in
the schedule of findings and questioned costs, including the reference
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number of the finding(s)? (If there are no reportable conditions, a
statement should be made that no material weaknesses were
noted.)

s. A separate paragraph at the end of the report stating that the report
is intended solely for the information and use of the audit commit
tee, management, specified legislative or regulatory bodies, fed
eral awarding agencies, and (if applicable) pass-through entities
and is not intended to be and should not be used by anyone other
than these specified parties?22
t.

The manual or printed signature of the auditor's firm?

u. The date of the auditor's report?
[AAG-SLA, par. 12.23]
8.

If the audit of the auditee's compliance with requirements applicable
to a major program detects material instances of noncompliance with
those requirements, does the auditor's report express a qualified or
adverse opinion?
[AAG-SLA, par. 12.19]

9.

Have scope limitations on the auditor's testing of the auditee's com
pliance with laws, regulations, and the provisions of contracts or grant
agreements been considered in the opinion on compliance with re
quirements applicable to each major program?
[AAG-SLA, pars. 12.20-12.22]

10. Have the cumulative effects of all instances of noncompliance with
federal programs and scope limitations been considered in the opin
ion on the financial statements?
[AAG-SLA, pars. 12.19 and 12.20]
11. If there are abuse findings reported in the federal awards section of
the schedule of findings and questioned costs that do not otherwise
meet the Circular A-133 requirements for reporting as findings, has
the auditor considered the need to modify the report on compliance
and on internal control over compliance?
[AAG-SLA, par. 12.36]
12. Is the report dated the same as or later than the date of the auditor's
report on the financial statements?

a. If the report is dated later than the date of the auditor's report on
the financial statements, have appropriate subsequent events pro
cedures been performed?
[AAG-SLA, par. 12.27]
13. If the audit of federal awards does not encompass the entirety of the
auditee's operations expending federal awards, are the operations
that are not included identified in a separate paragraph following the
first paragraph of the report?
[AAG-SLA, par. 12.30]
14. If the report on the financial statements refers to the work of other
auditors, has the auditor considered the need to refer to the major
federal programs audited by other auditors in the report on compli
ance and on internal control over compliance?
[AAG-SLA, par. 12.29]
22 See footnote 13. [AAG-SLA, par. 12.23s, fn. 18]
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____

___

____

___

a. A summary of the auditor's results?

____

___

b. Findings related to the financial statements that are required to be
reported in accordance with Government Auditing Standards? (See
the questions about those findings in Part I of this checklist.)

____

___

____

___

____

___

b. Where applicable, a statement that reportable conditions in inter
nal control were disclosed by the audit of the financial statements
and whether any such conditions were material weaknesses?

____

___

c. A statement on whether the audit disclosed any noncompliance
that is material to the financial statements?

____

___

____

___

____

___

Schedule of Findings and Questioned Costs
15. Does the report conform to the standard report language illustrated
in AAG-SLA?
[AAG-SLA, par. 12.54, Ex. 12-5]
16. Is the report presented even if there are no findings to report? (In a
situation in which there are no findings or questioned costs, the
auditor should prepare the summary of auditor's results section of
the schedule and either omit the other sections or include them,
indicating that no matters were reported.)
[AAG-SLA, par. 12.40]

17. Does the report contain the following three sections:

c. Findings and questioned costs for federal awards?
[AAG-SLA, pars. 12.31 and 12.40]
18. Does the summary of auditor's results include:

a. The type of report the auditor issued on the financial statements
of the auditee (that is, unqualified opinion, qualified opinion,
adverse opinion, or disclaimer of opinion)?
[AAG-SLA, par. 12.32a]

d. Where applicable, a statement that reportable conditions in the
internal control over major programs were disclosed by the audit
and whether any such conditions were material weaknesses?
[AAG-SLA, par. 12.32a]
e. The type of report the auditor issued on compliance for major
programs (that is, unqualified opinion, qualified opinion, adverse
opinion, or disclaimer of opinion)? (If the audit report for one or
more major programs is other than unqualified, indicate the type
of report issued for each program.)
[AAG-SLA, pars. 12.32a and 12.54, Ex. 12-5, fn. 27]

f.

A statement on whether the audit disclosed any audit findings that
the auditor is required to report under Circular A-133? (See Ques
tion 20 below.)

____

___

g. An identification of major programs?

____

___

h. The dollar threshold used to distinguish between type A and type
B programs?

____

___

____

___

____

___

i.

A statement on whether the auditee qualified as a low-risk auditee?
[AAG-SLA, par. 12.32a]

19. If there are abuse findings reported in the federal awards section of the
schedule of findings and questioned costs that do not otherwise meet the
Circular A-133 requirements for reporting as findings, has the auditor
considered the need to modify the summary of the auditor's results?
[AAG-SLA, par. 12.36]
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20. Are the following reported as audit findings related to federal awards:
a. Reportable conditions and material weaknesses in internal control
over major programs? (The auditor should identify reportable con
ditions that are individually or cumulatively material weaknesses.)
b. Material noncompliance with the provisions of laws, regulations,
contracts, or grant agreements related to a major program?
c. Known questioned costs that are greater than $10,000 for a type of
compliance requirement for a major program?

d. Known questioned costs when likely questioned costs are greater
than $10,000 for a type of compliance requirement for a major
program?
e. Known questioned costs that are greater than $10,000 for pro
grams that are not audited as major?
f.

The circumstances concerning why the auditor's report on com
pliance for major programs is other than an unqualified opinion,
if not otherwise reported as an audit finding?

g. Known fraud affecting a federal award, if not otherwise reported
as an audit finding? (An audit finding is not required if the fraud
was reported outside the entity as required by GAS.)
[A-133, sec. 510(a); AAG-SLA, par. 12.35]
h. Instances of material misrepresentation by the auditee of the status
of any prior audit findings?
[A-133, sec. 510(a); AAG-SLA, pars. 12.35 and 12.42]
i.

Abuse involving federal awards that is material to a major program?
[AAG-SLA, par. 12.36]

21. Does the audit finding detail include:
a. A reference number? (For example, findings identified and re
ported in the audit of fiscal year 20X1 would be assigned reference
numbers 20X1-1,20X1-2, and so forth.)
[A-133, sec. 510(c); AAG-SLA, par. 12.39]
b. Identification of the federal program and specific federal award,
including CFDA title and number, federal award number and
year, name of the federal agency, and name of the applicable
pass-through entity?2324

c. The criteria or specific requirement upon which the audit finding
is based, including the statutory, regulatory, or other citation?

d. The condition found, including facts that support the deficiency
identified in the audit finding?
e. Identification of questioned costs and how they were computed?
f.

Information to provide a proper perspective for judging the preva
lence and consequences of the audit findings?24

g. The possible asserted effect of the condition?
h. Recommendations to prevent future occurrences of the deficiency?
[A-133, sec. 510(b); AAG-SLA, par. 12.37]
23 When information such as the CFDA title and number or the federal award number is not available, the auditor should provide
the best information available to describe the federal award. (Chapter 7 of AAG-SLA discusses an alternative for presentation if a CFDA
number is not available.) [A-133, sec. 510(b)(1); AAG-SLA, par. 12.37a]
24 Where appropriate, the instances identified should be related to the universe and the number of cases examined and be quantified
in terms of the dollar value. [A-133, sec. 510(b)(5); AAG-SLA, par. 12.37e]
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____

____

____

a. And that relate to the same issue presented as one finding?

____

____

____

b. Organized by federal agency or pass-through entity, where practical?
[A-133, sec. 505(d)(3)(f) and (ii); AAG-SLA, par. 12.32c]

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

____

22. Do the audit findings related to federal awards also meet the presen
tation requirements of Government Auditing Standards? (See the Ques
tions about those presentation requirements in Part I of this checklist.)
[AAG-SLA, par. 12.38]
23. Are audit findings that relate to federal awards:

24. Are audit findings that relate to both the financial statements and the
federal awards reported in both sections of the schedule (an alterna
tive is to report the finding in one section of the schedule in summary
form, with a reference to a detailed reporting in the other section of
the schedule)?
[A-133, sec. 505(d)(3); AAG-SLA, par. 12.32c]
25. Do the findings report the views of responsible officials concerning
the findings, conclusions, and recommendations, as well as planned
corrective actions, as required by Government Auditing Standards, or
refer to the corrective action plan, depending on the status of the
development of the corrective action plan at the time the auditor's
reports are released?25
[AAG-SLA, pars. 12.34 and 12.38]

a. If the auditee's comments oppose the report's findings, conclusions,
or recommendations, and are not, in the auditors' opinion, valid—or
if the planned corrective actions do not adequately address the
auditors' recommendations—does the federal awards section of the
schedule of findings and questioned costs state the auditor's reasons
for disagreeing with the comments or planned corrective actions?
[A-133, sec. 510(b)(8); AAG-SLA, par. 12.38, fn. 25]
26. Do the audit report and any attached or referenced schedules not
include names, Social Security numbers, other personal identification,
or other potentially sensitive matters?
[AAG-SLA, par. 12.53]
Data Collection Form26

27. Has the auditor completed the appropriate parts of the data collection
form?
28. Has the auditor signed the form and dated it as of the date on which
the auditor completes and signs the form?
[AAG-SLA, par. 12.45]

29. Does the information on the data collection form agree to the infor
mation in the auditor's reports and the summary of auditor's results
in the schedule of findings and questioned costs?
[Federal Audit Clearinghouse, Data Collection Form No. SF-SAC]
25 See footnote 18.

26 The data collection form and related instructions are available from the Federal Audit Clearinghouse's (FAC's) Internet site at
http://harvester.census.gov/sac or by calling the FAC at (888) 222-9907. The form number is SF-SAC. The FAC prefers to receive the
data collection form via an online Internet Data Entry System (IDES). The Office of Management and Budget periodically revises the
data collection form and its accompanying instructions. Auditors should exercise caution to make sure they use the version of the form
and instructions that applies to the fiscal year audited. [AAG-SLA, par. 12.46 and fn. 27]
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Program-Specific Audits

Practice Tip
When an auditee expends federal awards under only one federal program (excluding research and devel
opment) and the federal program's laws, regulations, or grant agreements do not require a financial
statement audit of the auditee, the auditee may elect to have a program-specific audit. A program-specific
audit may not be elected for research and development unless all federal awards expended were received
from the same federal agency (or the same federal agency and the same pass-through entity) and that federal
agency (or pass-through entity, in the case of a subrecipient) approves a program-specific audit in advance.
[A-133, sec. 200; AAG-SLA, par. 13.02]
30. If a program-specific audit guide is available and current with regard
to the program's compliance requirements, has the auditor issued the
reports required by the guide?
[A-133, sec. 235(a); AAG-SLA, par. 13.04]
31. If a program-specific audit guide is not available or not current with
regard to the program's compliance requirements, has the auditor issued
the following reports:27,28

a. A report on the federal program's financial statements that provides
an opinion or disclaimer of opinion on the financial statements?
b. A report on compliance with requirements applicable to the federal
program and on the internal control over compliance in accordance
with the program-specific audit option under Circular A-133?

c. A schedule of findings and questioned costs for the program?
[A-133, sec. 235(b)(4); AAG-SLA, pars. 13.08 and 13.09]
32. Do the reports conform to the standard report language illustrated in
AAG-SLA?
[AAG-SLA, pars. 12.54, Ex. 12-5 and 13.16, Exs. 13-1-13-2)]

27 If the financial statement(s) of the program present only the activity of the federal program, the auditor is not required to issue a
separate report to meet the reporting requirements of GAS. However, if the financial statement(s) of the federal program present more
than the program's activity the auditor should issue a separate GAS report and modify it so that it refers only to the financial
statement(s) of the federal program. [AAG-SLA, par. 13.10]
28 See footnote 21.
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Illustrative Financial Statements
.01 The following illustrative financial statements demonstrate the practical applications of the reporting
practices discussed in the June 1996 AICPA Audit and Accounting Guide Health Care Organizations with
conforming changes as of May 1,2005 (the Guide). The checklists and illustrative financial statements do not
include all disclosures and presentation items promulgated. Pronouncements deemed remote for audits of
health care providers are not included in this document. Specific types of health care organizations have been
selected to illustrate a wide diversity of reporting practices; it is not intended that these illustrations represent
either the only types of disclosure or the only statement formats that would be appropriate. Health care
providers are urged to develop financial statement formats that are appropriate for their individual
circumstances while being consistent with the accounting and reporting practices discussed in the Guide.
This section contains illustrative financial statements, prepared using the illustrative financial statements in
the AICPA Audit and Accounting Guide Health Care Organizations (with conforming changes as of May 1,
2005), for the following types of health care organizations:
•

Not-for-Profit Hospital

•

For-Profit Nursing Home

•

Not-for-Profit Continuing Care Retirement Community

•

Not-for-Profit Home Health Agency

•

Not-for-Profit Health Maintenance Organization

•

Not-for-Profit Ambulatory Care Organization

These illustrative financial statements are not intended to include items that should be accounted for under
the requirements of SFAS 133, Accounting for Derivative Instruments and Hedging Activities, as amended, and
do not reflect the requirements of SFAS 133. SFAS 133, among other matters, amends the disclosure
requirements for securities in SFAS 115, Accounting for Certain Investments in Debt and Equity Securities (see
paragraph 534 of SFAS 133). In reporting disclosures about investments in securities, investor-owned entities
should comply primarily with the requirements of paragraphs 6, 17, 19, 20, 21, and 22 of SFAS 115, as
amended. Other disclosure requirements for investments in securities may also be applicable. Practitioners
should refer to SFAS 133, as amended, for guidance on reporting derivative instruments and hedging
activities.
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The checklists and illustrative financial statements do not include all disclosures
and presentation items promulgated.

ILLUSTRATIVE FINANCIAL STATEMENTS FOR A NOT-FOR-PROFIT HOSPITAL
.02

Sample Not-for-Profit Hospital

Balance Sheets

December 31,20X7 and 20X6
(in thousands)
20X7

20X6

Assets

Current assets:
Cash and cash equivalents
Short-term investments
Assets limited as to use
Patient accounts receivable, net of allowance for doubtful
accounts of $2,500 in 20X7 and $2,400 in 20X6
Other current assets

Total current assets

$

4,758
15,836
970

$

5,877
10,740
1,300

39,334

14,194
2,856
34,967

15,100
2,670

Interest in net assets of Sample Hospital Foundation’
Assets limited as to use:
Internally designated for capital acquisition
Held by trustee

510

462

12,000
6,949

12,500
7,341

Less amount required to meet current obligations

18,949
(970)

19,841
(1,300)

17,979

18,541

4,680
320
51,038
1,185

4,680
520
50,492
908

$115,046

$110,570

Long-term investments
Long-term investments restricted for capital acquisition
Property and equipment, net
Other assets
Total assets

(continued)

These illustrative financial statements include a presentation of an interest in the net assets of a financially interrelated foundation
that is based on the particular fact pattern described in Note 11 to the illustrative financial statements and the following additional facts:
• Sample Not-for-Profit Hospital can influence the financial decisions of Sample Hospital Foundation to such an extent that it can
determine the timing and amount of distributions from the Foundation. Thus, it is inappropriate for the Hospital to imply a time
restriction on amounts held by the Foundation.
• Contributions to Foundation are restricted by donors for property acquisitions. Those restrictions have been met by the Hospital
even though the net assets remain at the Foundation. Thus, the net assets related to the interest in the Foundation are classified
as unrestricted in the Hospital's financial statements.
• The Hospital's policy is to report restricted revenues as unrestricted if the restriction is met in the same period as the revenues
are recognized.
Because the change in the interest in net assets of the foundation results from contributions restricted to property acquisitions, this
presentation shows the change in that interest reported separately from the performance indicator, in the spirit of the guidance in
paragraph 10.20 for contributions restricted to property acquisitions. Readers should be aware that SFAS 136 is silent on this
classification. The AICPA has released a group of Technical Practice Aids (TPAs) (TIS section 6400.36 through .42) that address
recognition of the interests in the net assets of financially interrelated organizations and the classification of the changes in those
interests. TPAs are nonauthoritative and are not sources of established accounting principles as described in SAS 69, The Meaning of
Present Fairly in Conformity With Generally Accepted Accounting Principles.
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20X6

20X7
Liabilities and Net Assets
Current liabilities:
Current portion of long-term debt
Accounts payable and accrued expenses
Estimated third-party payor settlements
Other current liabilities

$

1,470
5,818
2,143
1,969

$

1,750
5,382
1,942
2,114

11,400
23,144
3,953

24,014
3,166

Total liabilities

38,497

38,368

Net assets:
Unrestricted
Temporarily restricted
Permanently restricted

70,846
2,115
3,588

66,199
2,470
3,533

76,549

72,202

$115,046

$110,570

Total current liabilities
Long-term debt, net of current portion
Other liabilities

Total net assets
Total liabilities and net assets

11,188

See accompanying notes to financial statements.
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.03

FORMAT A

Sample Not-for-Profit Hospital
Statements of Operations

Years Ended December 31,20X7 and 20X6

(in thousands)
Unrestricted revenues, gains and other support:
Net patient service revenue
Premium revenue
Other revenue
Net assets released from restrictions used for operations
Total revenues, gains and other support

Expenses:
Operating expenses
Depreciation and amortization
Interest
Allowance for bad debts
Other
Total expenses
Operating income
Other income:
Investment income

Other expense:
Loss from extinguishment of debt
Excess of revenues over expenses

Change in net unrealized gains and losses on other than
trading securities
Net assets released from restrictions used for purchase of
property and equipment
Change in interest in net assets of Sample Hospital
Foundation**
Transfers to parent

Increase in unrestricted net assets

20X7

20X6

$85,156
11,150
2,601
300
99,207

$78,942
10,950
5,212

88,521
4,782
1,752
1,000
2,000

80,585
4,280
1,825
1,300
1,300

98,055

1,152

89,290
5,814

3,900

3,025

(500)
4,552

8,839

300

95,104

375

200
283
(688)
$ 4,647

536
(3,051)

$ 6,699

See accompanying notes to financial statements.
These illustrative financial statements include a presentation of an interest in the net assets of a financially interrelated foundation
that is based on the particular fact pattern described in Note 11 to the illustrative financial statements and the following additional facts:
• Sample Not-for-Profit Hospital can influence the financial decisions of Sample Hospital Foundation to such an extent that it can
determine the timing and amount of distributions from the Foundation. Thus, it is inappropriate for the Hospital to imply a time
restriction on amounts held by the Foundation.
• Contributions to Foundation are restricted by donors for property acquisitions. Those restrictions have been met by the Hospital
even though the net assets remain at the Foundation. Thus, the net assets related to the interest in the Foundation are classified
as unrestricted in the Hospital's financial statements.
• The Hospital's policy is to report restricted revenues as unrestricted if the restriction is met in the same period as the revenues
are recognized.
Because the change in the interest in net assets of the foundation results from contributions restricted to property acquisitions, this
presentation shows the change in that interest reported separately from the performance indicator, in the spirit of the guidance in
paragraph 10.20 for contributions restricted to property acquisitions. Readers should be aware that SFAS 136 is silent on this
classification. The AICPA has released a group of Technical Practice Aids (TPAs) (TIS section 6400.36 through .42) that address
recognition of the interests in the net assets of financially interrelated organizations and the classification of the changes in those
interests. TPAs are nonauthoritative and are not sources of established accounting principles as described in SAS 69, The Meaning of
Present Fairly in Conformity With Generally Accepted Accounting Principles.
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.04

FORMAT B

Sample Not-for-Profit Hospital
Statements of Operations
Years Ended December 31,20X7 and 20X6

(in thousands)
Unrestricted revenues, gains and other support:
Net patient service revenue
Premium revenue
Other, primarily investment income
Net assets released from restrictions used for operations
Total revenues, gains and other support

Expenses:
Salaries and benefits
Medical supplies and drugs
Insurance
Depreciation and amortization
Interest
Allowance for bad debts
Loss from extinguishment of debt
Other
Total expenses

Excess of revenues, gains, and other support over expenses
Change in net unrealized gains and losses on other than
trading securities
Net assets released from restrictions used for purchase of
property and equipment
Change in interest in net assets of Sample Hospital
Foundation’
Transfers to parent

Increase in unrestricted net assets

20X7

20X6

$85,156
11,150
6,501
300

$78,942
10,950
8,237

103,107

98,129

53,900
26,532
8,089
4,782
1,752
1,000
500
2,000

49,938
22,121
8,526
4,280
1,825
1,300

98,555
4,552

89,290
8,839

300

375

1,300

200
283
(688)

$ 4,647

536
(3,051)

$ 6,699

See accompanying notes to financial statements.

These illustrative financial statements include a presentation of an interest in the net assets of a financially interrelated foundation
that is based on the particular fact pattern described in Note 11 to the illustrative financial statements and the following additional facts:
• Sample Not-for-Profit Hospital can influence the financial decisions of Sample Hospital Foundation to such an extent that it can
determine the timing and amount of distributions from the Foundation. Thus, it is inappropriate for the Hospital to imply a time
restriction on amounts held by the Foundation.
• Contributions to Foundation are restricted by donors for property acquisitions. Those restrictions have been met by the Hospital
even though the net assets remain at the Foundation. Thus, the net assets related to the interest in the Foundation are classified
as unrestricted in the Hospital's financial statements.
• The Hospital's policy is to report restricted revenues as unrestricted if the restriction is met in the same period as the revenues
are recognized.
Because the change in the interest in net assets of the foundation results from contributions restricted to property acquisitions, this
presentation shows the change in that interest reported separately from the performance indicator, in the spirit of the guidance in
paragraph 10.20 for contributions restricted to property acquisitions. Readers should be aware that SFAS 136 is silent on this
classification. The AICPA has released a group of Technical Practice Aids (TPAs) (TIS section 6400.36 through .42) that address
recognition of the interests in the net assets of financially interrelated organizations and the classification of the changes in those
interests. TPAs are nonauthoritative and are not sources of established accounting principles as described in SAS 69, The Meaning of
Present Fairly in Conformity With Generally Accepted Accounting Principles.
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.05

Sample Not-for-Profit Hospital
Statements of Changes in Net Assets
Years Ended December 31,20X7 and 20X6

(in thousands)

Unrestricted net assets:
Excess of revenues over expenses
Net unrealized gains on investments, other than trading
securities
Change in interest in net assets of Sample Hospital
*
Foundation
Transfers to parent
Net assets released from restrictions used for purchase
of property and equipment

Increase in unrestricted net assets
Temporarily restricted net assets:
Contributions for charity care
Net realized and unrealized gains on investments
Net assets released from restrictions
Increase (decrease) in temporarily restricted net assets

20X7

20X6

$ 4,552

$ 8,839

300

375

283
(688)

536
(3,051)

200

4,647

6,699

140
5
(500)

996
8

(355)

1,004

Permanently restricted net assets:
Contributions for endowment funds
Net realized and unrealized gains on investments

50
5

411
2

Increase in permanently restricted net assets

55

413

4,347

8,116

72,202

64,086

$76,549

$72,202

Increase in net assets

Net assets, beginning of year
Net assets, end of year

See accompanying notes to financial statements.

These illustrative financial statements include a presentation of an interest in the net assets of a financially interrelated foundation
that is based on the particular fact pattern described in Note 11 to the illustrative financial statements and the following additional facts:
• Sample Not-for-Profit Hospital can influence the financial decisions of Sample Hospital Foundation to such an extent that it can
determine the timing and amount of distributions from the Foundation. Thus, it is inappropriate for the Hospital to imply a time
restriction on amounts held by the Foundation.
• Contributions to Foundation are restricted by donors for property acquisitions. Those restrictions have been met by the Hospital
even though the net assets remain at the Foundation. Thus, the net assets related to the interest in the Foundation are classified
as unrestricted in the Hospital's financial statements.
• The Hospital's policy is to report restricted revenues as unrestricted if the restriction is met in the same period as the revenues
are recognized.
Because the change in the interest in net assets of the foundation results from contributions restricted to property acquisitions, this
presentation shows the change in that interest reported separately from the performance indicator, in the spirit of the guidance in
paragraph 10.20 for contributions restricted to property acquisitions. Readers should be aware that SFAS 136 is silent on this
classification. The AICPA has released a group of Technical Practice Aids (TPAs) (TIS section 6400.36 through .42) that address
recognition of the interests in the net assets of financially interrelated organizations and the classification of the changes in those
interests. TPAs are nonauthoritative and are not sources of established accounting principles as described in SAS 69, The Meaning of
Present Fairly in Conformity With Generally Accepted Accounting Principles.
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.06

Sample Not-for-Profit Hospital
Statements of Cash Flows (Indirect Method)

Years Ended December 31,20X7 and 20X6

(in thousands)
Cash flows from operating activities:
Change in net assets
Adjustments to reconcile change in net assets to net
cash provided by operating activities:
Loss from extinguishment of debt
Depreciation and amortization
Net realized and unrealized gains on investments,
other than trading
Undistributed portion of change in interest in net
assets of Sample Hospital Foundation
Transfers to parent
Allowance for bad debts
Restricted contributions and investment income
received
(Increase) decrease in:
Patient accounts receivable
Trading securities
Other current assets
Other assets
Increase (decrease) in:
Accounts payable and accrued expenses
Estimated third-party payor settlements
Other current liabilities
Other liabilities
Net cash provided by operating activities
Cash flows from investing activities:
Proceeds from sale of investments
Purchase of investments
Capital expenditures
Net cash used in investing activities
Cash flows from financing activities:
Transfers to parent
Proceeds from restricted contributions and restricted
investment income
Payments on long-term debt
Payments on capital lease obligations
Proceeds from issuance of long-term debt
Net cash used in financing activities
Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents, beginning of year
Cash and cash equivalents, end of year

20X7

20X6

$ 4,347

$ 8,116

500
4,782

4,280

(450)

(575)

(48)
688
1,000

(51)
3,051
1,300

(290)

(413)

(1,906)
215
186
(277)

(2,036)

436
201
(145)
787
10,026

679
305
(257)
(128)
11,600

45,100
(48,869)
(4,728)
(8,497)

50,650
(52,800)
(5,860)
(8,010)

(688)

(3,051)

290
(24,700)
(150)
22,600
(2,648)
(1,119)
5,877
$ 4,758

413
(804)
(100)
500
(3,042)
548
5,329
$ 5,877

(2,481)
(190)

Supplemental Disclosures of Cash Flow Information:
The Hospital entered into capital lease obligations in the amount of $600,000 for new
equipment in 20X7.
Cash paid for interest (net of amount capitalized) in 20X7 and 20X6 was $1,780,000
and $1,856,000, respectively.

See accompanying notes to financial statements.
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.07

Sample Not-for-Profit Hospital

Notes to Financial Statements
December 31,20X7 and 20X6

1. Description of Organization and Summary of Significant Accounting Policies1
Organization. The Sample Not-for-Profit Hospital (the Hospital), located in Tulsa, Oklahoma,
is a not-for-profit acute care hospital. The Hospital provides inpatient, outpatient and emergency
care services for residents of northeastern Oklahoma. Admitting physicians are primarily practi
tioners in the local area. The Hospital was incorporated in Oklahoma in 20X1 and is affiliated with
the Sample Health System.

Use of estimates. The preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the
date of the financial statements and the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates.
Cash and cash equivalents. Cash and cash equivalents include certain investments in highly
liquid debt instruments with original maturities of three months or less.

The Hospital routinely invests its surplus operating funds in money market mutual funds. These
funds generally invest in highly liquid U.S. government and agency obligations.
Investments. Investments in equity securities with readily determinable fair values and all
investments in debt securities are measured at fair value in the balance sheet. Investment income
or loss (including realized gains and losses on investments, interest and dividends) is included in
the excess of revenues over expenses unless the income or loss is restricted by donor or law.
Unrealized gains and losses on investments are excluded from the excess of revenues over
expenses unless the investments are trading securities.
Assets limited as to use. Assets limited as to use primarily include assets held by trustees under
indenture agreements and designated assets set aside by the Board of Trustees for future capital
improvements, over which the Board retains control and may at its discretion subsequently use
for other purposes. Amounts required to meet current liabilities of the hospital have been
reclassified in the balance sheet at December 31,20X7 and 20X6.

Property and equipment. Property and equipment acquisitions are recorded at cost. Depreciation
is provided over the estimated useful life of each class of depreciable asset and is computed using
the straight-line method. Equipment under capital lease obligations is amortized on the straightline method over the shorter period of the lease term or the estimated useful life of the equipment.
Such amortization is included in depreciation and amortization in the financial statements.
Interest cost incurred on borrowed funds during the period of construction of capital assets is
capitalized as a component of the cost of acquiring those assets.
Gifts of long-lived assets such as land, buildings, or equipment are reported as unrestricted
support, and are excluded from the excess of revenues over expenses, unless explicit donor
stipulations specify how the donated assets must be used. Gifts of long-lived assets with explicit
restrictions that specify how the assets are to be used and gifts of cash or other assets that must
1 Paragraph 13 of SOP 01-6, Accounting by Certain Entities (Including Entities With Trade Receivables) That Lend to or Finance the Activities
of Others, provides guidance on disclosures that should be included in the summary of significant accounting policies, including
accounting policies for loans, trade receivables, and doubtful accounts.
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be used to acquire long-lived assets are reported as restricted support. Absent explicit donor
stipulations about how long those long-lived assets must be maintained, expirations of donor
restrictions are reported when the donated or acquired long-lived assets are placed in service.
Temporarily and permanently restricted net assets. Temporarily restricted net assets are those whose
use by the Hospital has been limited by donors to a specific time period or purpose. Permanently
restricted net assets have been restricted by donors to be maintained by the Hospital in perpetuity.

Excess of revenues over expenses. The statement of operations includes excess of revenues over ex
penses. Changes in unrestricted net assets which are excluded from excess of revenues over expenses,
consistent with industry practice, include unrealized gains and losses on investments other than
trading securities, permanent transfers of assets to and from affiliates for other than goods and
services, and contributions of long-lived assets (including assets acquired using contributions which
by donor restriction were to be used for the purposes of acquiring such assets).
Net patient service revenue. The Hospital has agreements with third-party payors that provide
for payments to the Hospital at amounts different from its established rates. Payment arrange
ments include prospectively determined rates per discharge, reimbursed costs, discounted
charges, and per diem payments. Net patient service revenue is reported at the estimated net
realizable amounts from patients, third-party payors, and others for services rendered, including
estimated retroactive adjustments under reimbursement agreements with third-party payors.
Retroactive adjustments are accrued on an estimated basis in the period the related services are
rendered and adjusted in future periods as final settlements are determined.
Premium revenue. The Hospital has agreements with various Health Maintenance Organizations
(HMOs) to provide medical services to subscribing participants. Under these agreements, the Hospital
receives monthly capitation payments based on the number of each HMO's participants, regardless
of services actually performed by the Hospital. In addition, the HMOs make fee-for-service payments
to the Hospital for certain covered services based upon discounted fee schedules.

Charity care. The Hospital provides care to patients who meet certain criteria under its charity
care policy without charge or at amounts less than its established rates. Because the Hospital does
not pursue collection of amounts determined to qualify as charity care, they are not reported as
revenue.
Donor-restricted gifts. Unconditional promises to give cash and other assets to the Hospital are
reported at fair value at the date the promise is received. Conditional promises to give and
indications of intentions to give are reported at fair value at the date the gift is received. The gifts
are reported as either temporarily or permanently restricted support if they are received with
donor stipulations that limit the use of the donated assets. When a donor restriction expires, that
is, when a stipulated time restriction ends or purpose restriction is accomplished, temporarily
restricted net assets are reclassified as unrestricted net assets and reported in the statement of
operations as net assets released from restrictions. Donor-restricted contributions whose restric
tions are met within the same year as received are reported as unrestricted contributions in the
accompanying financial statements.

Estimated malpractice costs. The provision for estimated medical malpractice claims includes
estimates of the ultimate costs for both reported claims and claims incurred but not reported.

Income taxes. The Hospital is a not-for-profit corporation and has been recognized as taxexempt pursuant to Sec. 501(c)(3) of the Internal Revenue Code.

2. Net Patient Service Revenue

The Hospital has agreements with third-party payors that provide for payments to the Hospital
at amounts different from its established rates. A summary of the payment arrangements with
major third-party payors follows:
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•

Medicare. Inpatient acute care services and outpatient services rendered to Medicare
program beneficiaries are paid at prospectively determined rates. These rates vary
according to a patient classification system that is based on clinical, diagnostic, and other
factors. Inpatient nonacute services, and defined capital and medical education costs
related to Medicare beneficiaries are paid based on a cost reimbursement methodology.
The Hospital is reimbursed for cost reimbursable items at a tentative rate with final
settlement determined after submission of annual cost reports by the Hospital and audits
thereof by the Medicare fiscal intermediary. Beginning in 20X3, the Hospital claimed
Medicare payments based on an interpretation of certain "disproportionate share" rules.
The intermediary disagreed and declined to pay the excess reimbursement claimed under
that interpretation. Through 1996, the Hospital has not included the claimed excess in net
patient revenues pending resolution of the matter. In 20X7, the intermediary accepted the
claims and paid the outstanding claims, including $950,000 applicable to 20X6 and $300,000
applicable to 20X5 and prior, which has been included in 20X7 net revenues.

•

Medicaid. Inpatient and outpatient services rendered to Medicaid program beneficiaries
are reimbursed under a cost reimbursement methodology. The Hospital is reimbursed at
a tentative rate with final settlement determined after submission of annual cost reports
by the Hospital and audits thereof by the Medicaid fiscal intermediary.
Revenue from the Medicare and Medicaid programs accounted for approximately XX
percent and XX percent, respectively, of the Hospital's net patient revenue for the year
ended 20X7, and XX percent and XX percent, respectively, of the Hospital's net patient
revenue, for the year ended 20X6. Laws and regulations governing the Medicare and
Medicaid programs are extremely complex and subject to interpretation. As a result, there
is at least a reasonable possibility that recorded estimates will change by a material amount
in the near term. The 20X6 net patient service revenue increased approximately $XXX due
to removal of allowances previously estimated that are no longer necessary as a result of
final settlements and years that are no longer subject to audits, reviews, and investigations.
The 20X7 net patient service revenue decreased approximately $XXX due to prior-year
retroactive adjustments in excess of amounts previously estimated.

The Hospital also has entered into payment agreements with certain commercial insurance
carriers, health maintenance organizations, and preferred provider organizations. The basis for
payment to the Hospital under these agreements includes prospectively determined rates per
discharge, discounts from established charges, and prospectively determined daily rates.

3. Investments

Assets Limited as to Use
The composition of assets limited as to use at December 31, 20X7 and 20X6, is set forth in the
following table. Investments are stated at fair value.

20X7
Internally designated for capital acquisition:
Cash
U.S. Treasury obligations
Interest receivable

Held by trustee under indenture agreement:
Cash and short-term investments
U.S. Treasury obligation
Interest receivable

FSP §11,500.07

$

545,000
11,435,000
20,000
12,000,000

352,000
6,505,000
92,000
6,949,000
$18,949,000

20X6

$

350,000
12,115,000
35,000
12,500,000

260,000
7,007,000
74,000
7,341,000
$19,841,000
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Other Investments

Other investments, stated at fair value, at December 31,20X7 and 20X6, include:
Trading:
U.S. Corporate Bonds
Other:
U.S. Treasury obligations
Interest receivable

Less:
Long-term investments
Long-term investments restricted for capital acquisitions

Short-term investments

20X7

20X6

$ 1,260,000

$ 1,475,000

$19,266,000
310,000
20,836,000

$14,233,000
232,000

4,680,000
320,000

4,680,000
520,000

$15,836,000

$10,740,000

15,940,000

Investment income and gains for assets limited as to use, cash equivalents, and other invest
ments are comprised of the following for the years ending December 31,20X7 and 20X6:

Income:
Interest income
Realized gains on sales of securities
Unrealized gains on trading securities

Other Changes in Unrestricted Net Assets:
Unrealized gains on other than trading securities

20X7

20X6

$3,585,000
150,000
165,000

$2,725,000
200,000
100,000

$3,900,000

$3,025,000

$ 300,000

$ 375,000

4. Property and Equipment
A summary of property and equipment at December 31, 20X7 and 20X6, follows:
20X7

20X6

$ 3,000,000
472,000
46,852,000
29,190,000
2,851,000

$ 3,000,000
472,000
46,636,000
26,260,000
2,752,000

Less accumulated depreciation and amortization

82,365,000
34,928,000

79,120,000
30,661,000

Construction in progress

47,437,000
3,601,000

48,459,000
2,033,000

$51,038,000

$50,492,000

Land
Land improvements
Buildings and improvements
Equipment
Equipment under capital lease obligations

Property and equipment, net

Depreciation expense for the years ended December 31,20X7 and 20X6 amounted to approxi
mately $4,782,000 and $4,280,000. Accumulated amortization for equipment under capital lease
obligations was $689,000 and $453,000 at December 31,20X7 and 20X6, respectively. Construction
contracts of approximately $7,885,000 exist for the remodeling of Hospital facilities. At December
31,20X7, the remaining commitment on these contracts approximated $4,625,000.

5. Long-Term Debt
A summary of long-term debt and capital lease obligations at December 31, 20X7 and 20X6,
follows:
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20X7
7.25 percent 20X7 Tax-Exempt Revenue Bonds, principal mat
uring in varying annual amounts, due November 1,20XX,
collateralized by a pledge of the Hospital's gross receipts

20X6

$21,479,000

8.50 percent 20X2 Tax-Exempt Revenue Bonds, principal
maturing in varying annual amounts, due June 1,20XX

$22,016,000

7.75 percent mortgage loan, principal maturing in varying
annual amounts, due January 20XX, collateralized by a
mortgage on certain property and equipment

2,010,000

2,127,000

125,000

671,000

7.75 percent note payable, payable in monthly installments
of $12,000, including interest, due March 20XX, unsecured

Capital lease obligations, at varying rates of imputed interest from
6.8 percent to 9.3 percent collateralized by leased equipment

1,000,000

950,000

24,614,000
1,470,000

25,764,000
1,750,000

$23,144,000

$24,014,000

Less current portion

Under the terms of the 20X7 and 20X2 revenue bond indentures, the Hospital is required to
maintain certain deposits with a trustee. Such deposits are included with assets limited as to use.
The revenue note indenture also places limits on the incurrence of additional borrowings and
requires that the Hospital satisfy certain measures of financial performance as long as the notes
are outstanding.
Scheduled principal repayments on long-term debt and payments on capital lease obligations
are as follows:
Year Ending
December 31,

Long-Term
Debt

Capital Leases
Obligations

20X8
20X9
20Y0
20Y1
20Y2
Thereafter

970,000
912,000
983,000
1,060,000
1,143,000
18,546,000
$23,614,000

$ 550,000
260,000
260,000
45,000

$

Less amount representing interest under
capital leases obligations

1,115,000

115,000

$1,000,000

A summary of interest cost and investment income on borrowed funds held by the trustee under
the 20X7 and 20X2 revenue bond indentures during the years ended December 31,20X7 and 20X6,
follows:

Interest cost:
Capitalized
Charged to operations

Total
Investment income:
Capitalized
Credited to other revenue
Total
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20X7

20X6

$ 740,000
1,752,000

$ 700,000
1,825,000

$2,492,000

$2,525,000

$ 505,000
330,000

$ 663,000
386,000

$ 835,000

$1,049,000
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6. Temporarily and Permanently Restricted Net Assets

Temporarily restricted net assets are available for the following purposes or periods at Decem
ber 31,20X7 and 20X6:
Health care services
Purchase of equipment
Indigent care
Health education
For periods after December 31,20X9

20X7

20X6

$ 320,000
840,000
350,000
605,000

$ 520,000
950,000
400,000
600,000

$2,115,000

$2,470,000

Permanently restricted net assets at December 31,20X7 and 20X6, are restricted to:
20X7
20X6
Investments to be held in perpetuity, the income
from which is expendable to support health care
services (reported as operating income)
$2,973,000 $2,923,000
Endowment requiring income to be added to
original gift until fund value is $1,500,000
615,000
610,000
$3,588,000 $3,533,000
During 20X7, net assets were released from donor restrictions by incurring expenses satisfying
the restricted purposes of indigent care and health care education in the amounts of $250,000 and
$50,000, respectively.

7. Medical Malpractice Claims
The Hospital purchases professional and general liability insurance to cover medical malprac
tice claims. There are known claims and incidents that may result in the assertion of additional
claims, as well as claims from unknown incidents that may be asserted arising from services
provided to patients. The Hospital has employed independent actuaries to estimate the ultimate
costs, if any, of the settlement of such claims. Accrued malpractice losses have been discounted
at 7 percent and in management's opinion provide an adequate reserve for loss contingencies.
On March 15,20X7, a patient filed a suit against the Hospital for malpractice during care received
as an inpatient. The Hospital believes it has meritorious defenses against the suit; however, the
ultimate resolution of the matter could result in a loss. The patient has claimed $16 million in
actual damages. Under state law, punitive damages are determined at trial. The Hospital main
tains insurance coverage for malpractice claims. The coverage does not include punitive damages
awards. Trial is scheduled to occur within the next year.

8. Pension and Other Postretirement Benefit Plans2, 2†
Note: The following two paragraphs are encouraged but not required.
2 The disclosures for pensions and other postretirement benefits in this note to the illustrative financial statements have been modified to
reflect the requirements of SFAS 132, Employers' Disclosures about Pensions and Other Postretirement Benefits (revised 2003). SFAS 132 (revised
2003) is effective for fiscal years ending after December 15,2003, with certain exceptions. Interim-period disclosures are effective for interim
periods beginning after December 15,2003. The provisions of SFAS 132 remain in effect until the provisions of SFAS 132 (revised 2003) are
adopted. This note to the financial statements illustrates the financial statement disclosures about pension and postretirement benefit plans
for a public entity. Readers should refer to SFAS 132 (revised 2003) when considering disclosure requirements for nonpublic entities.

† Readers may also need to consider the accounting and disclosure requirements of FASB Staff Position (FSP) 106-1, Accounting and Disclosure
Requirements Related to the Medicare Prescription Drug, Improvement and Modernization Act of2003, and 106-2, Accounting and Disclosure Requirements
Related to the Medicare Prescription Drug, Improvement and Modernization Act of2003, when an employer provides postretirement prescription drug
coverage. FSP 106-2, which supersedes FSP 106-1, is effective, with exception for certain nonpublic entities, for the first interim or annual period
beginning after June 15,2004. For a nonpublic entity, as defined in SFAS 87, Employers' Accounting for Pensions, that sponsors one or more defined
benefit postretirement health care plans that provide prescription drug coverage but of which no plan has more than 100 participants, FSP 106-2
is effective for fiscal years beginning after December 15,2004. Earlier application is encouraged.
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The Hospital has a defined benefit pension plan covering substantially all of its employees. The
plan benefits are based on years of service and the employees' compensation during the last five
years of covered employment. Contributions are intended to provide not only for benefits
attributed to service to date but also for those expected to be earned in the future.

The Hospital also sponsors two defined benefit postretirement plans that cover both salaried
and nonsalaried employees. One plan provides medical and dental benefits, and the other
provides for the payment of life insurance premiums. The postretirement health care plan is
contributory, with retiree contributions adjusted annually; the life insurance plan is noncontribu
tory. The accounting for the health care plan anticipates future cost-sharing changes to the written
plan that are consistent with the Hospital's expressed intent to increase retiree contributions each
year to 50 percent of the excess of the expected general inflation rate over 6 percent. Beginning in
20X7, the Hospital adopted a funding policy for its postretirement health care plan similar to its
funding policy for its life insurance plan—an amount equal to a level percentage of the employees'
salaries is contributed to the plan annually. For 20X7, that percentage was 4.25, and the aggregate
contribution for both plans was $34,000.
The Hospital uses a December 31 measurement date for its plans.

The following table sets forth the changes in benefit obligations, changes in plan assets and
components of net periodic benefit cost for both the pension plan and the other postretirement
benefit plans:

Change in benefit obligation:
Benefit obligation at beginning of year
Service cost
Interest cost
Plan participants' contributions
Actuarial gain
Benefits paid

Pension Benefits

Other Benefits

20X7

20X6

20X7

20X6

$ 9,710
905
700

$ 9,700
770
650

$500
15
44
34

(1,410)

$585
14
50
34
(7)
(66)

10,920

9,710

610

9,800
759
866

9,610
810
790

(1,410)

89
4
39
34
(66)

40
4
19
34
(8)

9,800

100

89

(510)
(30)
16
445

(496)
(40)
19
470

$ (79)

$ (47)

(20)
(375)

Benefit obligation at end of year
Change in plan assets:
Fair value of plan assets at beginning of year
Actual return on plan assets
Employer contribution
Plan participants' contributions
Benefits paid

(375)

Fair value of plan assets at end of year

11,050

Funded status
Unrecognized net actuarial gain
Unrecognized prior service cost
Unrecognized transition obligation
Unrecognized transition asset

Prepaid (accrued) benefit cost

$

130
(30)
50

90
(40)
55

(15)

(20)

135

$

85

(8)

585

The accumulated benefit obligation for the defined benefit pension plan was $XXX and $XXX at
December 31,20X7, and 20X6, respectively.
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Other Benefits
20X7
20X6

Pension Benefits
20X7
20X6

Components of net periodic benefit cost:
Service cost
Interest cost
Expected return on plan assets
Amortization of prior service cost
Recognized net actuarial gain
Amortization of transition obligation
Amortization of transition asset

Net periodic benefit cost

$905
700
(784)
5
(5)

$770
650
(769)
7
(2)

(5)

(1)

$655

$816

$14
50
(6)
3
(15)
25

$15
44
(3)
2
(1)
25

$71

$82

Additional Information
Assumptions
Other Benefits

Pension Benefits
20X7
20X6
Weighted-average assumptions used to determine
benefit obligations at December 31:
Discount rate
Rate of compensation increase

7.00%
6.00%

7.00%
6.00%

20X7

20X6

7.00%

7.00%

Other Benefits
20X7
20X6

Pension Benefits
20X7
20X6
Weighted-average assumptions used to determine net
periodic benefit cost for years ended December 31:
Discount rate
Expected long-term return on plan assets
Rate of compensation increase

7.00%
8.00%
6.00%

7.00%
8.00%
6.00%

7.00%
6.60%

7.00%
6.60%

(Entity specific narrative description of the basis used to determine the overall expected long-term
rate of return on assets, as described in paragraph 5(d)(3) of SFAS 132, Employers' Disclosures About
Pensions and Other Postretirement Benefits (revised 2003) would be included here.)

Assumed health care cost trend rates at December 31:
Health care cost trend rate assumed for next year
Rate to which the cost trend rate is assumed to decline
(the ultimate trend rate)
Year that the rate reaches the ultimate trend rate

20X7

20X6

7%

7%

5%
20Y2

5%
20Y2

Assumed health care cost trend rates have a significant effect on the amounts reported for the
health care plans. A one-percentage-point change in assumed health care cost trend rates would
have the following effects:

Effect on total of service and interest cost
Effect on postretirement benefit obligation

1-PercentagePoint Increase

1-PercentagePoint Decrease

$13
73

$(11)
(67)
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Plan Assets

The composition of plan assets at December 31, 20X7, and 20X6, is as follows:
Pension Benefits
Other Benefits
20X7

20X6

20X7

20X6

Asset Category
Equity securities
Debt securities
Real estate
Other

XX%
XX
XX
XX

XX%
XX
XX
XX

XX%
XX
XX
XX

XX%
XX
XX
XX

Total

100%

100%

100%

100%

(Entity specific narrative description of investment policies and strategies for plan assets, includ
ing weighted-average target asset allocations [if used as part of those policies and strategies] as
described in paragraph 5(d)(2) of SFAS 132 (revised 2003) would be included here.)
Cash Flows
Contributions

The Hospital expects to contribute $XXX to its pension plan and $XXX to its other postretirement
benefit plan in 20X8.
Estimated Future Benefit Payments

The following benefit payments, which reflect expected future service, as appropriate, are ex
pected to be paid:

20X8
20X9
20Y0
20Y1
20Y2
Years 20Y3-20Y7

9.

Pension
Benefits

Other
Benefits

$XXX
XXX
XXX
XXX
XXX
XXX

$XXX
XXX
XXX
XXX
XXX
XXX

Concentrations of Credit Risk
The Hospital grants credit without collateral to its patients, most of whom are local residents
and are insured under third-party payor agreements. The mix of receivables from patients and
third-party payors at December 31,20X7 and 20X6, was as follows:

Medicare
Medicaid
Blue Cross
Other third-party payors
Patients

20X7

20X6

51%
17
18
7
7

53%
14
17
9
7

100%

100%

10. Commitments and Contingencies

Operating leases. The Hospital leases various equipment and facilities under operating leases
expiring at various dates through April 20Y2. Total rental expense in 20X7 and 20X6 for all
operating leases was approximately $859,000 and $770,000, respectively.
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The following is a schedule by year of future minimum lease payments under operating leases
as of December 31,20X7, that have initial or remaining lease terms in excess of one year.
Year Ending
December 31,
Amount
20X8
20X9
20Y0
20Y1
20Y2

$517,000
506,000
459,000
375,000
343,000

Litigation. The Hospital is involved in litigation and regulatory investigations arising in the
course of business. After consultation with legal counsel, management estimates that these
matters will be resolved without material adverse effect on the Hospital's future financial position
or results from operations.

Allowance for doubtful accounts. Beginning in 20X5, the Hospital has provided care under an
agreement with Associated HMO. The HMO currently owes the Hospital $950,000, substantially
all of which is overdue. The Hospital has notified the HMO that further services under the contract
cannot be provided without payment on the outstanding balance. The HMO has assured the
Hospital that additional funds are being obtained in order to pay the overdue balance and
continue service under the agreement, however, if the HMO is unable to make payments,
additional allowances for bad debts would need to be accrued.
11. Related Party Transactions
During the years ended December 31,20X7 and 20X6, the Hospital contributed capital to Sample
Health System, an affiliate with some board members in common with the Hospital, in the
amounts of $688,000 and $3,051,000, respectively.

The Sample Hospital Foundation (the Foundation), which is controlled by Sample Health
System, was established to solicit contributions from the general public solely for the funding of
capital acquisitions by the Hospital. Funds are distributed to the Hospital as determined by the
Foundation's Board of Directors. A summary of the foundation's assets, liabilities, net assets,
results of operations, and changes in net assets follows. The Hospital's interest in the net assets
of the Foundation is reported as a non-current asset in the balance sheets.
December 31,

20X6

20X7

$521,000

$472,000

11,000
510,000

10,000
462,000

Total liabilities and net assets

$521,000

$472,000

Support and revenue
Expenses
Distributions to Sample Hospital for property acquisitions
Other

$269,000

$535,000

235,000
13,000

485,000
16,000

248,000

501,000

21,000
27,000
462,000

34,000
17,000
411,000

$510,000

$462,000

Assets, principally cash and cash equivalents

Liabilities
Unrestricted net assets

Total expenses

Excess of support and revenue over expenses
Other changes in net assets
Unrestricted net assets, beginning of year
Unrestricted net assets, end of year

Liabilities include $10,000 payable at the end of each year to Sample Hospital. These amounts
were paid after the end of each year.
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12. Functional Expenses
The Hospital provides general health care services to residents within its geographic location.
Expenses related to providing these services are as follows (in thousands):
December 31,

Health care services
General and administrative

20X7

20X6

$86,000
12,055

$78,647
10,643

$98,055

$89,290

13. Fair Value of Financial Instruments

The following methods and assumptions were used by the Hospital in estimating the fair value
of its financial instruments:

Cash and cash equivalents: The carrying amount reported in the balance sheet for cash and cash
equivalents approximates its fair value.
Investments: Fair values, which are the amounts reported in the balance sheet, are based on
quoted market prices, if available, or estimated using quoted market prices for similar securities.

Assets limited as to use: These assets consist primarily of cash and short-term investments and
interest receivable. The carrying amount reported in the balance sheet is fair value.

Accounts payable and accrued expenses: The carrying amount reported in the balance sheet for
accounts payable and accrued expenses approximates its fair value.
Estimated third-party payor settlements: The carrying amount reported in the balance sheet for
estimated third-party payor settlements approximates its fair value.

Long-term debt: Fair values of the Hospital's revenue notes are based on current traded value.
The fair value of the Hospital's remaining long-term debt is estimated using discounted cash
flow analyses, based on the Hospital's current incremental borrowing rates for similar types
of borrowing arrangements.

The carrying amounts and fair values of the Hospital's financial instruments at December 31,20X7
and 20X6, are as follows (In thousands):
20X6

20X7

Cash and cash equivalents
Short-term investments
Assets limited as to use
Long-term investments
Long-term investments restricted
for capital acquisition
Accounts payable and
accrued expenses
Estimated third-party
payor settlements
Long-term debt

Carrying
Amount

Fair Value

Carrying
Amount

Fair Value

$ 4,758
15,836
18,949
4,680

$ 4,758
15,836
18,949
4,680

$ 5,877
10,740
19,841
4,680

$ 5,877
10,740
19,841
4,680

320

320

520

520

5,818

5,818

5,382

5,382

2,143
24,614

2,143
23,980

1,942
25,764

1,942
24,918

14. Promises to Contribute

At December 31,20X7, the Hospital had received $1,500,000 of conditional promises to contrib
ute to the building of a new facility for outpatient services. These contributions will be recorded
as temporarily restricted support when received. The Hospital had no material outstanding
unconditional promises of support at December 31,20X7.
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15. Charity Care

The amount of charges foregone for services and supplies furnished under the Hospital's charity
care policy aggregated approximately $4,500,000 and $4,100,000 in 20X7 and 20X6, respectively.
16. Subsequent Event
On February 9,20X8, the Hospital signed a contract in the amount of $1,050,000 for the purchase
of certain real estate.
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ILLUSTRATIVE FINANCIAL STATEMENTS FOR A NURSING HOME
.08

Sample For-Profit Nursing Home, Inc.
Balance Sheets

December 31,20X5 and 20X4
20X4

20X5
Assets
Current assets:
Cash and cash equivalents
Investments
Assets limited as to use
Patient accounts receivable, net of allowance
for doubtful accounts of $6,700 in 20X5 and
$5,300 in 20X4
Estimated third-party payor settlements
Interest receivable
Supplies
Prepaid expenses
Deferred tax asset
Total current assets
Assets limited as to use, net of amount required
for current liabilities
Property and equipment:
Land
Land improvements
Buildings
Furniture, fixtures, and equipment
Less accumulated depreciation
Property and equipment, net
Other assets
Total assets

Liabilities and Shareholders' Equity
Current liabilities:
Current maturities of long-term debt
Accounts payable
Accrued expenses
Deposits from patients
Other current liabilities
Total current liabilities
Deferred tax liability
Long-term debt, net of current maturities
Shareholders' equity:
Common stock, $20 par value; authorized
5,000 shares; issued and outstanding
3,500 shares
Retained earnings
Total shareholders' equity
Total liabilities and shareholders' equity
See accompanying notes to financial statements.
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$

95,000
150,000
50,000

$ 129,000

162,000
71,000
7,000
47,000
3,000
12,000
597,000

152,000
62,000

43,000
2,000
14,000
452,000

173,000

150,000

205,000
37,000
1,399,000
228,000
1,869,000
210,000
1,659,000
150,000
$2,579,000

205,000
32,000
1,399,000
189,000
1,825,000
141,000
1,684,000
127,000
$2,413,000

$

50,000
78,000
175,000
50,000
74,000
427,000
6,000
1,700,000

70,000
376,000
446,000
$2,579,000

50,000

$

50,000
52,000
188,000
45,000
15,000
350,000
14,000
1,750,000

70,000
229,000
299,000
$2,413,000
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Sample For-Profit Nursing Home, Inc.
Statements of Income and Retained Earnings
Years Ended December 31,20X5 and 20X4

Revenue:
Net patient service revenue
Other revenue
Interest on investments held by trustee
Total revenue

Expenses:
Salaries and benefits
Medical supplies and drugs
Insurance and other
Provision for bad debts
Depreciation
Interest
Total expenses
Operating income
Nonoperating income:
Other interest income
Income before provision for income taxes

Provision for income taxes
Net income
Retained earnings, beginning of year

Retained earnings, end of year

20X5

20X4

$2,163,000
67,000
13,000

$1,949,000
22,000
7,000

2,243,000

1,978,000

969,000
511,000
216,000
92,000
69,000
164,000

919,000
499,000
176,000
83,000
57,000
172,000

2,021,000

1,906,000

222,000

72,000

5,000

227,000

72,000

80,000

29,000

147,000

43,000

229,000

186,000

$ 376,000

$ 229,000

See accompanying notes to financial statements.
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Sample For-Profit Nursing Home, Inc.

Statements of Cash Flows

Years Ended December 31,20X5 and 20X4
Cash flows from operating activities:
Cash received from residents and third-party payors
Cash received from others
Cash paid to employees and suppliers
Interest and dividends received
Interest paid
Taxes paid
Deposits received from patients
Deposits refunded to patients

20X5

20X4

$2,019,000
67,000
(1,679,000)
10,000
(160,000)
(29,000)
35,000
(30,000)

$1,796,000
22,000
(1,495,000)
10,000
(170,000)
(30,000)
15,000
(20,000)

Net cash provided by operating activities

233,000

Cash flows from investing activities:
Purchase of investments
Proceeds from sale of property
Capital expenditures
Purchase of assets limited as to use

128,000

(150,000)
2,000
(79,000)

(44,000)
(23,000)

Net cash used in investing activities

(217,000)

(77,000)

(50,000)

(50,000)

(50,000)

(50,000)

Net increase (decrease) in cash and cash equivalents

(34,000)

1,000

Cash and cash equivalents, beginning of year

129,000

128,000

95,000

$ 129,000

Cash flows from financing activities:
Repayment of long-term debt

Net cash used in financing activities

Cash and cash equivalents, end of year

$

Reconciliation of net income to net cash
provided by operating activities:

Net income
Adjustments to reconcile net income to net cash
provided by operating activities:
Depreciation
Provision for bad debts
Loss on sale of property
Change in deferred income taxes
(Increase) decrease in:
Patient accounts receivable
Other current assets
Estimated third-party payor settlements
Interest receivable
Other assets

Increase (decrease) in:
Accounts payable and accrued expenses
Deposits from patients
Other current liabilities
Net cash provided by operating activities
See accompanying notes to financial statements.

FSP §11,500.10

$ 147,000

$

43,000

69,000
92,000
—
(6,000)

57,000
83,000
11,000
(14,000)

(102,000)
(21,000)
(9,000)
(7,000)
(7,000)

(41,000)
(15,000)
(10,000)
(3,000)
(10,000)

13,000
5,000
59,000

43,000
(5,000)
(11,000)

$ 233,000

$ 128,000
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Sample For-Profit Nursing Home, Inc.

Notes to Financial Statements
December 31,20X5 and 20X4
1. Description of Organization and Summary of Significant Accounting Policies3

Organization. The Sample Nursing Home, Inc. (the Company) was incorporated in New State
in 20X1 and operates a 128-bed nursing home in Abacus, New State. A summary of the Company's
significant accounting policies follows:
Use of estimates. The preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the
date of the financial statements and the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates.
Cash and cash equivalents. Cash and cash equivalents include investments in highly liquid debt
instruments with an original maturity of three months or less, excluding amounts whose use is
limited by note indenture.
Investments. Investments in debt instruments, including assets limited as to use, are classified
as held-to-maturity because the Company has the positive intent and ability to hold the securities
until maturity. Held-to-maturity securities are carried at cost adjusted for amortization of premi
ums and accretion of discounts.

Assets limited as to use. Assets deposited with a trustee under terms of the note indenture and
assets set aside by the Board of Directors for capital improvements are classified as assets limited
as to use. Amounts required to meet current liabilities have been reclassified in the balance sheet.

Property and equipment. Property and equipment are recorded at cost. Depreciation is calculated
on the straight-line method over the estimated useful Eves of depreciable assets.
Bond issuance costs. Costs incurred in issuing the Series 20X1 bonds are being amortized based
on the effective interest method.
Net patient service revenue. Net patient service revenue is reported at the estimated net realizable
amounts from residents, third-party payors, and others for service rendered.

Revenue under third-party payor agreements is subject to audit and retroactive adjustment.
Provisions for estimated third-party payor settlements are provided in the period the related
services are rendered. Differences between the estimated amounts accrued and interim and final
settlements are reported in operations in the year of settlement.

Income taxes. The provisions for income taxes are based on amounts estimated to be currently
payable and those deferred because of temporary differences between the financial statement and tax
bases of assets and liabilities. These differences consist principally of bad debts and depreciation.

3 Paragraph 13 of SOP 01-6, Accounting by Certain Entities (Including Entities With Trade Receivables) That Lend to or Finance the Activities
of Others, provides guidance on disclosures that should be included in the summary of significant accounting policies, including
accounting policies for loans, trade receivables, and doubtful accounts.
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2. Assets Limited as to Use

Assets limited as to use include:
Assets held by trustee under the Series 20X1 note indenture agreement
at December 31,20X5 and 20X4.
U.S. Government obligations
Cash
Accrued interest income

20X5

20X4

$150,000
24,000
2,000

$130,000
21,000
2,000

176,000

153,000

$ 45,000
2,000

$ 45,000
2,000

47,000

47,000

$223,000

$200,000

Internally designated by the Board of
Directors for capital improvements

Certificate of deposit
Accrued interest

3. Investments‡

4. Long-Term Debt
Long-term debt at December 31,20X5 and 20X4, was as follows:

9.5 percent bonds payable to the City
of Abacus, maturing $50,000 annually
through November 1,20YY, with a
final maturity of $1 million on
November 1,20YY
Less current maturities

20X5

20X4

$1,750,000
50,000

$1,800,000
50,000

$1,700,000

$1,750,000

The notes are collateralized by a first-mortgage lien on all property and equipment of the
Company and a security interest in all of its receipts. The note indenture requires the maintenance
of certain deposits with a trustee, which are included in assets limited as to use.

Future maturities of long-term debt as of December 31,20X5, follow:

Year ending December 31,

Amount

20X6
20X7
20X8
20X9
20Y0
Thereafter

$

Total

$1,750,000

50,000
50,000
50,000
50,000
50,000
1,500,000

* In reporting disclosures about investments in securities, entities should comply primarily with the requirements of paragraphs 6,
17,19,20,21, and 22 of SFAS 115, as amended. Other disclosure requirements may also be applicable.
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5.

Income Taxes
The provisions for income taxes are as follows:

Current:
Federal
State
Total current
Deferred:
Federal
State
Total deferred
Total provision for income taxes

20X5

20X4

$72,000
2,000
74,000

$15,000
_______
15,000

6,000
_______
6,000
$80,000

13,000
1,000
14,000
$29,000

Deferred income taxes are provided for the temporary differences between the financial report
ing basis and the tax basis of the Company's assets and liabilities.
For the years ended December 31, 20X5 and 20X4, the effective tax rate approximated the
statutory rate of 34 percent and 40 percent, respectively.

The net current and noncurrent components of deferred income taxes recognized in the balance
sheet at December 31,20X5 and 20X4, follows:
20X5
20X4
Net current assets
$12,000
$14,000
Net noncurrent liabilities
6,000
14,000
$ 6,000
$____ 0

Management has determined that no valuation allowance related to deferred tax assets is
necessary at December 31,20X5 and 20X4, respectively.

6. Concentration in State Medicaid Program
The Company has 100 of its 128 beds designated for care of patients under the state's Medicaid
program. The current funding of that program is 90 days behind filed claims. The current state budget
has no provision for reducing that lag and, while the proposed budget for 20X6 includes additional
funding, there is no assurance that the final budget will include the needed additional funds.
7. Third Party Rate Adjustments and Revenue

Revenue from the Medicaid program accounted for approximately XX percent for the year ended
20X5, and XX percent for the year ended 20X4, of the Company's net patient revenue. Laws and
regulations governing the Medicaid program are extremely complex and subject to interpretation. As
a result, there is at least a reasonable possibility that recorded estimates will change by a material
amount in the near term. The 20X5 net patient service revenue increased approximately $XXX due to
removal of allowances previously estimated that are no longer necessary as a result of final settlements
and years that are no longer subject to audits, reviews, and investigations. The 20X4 net patient service
revenue decreased approximately $XXX due to prior-year retroactive adjustments in excess of
amounts previously estimated.

8. Risks and Uncertainties Disclosures||
9. Pension Plan||
10. Postretirement Benefits||
11. Fair Values of Financial Instruments||
12. Concentrations of Credit Risk||
|| The disclosures contained in these notes would be similar to the disclosures contained in the notes to the financial statements for
the not-for-profit hospital and, therefore, are not repeated here.
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FOR A CONTINUING CARE RETIREMENT COMMUNITY
.12

Sample Not-for-Profit Continuing Care Retirement Community
Balance Sheets

December 31,20X5 and 20X4
20X4

20X5
Assets
Current assets:
Cash
Assets limited as to use
Accounts receivable, net of allowance for
doubtful accounts of $4,000 in 20X5 and
$5,000 in 20X4
Supplies
Prepaid expenses

$

$

330,000
170,000

187,000
40,000
115,000

197,000
21,000
73,000

982,000

791,000

1,865,000
14,893,000

1,583,000
15,280,000

83,000

90,000

$17,823,000

$17,744,000

$

$

Total current assets
Assets limited as to use, net of amount required
for current liabilities
Property and equipment, net
Deferred financing costs, net of accumulated
amortization of $28,000 in 20X5 and
$21,000 in 20X4
Total assets

375,000
265,000

Liabilities and Net Assets
Liabilities:
Current maturities of long-term debt
Accounts payable
Accrued expenses
Deposits on unoccupied units

Total current liabilities

Long-term debt, less current maturities
Refundable fees
Estimated obligation to provide future
services, in excess of amounts received
or to be received
Deferred revenue from advance fees
Total liabilities

Net assets:
Unrestricted
Temporarily restricted
Permanently restricted
Total net assets

Total liabilities and net assets
See accompanying notes to financial statements.
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90,000
180,000
161,000
22,000

77,000
174,000
178,000
40,000

453,000

469,000

8,871,000
59,000

8,935,000
144,000

88,000
6,304,000

100,000
6,585,000

15,775,000

16,233,000

1,286,000
311,000
451,000

833,000
294,000
384,000

2,048,000

1,511,000

$17,823,000

$17,744,000
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Sample Not-for-Profit Continuing Care Retirement Community

Statements of Operations

Years Ended December 31,20X5 and 20X4

Revenue, gains, and other support:
Resident services, including amortization
of advance fees of $935,000 in 20X5
and $915,000 in 20X4
Patient revenue from nonresidents
Change in obligation to provide future services
Contributions
Net assets released from restrictions used for
operations
Investment income
Other
Total revenue, gains, and other support
Expenses:
Salaries and benefits
Medical supplies and drugs
Insurance
Depreciation
Interest

Total expenses
Operating income (loss)

Net assets released from restriction—
purchase of equipment

Increase (decrease) in unrestricted net assets

20X5

20X4

$3,946,000
249,000
12,000
54,000

$3,152,000
275,000
(82,000)
39,000

24,000
29,000
75,000

50,000
30,000
68,000

4,389,000

3,532,000

1,708,000
543,000
291,000
452,000
967,000

1,250,000
742,000
311,000
447,000
955,000

3,961,000

3,705,000

428,000

(173,000)

25,000

45,000

$ 453,000

$ (128,000)

See accompanying notes to financial statements.
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Sample Not-for-Profit Continuing Care Retirement Community
Statements of Changes in Net Assets

Years Ended December 31,20X5 and 20X4

Unrestricted net assets:
Operating income (loss)

Net assets released from restriction—
purchase of equipment

Increase (decrease) in unrestricted net assets
Temporarily restricted net assets:
Contributions
Net assets released from restrictions used
for operations
Net assets released from restriction—
purchase of equipment
Investment income
Increase (decrease) in temporarily restricted
net assets

Permanently restricted net assets:
Contributions

Increase in permanently restricted net assets
Increase (decrease) in net assets
Net assets, beginning of year
Net assets, end of year

See accompanying notes to financial statements.
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20X5

20X4

$ 428,000

$ (173,000)

25,000

45,000

453,000

(128,000)

40,000

15,000

(24,000)

(50,000)

(25,000)
26,000

(45,000)
15,000

17,000

(65,000)

67,000

52,000

67,000

52,000

537,000

(141,000)

1,511,000

1,652,000

$2,048,000

$1,511,000
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Sample Not-for-Profit Continuing Care Retirement Community

Statements of Cash Flows
Years Ended December 31,20X5 and 20X4
Cash flows from operating activities:
Cash received from residents and
third-party payors
Advance fees received
Other receipts from operations
Investment income received
Contributions received
Cash paid to employees and suppliers
Interest paid

Net cash provided by operating activities

Cash flows from investing activities:
Purchase of property and equipment
Purchase of assets limited as to use
Net cash used in investing activities

20X5

20X4

$3,252,000
654,000
75,000
68,000
51,000
(2,576,000)
(950,000)

$2,341,000
857,000
68,000
53,000
44,000
(2,040,000)
(945,000)

574,000

378,000

(65,000)
(377,000)

(250,000)
229,000

(442,000)

(21,000)

Cash flows from financing activities:
Permanently restricted funds received
Refunds of deposits and refundable fees
Proceeds from issuance of long-term debt
Principal payments of long-term debt

67,000
(103,000)
26,000
(77,000)

52,000
(52,000)

(307,000)

Net cash used in financing activities

(87,000)

(307,000)

45,000

50,000

Net increase in cash

Cash, beginning of year
Cash, end of year

330,000

280,000

$ 375,000

$ 330,000

$ 537,000

$ (141,000)

Reconciliation of change in net assets to
net cash provided by operating activities:

Change in net assets
Adjustments to reconcile change in net assets
to net cash provided by operating activities:
Advance fees received
Restricted net assets received
Amortization of advance fees
Loss (gain) on obligation to provide
future services
Depreciation
Amortization of deferred financing costs
Provision for bad debts

654,000
(67,000)
(935,000)

857,000
(52,000)
(915,000)

(12,000)
452,000
7,000
3,000

82,000
447,000
34,000
3,000

(Increase) decrease in:
Accounts receivable
Other assets

7,000
(61,000)

(33,000)
(4,000)

Increase (decrease) in:
Accounts payable and accrued expenses

(11,000)

100,000

Net cash provided by operating
activities

$ 574,000

$ 378,000

See accompanying notes to financial statements.
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Sample Not-for-Profit Continuing Care Retirement Community

Notes to Financial Statements4

December 31,20X5 and 20X4
1. Description of Organization and Summary of Significant Accounting Policies#,5

Organization. The Sample Continuing Care Retirement Community (the CCRC) is a nonprofit
organization that principally provides housing, health care, and other related services to residents
through the operation of a retirement facility containing 249 apartments and a 78-bed health care
facility located in Evergreen Park, Illinois. The CCRC was incorporated in Illinois in 20X1. A
summary of significant accounting policies follows.

Use of estimates. The preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the
date of the financial statements and the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates.

Investments. Investments, which consist of U.S. Treasury obligations, are measured at fair value
in the balance sheet. Investment income (including realized gains and losses on investments,
interest, and dividends) is included in operating income (loss) unless restricted by donor or law.
Unrealized gains and losses on investments, if any, are excluded from operating income (loss).
Deferred financing costs. Deferred financing costs are amortized using the effective interest
method over the term of the related financing agreement.
Advance fees. Fees paid by a resident upon entering into a continuing care contract, net of the portion
thereof that is refundable to the resident, are recorded as deferred revenue and are amortized to
income using the straight-line method over the estimated remaining life expectancy of the resident.
Obligation to provide future services. The CCRC annually calculates the present value of the net cost
of future services and the use of facilities to be provided to current residents and compares that amount
with the balance of deferred revenue from advance fees. If the present value of the net cost of future
services and the use of facilities exceeds the deferred revenue from advance fees, a liability is recorded
(obligation to provide future services and use of facilities) with the corresponding charge to income.
The obligation is discounted at 9 percent, based on the expected long-term rate of return on
government obligations.

Donor restrictions. The CCRC reports gifts of cash and other assets as restricted support if they
are received with donor stipulations that limit the use of the donated assets. When a donor
restriction expires (that is, when a stipulated time restriction ends or a purpose restriction is
accomplished), temporarily restricted net assets are reclassified as unrestricted net assets and
reported in the statement of operations as net assets released from restrictions. Donor-restricted
contributions whose restrictions are met within the same year as received are reflected as
unrestricted contributions in the accompanying financial statements.

The CCRC reports gifts of property and equipment (or other long-lived assets) as unrestricted
support unless explicit donor stipulations specify how the donated assets must be used. Gifts of
4 SOP 00-1 provides auditors with guidance regarding uncertainties in health care revenue recognition and includes a sample
disclosure in paragraph 37 of the SOP for material differences between an original estimate and subsequent revisions regarding
third-party payments. SOP 00-1 is included in Appendix E to the Guide.

# Does not include all disclosures common to all health care entities.
5 Paragraph 13 of SOP 01-6, Accounting by Certain Entities (Including Entities With Trade Receivables) That Lend to or Finance the Activities
of Others, provides guidance on disclosures that should be included in the summary of significant accounting policies, including
accounting policies for loans, trade receivables, and doubtful accounts.
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long-lived assets with explicit restrictions that specify how the assets are to be used and gifts of
cash or other assets that must be used to acquire long-lived assets are reported as restricted support.
Absent explicit donor stipulations about how long those long-lived assets must be maintained, the
CCRC reports expirations of donor restrictions when the donated or acquired long-lived assets are
placed in service.
Income taxes. The CCRC has been recognized by the Internal Revenue Service as a not-for-profit
corporation as described in Sec. 501(c)(3) of the Internal Revenue Code (IRC) and is exempt from
federal income taxes pursuant to Sec. 501(a) of the IRC.

Property and equipment. Property and equipment are stated at cost. Donated property is re
corded at its estimated fair value at the date of receipt. Depreciation is computed on the
straight-line method based on the following estimated useful lives:

20 years
40 years
5-15 years

Land improvements
Buildings and improvements
Furniture and equipment

Operating income (loss). The statement of operations includes operating income (loss). Changes in
unrestricted net assets which are excluded from operating income (loss), consistent with industry
practice, include unrealized gains and losses on investments other than trading securities,
permanent transfers of assets to and from affiliates for other than goods and services, and
contributions of long-lived assets (including assets acquired using contributions which by donor
restriction were to be used for the purposes of acquiring such assets).

2. Property and Equipment

A summary of property and equipment at December 31,20X5 and 20X4, follows:

20X4

20X5

Land
Land improvements
Buildings and improvements
Furniture and equipment

$

557,000
205,000
14,573,000
752,000
16,087,000

Less: accumulated depreciation

$

557,000
203,000
14,564,000
698,000
16,022,000

(1,194,000)

$14,893,000

(742,000)

$15,280,000

3. Temporarily Restricted Net Assets
Temporarily restricted net assets are available for the following purposes:
Purchase of equipment
Charity care

20X5
$169,000
142,000
$311,000

20X4
$152,000
142,000
$294,000

Net assets were released from donor restrictions by incurring expenses satisfying the restricted
purposes or by occurrence of other events specified by donors:

20X4

Charity care

20X5
$24,000

$50,000

Purchase of equipment

$25,000

$45,000

4. Permanently Restricted Net Assets
Permanently restricted net assets are restricted to investment in perpetuity, the income from
which is expendable to support:

FSP §11,500.16

156

Health Care Organizations

Charity care
Community activities

20X5
$168,000
283,000
$451,000

20X4
$168,000
216,000
$384,000

5. Long-Term Debt
Long-term debt at December 31,20X5 and 20X4, is as follows:

10.75 percent mortgage note payable
Notes payable to bank—unsecured
Other
Less current maturities

20X5

20X4

$8,901,000
34,000
26,000

$8,965,000
14,000
33,000

8,961,000
90,000

9,012,000
77,000

$8,871,000

$8,935,000

The mortgage note is payable in consecutive monthly installments of principal and interest of
$85,425 to May 20XX. The note is collateralized by a first mortgage on property and equipment
with a depreciated cost at December 31, 20X5, of $14,893,000 and by a pledge of all operating
revenue.
As required by the mortgage note agreement, the CCRC established an initial debt service
reserve fund of $1,000,000 at April 15, 20X3. All resident fees received thereafter, net of resident
fee refunds and debt service payments not to exceed $300,000 annually in the first four years and
$200,000 annually thereafter, are to be added to the debt service reserve fund until the total sum
of $2,050,000 is accumulated. Since June 1, 20X4, the CCRC has been required to deliver to the
trustee $5,500 per month to establish maintenance reserves until the aggregate of such payments
equals a residential unit reserve and a health care center reserve of $240,000 and $90,000,
respectively. At December 31,20X5 and 20X4, the trustee held investments aggregating $2,130,000
and $1,753,000, respectively. Such amount has been classified as assets limited as to use.
Scheduled annual principal maturities of long-term debt for the next five years are as follows:
Year ending December 31,
Amount

20X6
20X7
20X8
20X9
20Y0

$ 90,000
90,000
95,000
105,000
105,000

6. Classification of Expenses

3,368,000
593,000

20X4
3,135,000
570,000

$3,961,000

$3,705,000

20X5

Program activities
General and administrative

7. Assets Limited as to Use||
8. Risks and Uncertainties Disclosures||
9. Pension and Other Postretirement Benefit Plans||

10. Fair Values of Financial Instruments||
11. Concentrations of Credit Risk||
12. Investments||
|| The disclosures contained in these notes would be similar to the disclosures contained in the notes to the financial statements for
the not-for-profit hospital and, therefore, are not repeated here.
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ILLUSTRATIVE FINANCIAL STATEMENTS FOR A HOME HEALTH AGENCY
.17

Sample Not-for-Profit Home Health Agency

Balance Sheets
December 31,20X5 and 20X4
20X5

20X4

Assets
Current assets:
Cash and cash equivalents
Investments
Accounts receivable, net of allowance for doubtful
accounts of $61,000 in 20X5 and $30,000 in 20X4
Other receivables

74,000
147,000

$ 41,000
137,000

752,000
27,000

476,000
22,000

1,000,000

676,000

100,000

100,000

56,000
50,000

39,000
37,000

106,000
(45,000)

76,000
(24,000)

61,000

52,000

20,000

25,000

$1,181,000

$853,000

13,000
40,000
496,000
28,000
70,000

$ 13,000
21,000
352,000
31,000
66,000

647,000

483,000

105,000

118,000

752,000

601,000

330,000
9,000
90,000

167,000
5,000
80,000

429,000

252,000

$1,181,000

$853,000

$

Total current assets
Investments

Equipment:
Medical and office equipment
Vehicles
Less accumulated depreciation

Equipment, net
Deferred finance charges, net of accumulated amort
ization of $15,000 in 20X5 and $10,000 in 20X4

Total assets

Liabilities and Net Assets

Current liabilities:
Current maturities of long-term debt
Accounts payable
Accrued payroll and vacation costs
Estimated third-party payor settlements
Advances from third-party payors
Total current liabilities
Long-term debt, less current maturities

Total liabilities
Net assets:
Unrestricted
Temporarily restricted
Permanently restricted

Total net assets

Total liabilities and net assets

$

See accompanying notes to financial statements.
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FORMAT A

Sample Not-for-Profit Home Health Agency
Statements of Operations
Years Ended December 31,20X5 and 20X4

Revenue, gains, and other support:
Net patient service revenue
Contributions
Net assets released from restrictions
Investment income
Other revenue

Total revenue, gains, and other support
Expenses:
Salaries and benefits
Medical supplies and drugs
Insurance and other
Provision for bad debts
Depreciation
Interest

Total expenses
Excess of revenue over expenses and
change in unrestricted net assets
See accompanying notes to financial statements.
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20X5

20X4

$4,042,000
5,000
5,000
13,000
27,000

$2,687,000
22,000
—
6,000
32,000

4,092,000

2,747,000

2,714,000
1,042,000
90,000
46,000
21,000
16,000

1,835,000
675,000
83,000
21,000
15,000
19,000

3,929,000

2,648,000

$ 163,000

$

99,000
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FORMAT B

Sample Not-for-Profit Home Health Agency
Statements of Operations
Years Ended December 31,20X5 and 20X4
20X5

20X4

$4,042,000
5,000
5,000
27,000

$2,687,000
22,000
—
32,000

4,079,000

2,741,000

2,714,000
1,042,000
90,000
46,000
21,000
16,000

1,835,000
675,000
83,000
21,000
15,000
19,000

Total expenses

3,929,000

2,648,000

Operating income

150,000

93,000

13,000

6,000

Revenue, gains, and other support:
Net patient service revenue
Contributions
Net assets released from restrictions
Other revenue

Total revenue, gains, and other support
Expenses:
Salaries and benefits
Medical supplies and drugs
Insurance and other
Provision for bad debts
Depreciation
Interest

Other income:
Investment income

Excess of revenue over expenses and
change in unrestricted net assets

$ 163,000

$

99,000

See accompanying notes to financial statements.
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Sample Not-for-Profit Home Health Agency
Statements of Changes in Net Assets
Years Ended December 31,20X5 and 20X4
20X5

20X4

$163,000

$ 99,000

163,000

99,000

Unrestricted net assets:

Excess of revenue over expenses

Increase in unrestricted net assets
Temporarily restricted net assets:
Contributions
Net assets released from restrictions

9,000
(5,000)

5,000
—

4,000

5,000

10,000

6,000

10,000

6,000

Increase in net assets

177,000

110,000

Net assets, beginning of year

252,000

142,000

$429,000

$252,000

Increase in temporarily restricted net assets
Permanently restricted net assets:
Contributions

Increase in permanently restricted net assets

Net assets, end of year
See accompanying notes to financial statements.
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Sample Not-for-Profit Home Health Agency
Statements of Cash Flows

Years Ended December 31,20X5 and 20X4

Cash flows from operating activities:
Cash received from patients and
third-party payors
Other receipts from operations
Cash paid to employees and suppliers
Interest paid
Nonoperating revenue

20X5

20X4

$3,721,000
22,000
(3,679,000)
(11,000)
23,000

$2,542,000
32,000
(2,541,000)
(14,000)
22,000

Net cash provided by operating activities

Cash flows from investing activities:
Purchase of equipment
Purchase of investments
Net cash used in investing activities
Cash flows from financing activities:
Proceeds from contributions restricted for:
Endowment

Other financing activities:
Payment of long-term debt

76,000

41,000

(30,000)
(10,000)

(19,000)
(15,000)

(40,000)

(34,000)

10,000

6,000
__

(13,000)

Net cash provided by (used in) financing activities

(3,000)

6,000

Net increase in cash and cash equivalents

33,000

13,000

Cash and cash equivalents, beginning of year

41,000

28,000

Cash and cash equivalents, end of year

$

74,000

$

41,000

Reconciliation of change in net assets to net
cash provided by operating activities:
Change in net assets
Adjustments to reconcile change in net assets
to net cash provided by operating activities:
Increase in permanently restricted net assets
Provision for bad debts
Depreciation
Amortization of deferred financing charges
(Increase) decrease in:
Accounts receivable
Other receivables

$ 177,000

Increase (decrease) in:
Accounts payable, accrued payroll, and
vacation costs
Estimated third-party payor settlements
Net cash provided by operating activities

$

$ 110,000

(10,000)
46,000
21,000
5,000

(6,000)
21,000
15,000
5,000

(322,000)
(5,000)

(150,000)
4,000

163,000
1,000

38,000
4,000

76,000

$

41,000

See accompanying notes to financial statements.
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Sample Not-for-Profit Home Health Agency
Notes to Financial Statements
Years Ended December 31,20X5 and 20X4
1. Description of Organization and Summary of Significant Accounting Policies6
Organization. The Sample Home Health Agency (the Agency) was incorporated in 20X0 in New
State as a not-for-profit corporation. The Agency provides health and supportive services to
individuals at their homes, primarily in the New State area.

Use of estimates. The preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the
date of the financial statements and the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates.
Cash and cash equivalents. Cash and cash equivalents include investments in highly liquid debt
instruments with an original maturity of three months or less.

Investments. Investments, which consist of U.S. Treasury obligations, are measured at fair value in
the balance sheet. Investment income (including realized gains and losses on investments, interest and
dividends) is included in excess of revenues over expenses unless restricted by donor or law. Unrealized
gains and losses on investments, if any, are excluded from excess of revenues over expenses.
Equipment. Equipment is recorded at cost. Depreciation is computed using the straight-line
method over the estimated useful lives of the assets.

Deferred financing costs. Deferred financing costs are being amortized using the effective interest
method over the term of the related financing agreement.

Donor restrictions. The Agency reports gifts of cash and other assets as restricted support if they
are received with donor stipulations that limit the use of the donated assets. When a donor restriction
expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished,
temporarily restricted net assets are reclassified as unrestricted net assets and reported in the statement
of operations as net assets released from restrictions. When long-lived assets are placed in service,
thus satisfying purpose restrictions, the amount is included as a change in net assets, restricted and
unrestricted. Donor-restricted contributions whose restrictions are met within the same year as
received are reflected as unrestricted contributions in the accompanying financial statements.

The Agency reports gifts of equipment (or other long-lived assets) as unrestricted support unless
explicit donor stipulations specify how the donated assets must be used. Gifts of long-lived assets
with explicit restrictions that specify how the assets are to be used and gifts of cash or other assets that
must be used to acquire long-lived assets are reported as restricted support. Absent explicit donor
stipulations about how long those long-lived assets must be maintained, the Agency reports expira
tions of donor restrictions when the donated or acquired long-lived assets are placed in service.
Net patient service revenue. Net patient service revenue represents the estimated net realizable
amounts from patients, third-party payors, and others for services rendered.

Charity care. The Agency has a policy of providing charity care to patients who are unable to
pay. Such patients are identified based on financial information obtained from the patient and
subsequent analysis. Since the Agency does not expect payment, estimated charges for charity
care are not included in revenue.
6 Paragraph 13 of SOP 01-6, Accounting by Certain Entities (Including Entities With Trade Receivables) That Lend to or Finance the Activities
of Others, provides guidance on disclosures that should be included in the summary of significant accounting policies, including
accounting policies for loans, trade receivables, and doubtful accounts.
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Income taxes. The Agency has been recognized by the Internal Revenue Service as a not-forprofit corporation as described in Sec. 501(c)(3) of the Internal Revenue Code (IRC) and is exempt
from federal income taxes on related income pursuant to Sec. 501(a) of the IRC.

Excess of revenue over expenses. The statement of operations includes excess of revenue over expenses.
Changes in unrestricted net assets which are excluded from excess of revenue over expenses, consistent
with industry practice, include unrealized gains and losses on investments other than trading
securities, permanent transfers of assets to and from affiliates for other than goods and services, and
contributions of long-lived assets (including assets acquired using contributions which by donor
restriction were to be used for the purposes of acquiring such assets).
2. Temporarily Restricted Net Assets

Temporarily restricted net assets are available for the following purposes:

Charity care
Purchase of equipment

20X5

20X4

$ —
9,000

$5,000

$9,000

$5,000

Net assets were released from donor restrictions by incurring expenses satisfying the restricted
purposes or by occurrence of other events specified by donors:
20X5

Charity care expenditures

$5,000

20X4
$ —

3. Permanently Restricted Net Assets

Permanently restricted net assets are restricted in perpetuity, the income from which is expend
able to support:

Program A activities
Any activities of the Agency

20X5

20X4

$10,000
80,000

$ —
80,000

$90,000

$80,000

4. Third-Party Rate Adjustments and Revenue

Approximately 38 percent in 20X5 and 37 percent in 20X4 of net patient service revenue was derived
under federal and state third-party reimbursement programs. These revenues are based, in part, on
cost reimbursement principles and are subject to audit and retroactive adjustment by the respective
third-party fiscal intermediaries. Laws and regulations governing these programs are extremely
complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded
estimates will change by a material amount in the near term. The 20X5 net patient service revenue
increased approximately $XXX due to removal of allowances previously estimated that are no longer
necessary as a result of final settlements and years that are no longer subject to audits, reviews, and
investigations. The 20X4 net patient service revenue decreased approximately $XXX due to prior-year
retroactive adjustments in excess of amounts previously estimated.
5. Internally-Designated Assets

The Board of Directors has designated investments aggregating $100,000 to be used for future major
capital improvements. Those assets are classified in the balance sheet as long-term investments.

FSP §11,500.22

164

Health Care Organizations

6. Long-Term Debt
Long-term debt at December 31,20X5 and 20X4, is as follows:
Note payable to bank, interest at 15 percent,
payable in monthly installments of $2,200 per
month, including interest, collateralized by
equipment with a depreciated cost of $42,000
Less current maturities

20X5

20X4

$118,000
13,000

$131,000
13,000

$105,000

$118,000

Scheduled maturities of long-term debt at December 31,20X5, are as follows:
Year ending December 31,

Amount

20X6
20X7
20X8
20X9
20Y0
Thereafter
Total

$ 13,000
13,000
13,000
13,000
13,000
53,000
$118,000

7. Classification of Expenses
Program_____________
B
C

General and
Administrative

Total

A

$2,714,000
1,042,000
90,000
46,000
21,000
16,000

$1,363,000
511,000
58,000
16,000
5,000
10,000

$699,000
246,000

$3,929,000

$1,963,000

$978,000

$648,000

$340,000

$1,835,000
675,000
83,000
21,000
15,000
19,000

$ 915,000
335,000
64,000
21,000
6,000
12,000

$463,000
211,000

$216,000
129,000

$241,000

$2,648,000

$1,353,000

$679,000

Expenses incurred for the
year ended December 31,
20X5, were for:
Salaries and benefits
Medical supplies and drugs
Insurance and other
Provision for bad debts
Depreciation
Interest

Total expenses

$363,000
285,000

$289,000

32,000

30,000
16,000
3,000

3,000

Expenses incurred for the
year ended December 31,
20X4, were for:
Salaries and benefits
Medical supplies and drugs
Insurance and other
Provision for bad debts
Depreciation
Interest

Total expenses

19,000
9,000
2,000

5,000
$345,000

$271,000

(The preparer of the financial statements may wish to include a brief description of the types of
programs.)
8. Charity Care
Charity care represented approximately 3 percent and 4 percent of visits in 20X5 and 20X4,
respectively.

FSP §11,500.22

Illustrative Financial Statements

165

9. Risks and Uncertainties Disclosures||

10. Pension and Other Postretirement Benefit Plans||

11. Fair Value of Financial Statements||
12. Concentrations of Credit Risk||

13. Investments||

|| The disclosures contained in these notes would be similar to the disclosures contained in the notes to the financial statements for
the not-for-profit hospital and, therefore, are not repeated here.
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Sample Not-for-Profit Health Maintenance Organization
Balance Sheets

June 30,20X5 and 20X4
20X5

20X4

$2,937,000

$1,021,000

358,000
263,000
190,000
197,000

407,000
261,000
184,000
99,000

3,945,000

1,972,000

5,756,000

5,626,000

150,000

150,000

18,000

21,000

$9,869,000

$7,769,000

$

$

Assets
Current assets:
Cash and cash equivalents
Premiums receivable, net of allowance for
doubtful accounts of $36,000 in 20X5
and $42,000 in 20X4
Other receivables
Supplies
Prepaid expenses
Total current assets
Property and equipment, net
State guaranty fund deposit

Debt issuance costs, net of accumulated
amortization of $42,000 in 20X5 and
$39,000 in 20X4
Total assets

Liabilities and Net Assets
Current liabilities:
Unsecured 12 percent note payable to a bank
Current maturities of long-term debt
Accounts payable—medical services
Other accounts payable and accrued expenses
Unearned premium revenue
Total current liabilities
Long-term debt, less current maturities

Total liabilities

Net assets—unrestricted
Total liabilities and net assets
See accompanying notes to financial statements.

FSP §11,500.23

—
241,000
2,245,000
829,000
141,000

44,000
109,000
1,471,000
661,000
202,000

3,456,000

2,487,000

4,295,000

2,382,000

7,751,000

4,869,000

2,118,000

2,900,000

$9,869,000

$7,769,000
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Sample Not-for-Profit Health Maintenance Organization

Statements of Operations and Changes in Net Assets
Years Ended June 30,20X5 and 20X4

Revenue:
Premiums earned
Coinsurance
Interest and other income
Total revenue

Expenses:
Salaries and benefits
Medical supplies and drugs
Insurance
Provision for bad debts
Depreciation
Interest
Total expenses

Operating income (loss)
Net assets, beginning of year
Net assets, end of year

20X5

20X4

$27,682,000
689,000
242,000

$22,500,000
500,000
100,000

28,613,000

23,100,000

16,154,000
8,507,000
3,963,000
19,000
367,000
385,000

13,328,000
5,988,000
2,463,000
20,000
336,000
375,000

29,395,000

22,510,000

(782,000)

590,000

2,900,000

2,310,000

$ 2,118,000

$ 2,900,000

See accompanying notes to financial statements.
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Sample Not-for-Profit Health Maintenance Organization
Statements of Cash Flows
Years Ended June 30,20X5 and 20X4
Cash flows from operating activities:
Cash received from premiums, stop-loss
insurance recoveries, and coinsurance
Cash paid to employees and to providers
of health care services
Interest and other income received
Interest paid
Net cash provided by operating activities

Cash flows from investing activities:
Capital expenditures
Net cash used in investing activities

Cash flows from financing activities:
Proceeds from long-term debt
Principal payments on long-term debt
Principal payments on note payable

Net cash provided by (used in)
financing activities
Net increase in cash and cash equivalents
Cash and cash equivalents, beginning of year

Cash and cash equivalents, end of year

20X5

20X4

$28,969,000

$24,410,000

(28,405,000)
230,000
(382,000)

(22,818,000)
90,000
(372,000)

412,000

1,310,000

(497,000)

(121,000)

(497,000)

(121,000)

2,300,000
(255,000)
(44,000)

—
(1,000,000)
—

2,001,000

(1,000,000)

1,916,000
1,021,000

189,000
832,000

$ 2,937,000

$ 1,021,000

$ (782,000)

$

Reconciliation of change in net assets to net cash
provided by operating activities:

Change in net assets
Adjustments to reconcile change in net assets to
net cash provided by operating activities:
Depreciation and amortization
Provision for bad debts

(Increase) decrease in:
Premiums receivables
Other current assets
Increase (decrease) in:
Accounts payable—medical services
Other accounts payable and accrued expenses
Unearned premium revenue
Net cash provided by operating activities

See accompanying notes to financial statements.
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590,000

370,000
19,000

339,000
20,000

30,000
230,000

64,000
(93,000)

774,000
(168,000)
(61,000)

335,000
(60,000)
115,000

$ 412,000

$ 1,310,000
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Sample Not-for-Profit Health Maintenance Organization

Notes to Financial Statements7
June 30,20X5 and 20X4
1. Organization
The Sample Health Maintenance Organization (the HMO) was incorporated in 20X0 in New
State as a not-for-profit corporation for the purpose of providing comprehensive health care
services on a prepaid basis and for the purpose of establishing and operating organized health
maintenance and health care delivery systems.
The HMO has been determined to be a qualified health maintenance organization under Title
XIII of the Public Health Service Act.

2. Summary of Significant Accounting Policies8
Use of estimates. The preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the
date of the financial statements and the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates.

Cash and cash equivalents. Cash and cash equivalents include investments in highly liquid debt
instruments with an original maturity of three months or less.

Supplies. Inventories of drugs and other supplies are stated at the lower of cost (first-in,
first-out) or market.

Property and equipment. Property and equipment are recorded at cost. Maintenance and repairs
are charged to expense, and betterments are capitalized. Property and equipment costing approxi
mately $700,000 was financed by health maintenance organization initial development grants
received in 20X1 and 20X2 from the U.S. Department of Health and Human Services (HHS). This
property will be owned by the HMO as long as the equipment and facilities are used for projects
related to the objectives of the Public Health Service Act.
Depreciation is computed using the straight-line method over the estimated useful lives of the
related assets as follows:
Building
Improvements
Data processing and laboratory
equipment and automobiles
Medical equipment
Office equipment

40 years
20-25 years
3-7 years
10 years
5-10 years

Amortization of debt issuance costs. Debt issuance costs are deferred and amortized using the
effective interest method over the term of the related debt.
Health care service cost recognition. The HMO contracts with various health care providers for
the provision of certain medical care services to its members. The HMO compensates these providers
7 SOP 00-1 provides auditors with guidance regarding uncertainties in health care revenue recognition and includes a sample
disclosure in paragraph 37 of the SOP for material differences between an original estimate and subsequent revisions regarding
third-party payments. SOP 00-1 is included in appendix E to the Guide.
8 Paragraph 13 of SOP 01-6, Accounting by Certain Entities (Including Entities With Trade Receivables) That Lend to or Finance the Activities
of Others, provides guidance on disclosures that should be included in the summary of significant accounting policies, including
accounting policies for loans, trade receivables, and doubtful accounts.
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on a capitation basis. As part of a cost control incentive program, the HMO retains up to 20 percent
of the capitation as a risk-sharing fund. In the event of hospital utilization in excess of budget,
those providers bear the risk to the extent of 15 percent of the capitation fee. Operating expenses
include all amounts incurred by the HMO under the aforementioned contracts.

The cost of other health care services provided or contracted for is accrued in the period in which
it is provided to a member based in part on estimates, including an accrual for medical services
provided but not reported to the HMO.
Premiums revenue. Membership contracts are on a yearly basis subject to cancellation by the
employer group or the HMO upon 30 days written notice. Premiums are due monthly and are
recognized as revenue during the period in which the HMO is obligated to provide services to members.
Reinsurance (stop-loss insurance). Reinsurance premiums are reported as health care costs, and
reinsurance recoveries are reported as a reduction of related health care costs.

Federal income tax. The HMO is exempt from federal income taxes under Sec. 501(c)(4) of the
Internal Revenue Code; accordingly, no provision for federal income taxes has been made in the
accompanying financial statements.

3. Property and Equipment

Property and equipment at June 30,20X5 and 20X4, consists of the following:
20X5

20X4

Land
Buildings and improvements
Furniture and equipment

$ 300,000
5,473,000
1,786,000

$ 300,000
5,459,000
1,303,000

Less accumulated depreciation

7,559,000
(1,803,000)

7,062,000
(1,436,000)

$5,756,000

$5,626,000

4. Long-Term Debt
Long-term debt is collateralized by assets with a depreciated cost of $4,943,000. A summary of
long-term debt at June 30,20X5 and 20X4, follows.

HHS loan, interest at 7.5 percent,
payable in monthly installments
of $50,000, including interest
HHS loan, interest at 9.25 percent,
payable in monthly installments
of $10,000, including interest
Secured equipment loans, payable
in monthly installments of $15,000,
including interest
Less current maturities
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20X5

20X4

$2,020,000

$ 111,000

1,658,000

1,694,000

858,000

686,000

4,536,000
241,000

2,491,000
109,000

$4,295,000

$2,382,000
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Scheduled principal payments on long-term debt are as follows:
Year ending December 31,
20X6
20X7
20X8
20X9
20Y0

Amount
$ 241,000
259,000
280,000
800,000
2,956,000
$4,536,000

5. State Guarantee Fund Deposit
In August 20X4 the state in which the HMO is domiciled enacted legislation specifically
governing HMOs. Under this legislation, the corporation is required to maintain a deposit of
$150,000 with the director of the division of insurance of the state.

6. Employee Retirement Plan
The HMO has a contributory defined contribution retirement plan covering substantially all
employees. Expense determined in accordance with the plan formula (4 percent to 10 percent of
eligible covered compensation) was $354,000 and $275,000 for the years ended June 30,20X5 and
20X4, respectively.

7. Stop-Loss Insurance
The HMO entered into a stop-loss insurance agreement with an insurance company to limit its
losses on individual claims. Under the terms of this agreement, the insurance company will
reimburse the HMO approximately 25 percent of the cost of each member's annual hospital
services, in excess of a $1,000 deductible, up to a lifetime limitation of $500,000 per member. In
the event the HMO ceases operations, (a) plan benefits will continue for members who are
confined in an acute care hospital on the date of insolvency until their discharge, and (b) plan
benefits will continue for any other member until the end of the contract period for which
premiums have been paid.

Stop-loss insurance premiums of approximately $700,000 and $500,000 are included in insur
ance expense (Note 9) in 20X5 and 20X4, respectively. Approximately $600,000 and $400,000 in
stop-loss insurance recoveries are deducted from insurance expense in 20X5 and 20X4, respec
tively.

Included in other receivables is approximately $50,000 recoverable from insurers.

8. Malpractice Claims

Malpractice claims have been asserted against the HMO by various claimants. The claims are
in various stages of processing, and some may ultimately be brought to trial. In the opinion of
counsel, the outcome of these actions will not have a significant effect on the financial position or
the operating income of the HMO. Incidents occurring through June 30,20X5, may result in the
assertion of additional claims. Other claims may be asserted arising from past services provided.
Management believes that these claims, if asserted, would be settled within the limits of insurance
coverage.

9. Classification of Expenses
Program activities
General and administrative

20X5
26,921,000
2,474,000
$29,395,000

20X4
20,909,000
1,601,000

$22,510,000
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10. Risks and Uncertainties Disclosures||
11. Pension and Other Postretirement Benefit Plans||
12. Fair Value of Financial Instruments||
13. Concentrations of Credit Risk||

|| The disclosures contained in these notes would be similar to the disclosures contained in the notes to the financial statements for
the not-for-profit hospital and, therefore, are not repeated here.
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ILLUSTRATIVE FINANCIAL STATEMENTS
FOR AN AMBULATORY CARE ORGANIZATION
.27

Sample Not-for-Profit Ambulatory Care, Inc.
Balance Sheets

December 31,20X5 and 20X4
20X4

20X5
Assets

Current assets:
Cash
Patient accounts receivable, net of allowance for
doubtful accounts of $15,000 in 20X5 and
$5,000 in 20X4
Estimated retroactive adjustments—third-party payors
Accounts receivable—other
Supplies
Prepaid expenses and deposits

$

65,000

$

76,000

290,000
19,000
13,000
21,000
5,000

278,000
32,000
8,000
18,000
9,000

413,000

421,000

Property and equipment, at cost:
Land
Land improvements
Buildings
Equipment

100,000
322,000
682,000
1,390,000

100,000
322,000
682,000
1,389,000

Less accumulated depreciation

2,494,000
217,000

2,493,000
100,000

Property and equipment, net

2,277,000

2,393,000

Total current assets

Other assets:
Advances receivable
Total assets

14,000

5,000

$2,704,000

$2,819,000

$ 138,000
42,000
33,000
30,000
—

$ 144,000
77,000
22,000
24,000
1,000

243,000

268,000

10,000

10,000

Liabilities and Net Assets

Current liabilities:
Notes payable
Accounts payable
Accrued payroll, benefits, and taxes
Estimated retroactive adjustments—third-party payors
Financing advance from third-party payors
Total current liabilities

Guarantee liability

Total liabilities
Net assets—unrestricted

Total liabilities and net assets

253,000

278,000

2,451,000

2,541,000

$2,704,000

$2,819,000

See accompanying notes to financial statements.
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Sample Not-for-Profit Ambulatory Care, Inc.

Statements of Operations and Changes in Net Assets

Years Ended December 31,20X5 and 20X4

Revenue and gains:
Net patient service revenue
Other

Total revenue and gains
Expenses:
Salaries and benefits
Medical supplies and drugs
Insurance
Provision for bad debts
Depreciation
Interest

Total expenses
Operating loss

Net assets, beginning of year
Net assets, end of year
See accompanying notes to financial statements.
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20X5

20X4

$ 860,000
29,000

$ 357,000
15,000

889,000

372,000

485,000
189,000
154,000
14,000
117,000
20,000

243,000
66,000
98,000
4,000
100,000
18,000

979,000

529,000

(90,000)

(157,000)

2,541,000

2,698,000

$2,451,000

$2,541,000
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Sample Not-for-Profit Ambulatory Care, Inc.
Statements of Cash Flows

Years Ended December 31,20X5 and 20X4

Cash flows from operating activities:
Cash received from patients and third-party payors
Cash received from others
Interest received
Interest paid
Cash paid to employees and suppliers

20X5

20X4

$866,000
21,000
3,000
(15,000)
(870,000)

$ 368,000
6,000
11,000
(16,000)
(432,000)

Net cash provided by (used in) operating activities

Cash flows from investing activities:
Purchase of equipment
Advances made to XYZ Affiliate

Net cash used in investing activities
Cash flows from financing activities:
Proceeds from notes payable
Payments on notes payable

(63,000)

(1,000)
(9,000)

(4,000)
(5,000)

(10,000)

(9,000)

(6,000)

144,000
—

(6,000)

144,000

(11,000)

72,000

76,000

4,000

$ 65,000

$ 76,000

$(90,000)

$(157,000)

Net cash provided by (used in) financing activities

Net increase (decrease) in cash
Cash, beginning of year

Cash, end of year

5,000

Reconciliation of change in net assets
to net cash provided by (used in)
operating activities:
Change in net assets
Adjustments to reconcile change in net
assets to net cash provided by (used in)
operating activities:
Depreciation
Provision for bad debts

117,000
14,000

100,000
4,000

(Increase) decrease in:
Patient accounts receivable
Other current assets

(12,000)
1,000

(19,000)
(2,000)

Increase (decrease) in:
Accounts payable and accrued payroll,
benefits, and taxes
Other current liabilities

(24,000)
(1,000)

10,000
1,000

Net cash provided by (used in)
operating activities

$

5,000

$ (63,000)

See accompanying notes to financial statements.
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Sample Not-for-Profit Ambulatory Care, Inc.

Notes to Financial Statements

December 31,20X5 and 20X4
1. Description of Organization and Summary of Significant Accounting Policies9
Organization. Ambulatory Care, Inc. was incorporated on September 7,20X3, in New State, to
operate an ambulatory care health facility to treat or prevent injury and disease, to provide funds
or to expend funds to further the treatment or prevention of injury or disease, and to develop and
participate in activities designed to promote the general health of the community.

Three area hospitals—ABC Hospital and Health Center, DEF Hospital, and GHI Hospital—
entered into a members' agreement to develop this ambulatory care center. In accordance with
this agreement, each hospital contributed capital of $947,000 to Ambulatory Care, Inc. Ambula
tory Care, Inc. began operations in October 20X3.

Use of estimates. The preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the
date of the financial statements and the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates.
Supplies. Supplies are stated at the lower of cost (first-in, first-out) or net realizable value.
Depreciation. Depreciation of property and equipment is computed on the straight-line method
over the estimated Eves of depreciable assets.

Third-party contractual adjustments. Retroactively calculated third-party contractual adjust
ments are accrued on an estimated basis in the period the related services are rendered. Net patient
service revenue is adjusted as required in subsequent periods based on final settlements.
Net patient service revenue. Patient service revenue is reported at the estimated net realizable
amounts from patients, third-party payors, and others for services rendered.
Charity care. Ambulatory Care, Inc. has a policy of providing charity care to patients who are
unable to pay. Such patients are identified and related charges are estimated, based on financial
information obtained from the patient and subsequent analysis. Since management does not
expect payment for charity care, the estimated charges are excluded from revenue.
Income taxes. Ambulatory Care, Inc. has been recognized by the Internal Revenue Service as a
not-for-profit corporation as described in Sec. 501(c)(3) of the Internal Revenue Code (IRC) and
is exempt from federal income taxes on related income pursuant to Sec. 501(a) of the IRC.

2. Advances Receivable
In May 20X4, Ambulatory Care, Inc. entered into a five-year agreement with XYZ Affiliates
(XYZ). Under this agreement, XYZ is to provide emergency medical services as well as charge
and bill each patient treated at Ambulatory Care, Inc. Ambulatory Care, Inc. has guaranteed that
XYZ will collect at least $18,000 per month during the term of this agreement. In any month in
which XYZ does not collect the minimum guarantee, Ambulatory Care, Inc. advances funds to
XYZ to cover the deficiency. Such advances are to be repaid to the extent XYZ's net cash
collections exceed the minimum guarantee amount. Management estimates that the advances
will be fully recovered in 20X8.
9 Paragraph 13 of SOP 01-6, Accounting by Certain Entities (Including Entities With Trade Receivables) That Lend to or Finance the Activities
of Others, provides guidance on disclosures that should be included in the summary of significant accounting policies, including
accounting policies for loans, trade receivables, and doubtful accounts.
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3. Related-Party Transactions
During 20X3, Ambulatory Care, Inc. entered into a contract with one of the member hospitals
(the managing hospital) for the management of the business and affairs of Ambulatory Care, Inc.
Under this agreement, Ambulatory Care, Inc. pays $4,000 per month to the managing hospital.
The agreement with the managing hospital was to remain in effect through December 31, 20X5,
but has been extended on a month-to-month basis.

In addition, during 20X4 each hospital loaned $48,000 to Ambulatory Care, Inc. in the form of
promissory notes at an interest rate of prime rate plus 1 percent (effective rates of 10 percent and 9
percent in 20X5 and 20X4, respectively). Of the total $144,000 liability, $48,000 is payable on demand
after November 28,20X5, to one member hospital, with the remaining portion ($96,000) payable on
demand after December 8,20X5, to the other two member hospitals. During 20X5, Ambulatory Care,
Inc. paid $2,000 to each member hospital, thereby reducing the obligation to $138,000.
4. Revenue From Contracting Agencies
Ambulatory Care, Inc. participates as a provider of health care services to Blue Cross, Medicare,
and County Indigent Plan patients. Reimbursement for covered services is based on tentative
payment rates. Final reimbursement is determined after submission of annual cost reports and
audits thereof by the fiscal intermediaries. Provisions for estimated reimbursement adjustments
are reported in the financial statements in the period that the services are rendered.

Revenue from the Medicare program accounted for approximately XX percent for the year
ended 20X5, and XX percent for the year ended 20X4, of Ambulatory Care, Inc.'s net patient
revenue. Laws and regulations governing the Medicare program are extremely complex and
subject to interpretation. As a result, there is at least a reasonable possibility that recorded
estimates will change by a material amount in the near term. The 20X5 net patient service
revenue increased approximately $XXX due to removal of allowances previously estimated
that are no longer necessary as a result of final settlements and years that are no longer subject
to audits, reviews, and investigations. The 20X4 net patient service revenue decreased ap
proximately $XXX due to prior-year retroactive adjustments in excess of amounts previously
estimated.
5. Charity Care

Ambulatory Care, Inc. has a policy of providing charity care to indigent patients in emer
gency situations. These services, which are excluded from revenues, amounted to $27,000 and
$13,000 in 20X5 and 20X4, respectively, when measured at Ambulatory Care, Inc.'s established
rates.
6. Classification of Expenses
Program

Total

ABC

General and
Administrative

Expenses incurred for the
year ended December 31,
20X5, were for:

Salaries and benefits
Medical supplies and drugs
Insurance
Provision for bad debts
Depreciation
Interest

Total expenses

$485,000
189,000
154,000
14,000
117,000
20,000

$216,000
98,000
79,000
9,000
100,000
9,000

$102,000
43,000
45,000
—
—
—

$121,000
48,000
14,000
5,000
17,000
—

$46,000
—
16,000
—
—
11,000

$979,000

$511,000

$190,000

$205,000

$73,000
(continued)
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Health Care Organizations

Program

ABC

Total

General and
Administrative

Expenses incurred for the
year ended December 31,
20X4, were for:
Salaries and benefits
Medical supplies and drugs
Insurance
Provision for bad debts
Depreciation
Interest

Total expenses

$243,000
66,000
98,000
4,000
100,000
18,000

$111,000
31,000
45,000
—
56,000
7,000

$ 46,000
15,000
19,000
4,000
—
—

$ 57,000
20,000
26,000
—
44,000
—

$29,000
—
8,000
—
—
11,000

$529,000

$250,000

$ 84,000

$147,000

$48,000

(The preparer of the financial statements may wish to include a brief description of the types of
programs.)

7.

Risks and Uncertainties Disclosures||

8.

Pension and Other Postretirement Benefit Plans||

9.

Fair Value of Financial Instruments||

10. Concentrations of Credit Risk||

|| The disclosures contained in these notes would be similar to the disclosures contained in the notes to the financial statements for
the not-for-profit hospital and, therefore, are not repeated here.
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Get online access to AICPA's core accounting and auditing guidance
AICPA's set of core A&A guidance—available through AICPA RESOURCE: Accounting &
Auditing Literature—gives you instant access to the important information you need. Each
set includes:

• AICPA’s Audit and Accounting Guide
• AICPA's Audit Risk Alert
• AICPA's Checklist and Illustrative Financial Statements

The one-year online subscription:
• Links the titles together for quick navigation and easy response.
• Gives you downloadable Checklists in Word® format.
• Allows your searches to be targeted and simplified—by refining and narrowing your search targets.
• Is always current...the guidance is updated periodically throughout the year.
You'll find these A&A sets available through AICPA RESOURCE: A&A Literature—online:
• Common Interest Realty Associations (WCM-ST)
• Construction Contractors (WCN-ST)
• Depository and Lending Institutions (WDE-ST)
• Employee Benefit Plans (WEM-ST)
• Health Care Organizations (WHO-ST)
• Investment Companies (WIV-ST)
• Life and Health Insurance (WHI-ST)
• Not-for-Profit Organizations (WNO-ST)
• Oil and Gas (WGA-ST)
• Personal Financial Statements (WFI-ST)
• Property and Liability Insurance Companies (WLA-ST)
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Log onto www.cpa2biz.com/AICPAresource
for more information or to purchase your subscription.
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